WO1995023222A1 - Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups - Google Patents

Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups Download PDF

Info

Publication number
WO1995023222A1
WO1995023222A1 PCT/US1995/002252 US9502252W WO9523222A1 WO 1995023222 A1 WO1995023222 A1 WO 1995023222A1 US 9502252 W US9502252 W US 9502252W WO 9523222 A1 WO9523222 A1 WO 9523222A1
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine protease
protease inhibitor
amino
inhibitor according
phenylsulfonyl
Prior art date
Application number
PCT/US1995/002252
Other languages
French (fr)
Inventor
James T. Palmer
David Rasnick
Jeffrey Lee Klaus
Original Assignee
Khepri Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Khepri Pharmaceuticals, Inc. filed Critical Khepri Pharmaceuticals, Inc.
Priority to US08/700,518 priority Critical patent/US5976858A/en
Priority to AU20910/95A priority patent/AU708414B2/en
Priority to NZ282946A priority patent/NZ282946A/en
Priority to EP95913490A priority patent/EP0756625A4/en
Publication of WO1995023222A1 publication Critical patent/WO1995023222A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to novel cysteine protease inhibitors.
  • the inhibitors are novel cysteine protease inhibitors.
  • cysteine proteases are specific to cysteine proteases and do not inhibit serine, aspartyl or zinc protease.
  • Cysteine or thiol proteases contain a cysteine residue at the active site
  • cysteine proteases have been implicated in a number of diseases, including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, and other parasite-borne
  • R alkyl, aryl, etc.
  • EWG COOEt, SO 2 Me, etc. ⁇ , ⁇ -unsaturated esters (Hanzlik et al., J. Med. Chem., 27(6):711-712 (1984), Thompson et al., J. Med. Chem. 29:104-111 (1986), Liu et al., J. Med. Chem., 35(6): 1067 (1992)) and an ⁇ , ⁇ -unsaturated sulfones (Thompson et al., supra, Liu et al., supra) were made using this method and tested as inhibitors of two cysteine proteases, papain and dipeptidyl amino-peptidase I (also called cathepsin C).
  • R 1 , R 2 amino acid side chains
  • X Cl, F, N 2 , OC(O)R, (+)S(CH 3 ) 3
  • cysteine protease inhibitors include epoxysuccinyl peptides, including E-64 and its analogs (Hanada, K. et al., Agric. Biol. Chem (1978), 42, 523; Sumiya, S. et al., Chem. Pharm. Bull. ((1992), 40, 299 Gour-Salin, B.J. et al., J. Med. Chem., (1993), 36, 720), ⁇ -dicarbonyl compounds, reviewed by Mehdi, S., Bioorganic Chemistry, (1993), 21, 249, and
  • N-peptidyl-O-acyl hydroxamates (Bromme, D., Neumann, U., Kirschke, H., Demuth, H-U., Biochim. Biophys. Acta, (1993), 1202, 271.
  • the present invention provides cysteine protease inhibitors comprising a targeting group linked to an alkene bond electronically conjugated with an electron withdrawing group (EWG).
  • EWG electron withdrawing group
  • the second order rate constant for inhibition of a cysteine protease with the inhibitor, expressed as k irr /K I preferably is at least about 1000 M -1 sec -1 .
  • An additional aspect of the present invention is to provide chiral cysteine protease inhibitors comprising a targeting group linked to an alkene bond conjugated with an EWG. Additionally provided are these chiral cysteine protease inhibitors wherein the second order rate constant for inhibition of a cysteine protease with the inhibitor, expressed as k irr /K I , is at least about 1000 M -1 sec -1 .
  • cysteine protease inhibitor is provided with the formula:
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group or a label.
  • X and Y are amino side chains, with either (R) or (S) configuration.
  • the A-B linkage is a peptide or peptidomimetic linkage, and EWG is an electron withdrawing group.
  • cysteine protease inhibitors wherein the second order rate constant for inhibition of a cysteine protease with the inhibitor, expressed as k irr /K I , is at least about 1000 M -1 sec "1 .
  • cysteine protease inhibitors and cysteine protease inhibitors that contain additional targeting groups linked to the EWG.
  • cysteine protease inhibitors are provided wherein the EWG is a moiety or group that will work in the Wadsworth-Emmons reaction for olefin synthesis when directly attached to a methylenephosphonate species.
  • the EWG group when functionally included as a component of the cysteine protease inhibitor, may be selected from the group consisting of vinylogous esters, vinylogous sulfones, vinylogous carboxylates, vinylogous amides, vinylogous phosphonates, vinylogous ketones, vinylogous nitriles, vinylogous sulfoxides, vinylogous sulfonamides, vinylogous sulfinamides, vinylogous sulfonates and vinylogous sulfoximines.
  • vinylogous esters vinylogous sulfones, vinylogous carboxylates, vinylogous amides, vinylogous phosphonates, vinylogous ketones, vinylogous nitriles, vinylogous sulfoxides, vinylogous sulfonamides, vinylogous sulfinamides, vinylogous sulfon
  • An additional aspect of the present invention relates to methods for making a cysteine protease inhibitor.
  • the method comprises: a) a protected ⁇ -amino aldehyde is coupled with a Wadsworth-Emmons reagent containing an EWG to form a cysteine protease inhibitor intermediate; b) the cysteine protease inhibitor intermediate is then deprotected at the N-terminus; and c) the deprotected cysteine protease inhibitor intermediate is then coupled to N-terminally protected amino acids.
  • the invention also includes a method for inhibiting a cysteine protease, comprising irreversibly binding an cysteine protease inhibitor to the protease.
  • the invention further provides a method of treating cysteine protease-associated disorders, comprising administering a therapeutically effective dose of a cysteine protease inhibitor to a patient.
  • pharmaceutical compositions of cysteine protease inhibitors are also provided.
  • the invention provides methods of detecting a cysteine protease in a sample, comprising assaying the sample in the presence and absence of a cysteine protease inhibitor of the present invention and calculating the difference in activity due to the protease.
  • cysteine protease inhibitors with the formula:
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group, or a label.
  • Y are amino side chains, with either (R) or (S) configuration.
  • the A-B linkage is a peptide or peptidomimetic linkage, and EWG is an electron withdrawing group.
  • cysteine protease inhibitors with the formula:
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group or a label.
  • X and Y are amino side chains, with either (R) or (S) configuration.
  • the A-B linkage is a peptide or peptidomimetic linkage, and EWG is an electron withdrawing group.
  • the present invention relates to novel cysteine protease inhibitors. It is believed that the inhibitors function to inactivate cysteine proteases based on the following mechanism:
  • the serine at the active site reacts with the carbonyl of the substrate, forming a tetrahedral intermediate.
  • the inhibitors of this invention have no carbonyl at the site of nucleophilic attack, and are not susceptible to attack by serine proteases.
  • Cysteine proteases are a family of proteases that bear a thiol group at the active site. These proteases are found in bacteria, viruses, eukaryotic microorganisms, plants, and animals. Cysteine proteases may be generally classified as belonging to one of four or more distinct superfamilies.
  • cathepsin C is also known as dipeptidyl peptidase I), interleukin converting enzyme (ICE), calcium-activated neutral proteases, calpain I and II; viral cysteine proteases such as picornian 2A and 3C, aphthovirus endopeptidase, cardiovirus endopeptidase, comovirus endopeptidase, potyvirus endopeptidases I and II, adenovirus endopeptidase, the two endopeptidases from chestnut blight virus, togavirus cysteine endopeptidase, as well as cysteine proteases of the polio and rhinoviruses; and cysteine proteases known to be essential for parasite lifecycles, such as the proteases from species of Plasmodia, Entamoeba, Onchocera, Trypansoma,
  • cysteine protease inhibitors of the present invention For an extensive listing of cysteine proteases that may be inhibited by the cysteine protease inhibitors of the present invention, see Rawlings et al., Biochem. J. 290:205-218 (1993), hereby expressly incorporated by reference.
  • inhibitors of cysteine proteases are useful in a wide variety of applications.
  • the inhibitors of the present invention are used to quantify the amount of cysteine protease present in a sample, and thus are used in assays and diagnostic kits for the quantification of cysteine proteases in blood, lymph, saliva, or other tissue samples, in addition to bacterial, fungal, plant, yeast, viral or mammalian cell cultures.
  • the sample is assayed using a standard protease substrate.
  • a cysteine protease inhibitor is added, and allowed to bind to any cysteine protease present.
  • the protease assay is then rerun, and the loss of activity is correlated to cysteine protease activity using techniques well known to those skilled in the ait
  • the cysteine protease inhibitors are also useful to remove or inhibit contaminating cysteine proteases in a sample.
  • the cysteine protease inhibitors of the present invention are added to samples where proteolytic degradation by contaminating cysteine proteases is undesirable.
  • the cysteine protease inhibitors of the present invention may be bound to a chromatographic support, using techniques well known in the art, to form an affinity chromatography column. A sample containing an undesirable cysteine protease is run through the column to remove the protease.
  • cysteine protease inhibitors are useful for inhibiting cysteine proteases implicated in a number of diseases.
  • cathepsins B, L, and S, cruzain, and interleukin 1 ⁇ converting enzyme are inhibited.
  • These enzymes are examples of lysosomal cysteine proteases implicated in a wide spectrum of diseases characterized by tissue degradation.
  • diseases include, but are not limited to, arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, parasite-borne infections, Alzheimer's disease, periodontal disease, and cancer metastasis.
  • mammalian lysosomal thiol proteases play an important role in intracellular degradation of proteins and possibly in the activation of some peptide hormones. Enzymes similar to cathepsins B and L are released from tumors and may be involved in tumor metastasis. Cathepsin L is present in diseased human synovial fluid and transformed tissues. Similarly, the release of cathepsin B and other lysosomal proteases from
  • cysteine protease inhibitors also find application in a multitude of other diseases, including, but not limited to, gingivitis, malaria, leishmaniasis, filariasis, and other bacterial and parasite-borne infections.
  • the compounds also offer application in viral diseases, based on the approach of inhibiting proteases necessary for viral replication. For example, many picornoviruses including poliovirus, foot and mouth disease virus, and rhinovirus encode for cysteine proteases that are essential for cleavage of viral polyproteins.
  • these compounds offer application in disorders involving interleukin-1 ⁇ converting enzyme (ICE), a cysteine protease responsible for processing interleukin 1 ⁇ ; for example, in the treatment of inflammation and immune based disorders of the lung, airways, central nervous system and surrounding membranes, eyes, ears, joints, bones, connective tissues, cardiovascular system including the pericardium, gastrointestinal and urogenital systems, the skin and the mucosal membranes.
  • ICE interleukin-1 ⁇ converting enzyme
  • infectious diseases where active infection exists at any body site, such as meningitis and salpingitis; complications of infections including septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome; acute or chronic inflammation due to antigen, antibody and/or complement deposition; inflammatory conditions including arthritis, chalangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury and vasculitis.
  • Immune-based diseases include but are not limited to conditions involving T-cells and/or macrophages such as acute and delayed hypersensitivity, graft rejection, and graft- versus-host disease; auto-immune diseases including Type I diabetes mellitus and multiple sclerosis. Bone and cartilage reabsorption as well as diseases resulting in excessive deposition of extracellular matrix such as interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, and keloid formation may also be treated with the inhibitors of the present invention. The inhibitors may also be useful in the treatment of certain tumors that produce IL 1 as an autocrine growth factor and in preventing the cachexia associated with certain tumors.
  • cysteine protease inhibitors of the present invention find use in drug potentiation applications.
  • therapeutic agents such as antibiotics or antitumor drugs can be inactivated through proteolysis by endogeneous cysteine proteases, thus rendering the administered drug less effective or inactive.
  • bleomycin an antitumor drug
  • bleomycin hydrolase a cysteine protease
  • cysteine protease inhibitors of the invention may be administered to a patient in conjunction with a therapeutic agent in order to potentiate or increase the activity of the drug.
  • This co-administration may be by simultaneous administration, such as a mixture of the cysteine protease inhibitor and the drug, or by separate simultaneous or sequential
  • cysteine protease inhibitors have been shown to inhibit the growth of bacteria, particularly human pathogenic bacteria (see Bjorck et al., Nature 337:385 (1989)). Accordingly, the cysteine protease inhibitors of the present invention may be used as antibacterial agents to retard or inhibit the growth of certain bacteria.
  • the cysteine protease inhibitors of the invention also find use as agents to reduce the damage of bacterial cysteine proteases to host organisms.
  • staphylococcus produces a very active extracellular cysteine protease which degrades insoluble elastin, possibly contributing to the connective tissue destruction seen in bacterial infections such as septicemia, septic arthritis and otitis.
  • the cysteine protease inhibitors of the invention may be used to treat bacterial infections to prevent tissue damage.
  • the present invention generally provides new peptide-based and
  • cysteine protease inhibitors for use as irreversible, mechanism-based cysteine protease inhibitors.
  • these cysteine protease inhibitors are Michael acceptors.
  • Michael acceptor or grammatical equivalents herein is meant an alkene conjugated with an electron-withdrawing group, such as an ⁇ , ⁇ -unsaturated, vinylogous electron withdrawing group.
  • the cysteine protease inhibitors are comprised of a targeting group linked to an alkene conjugated with an EWG.
  • a preferred embodiment exhibits the structure shown below in Formula 1:
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • a - B is a peptide linkage
  • EWG is an electron withdrawing group.
  • targeting group or grammatical equivalents, herein is meant a portion of a cysteine protease inhibitor that allows the binding of the inhibitor to a cysteine protease.
  • the targeting group of a cysteine protease inhibitor comprises at least one amino acid side chain.
  • the targeting group comprises at least two amino acids linked via a peptide bond.
  • the carbon to which the "Y" amino acid side chain is attached is directly attached to the carbon-carbon double bond.
  • the targeting group may include up to about 15 amino acids, although cysteine protease inhibitors are generally from 1 to 7 amino acids, since smaller inhibitors are usually desired in therapeutic applications.
  • the targeting group may comprise naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures.
  • amino acid or “peptide residue”, as used herein means both naturally occurring and synthetic amino acids, although preferably a single cysteine protease inhibitor does not contain more than one non-naturally occurring amino acid side chain.
  • cysteine or peptide residue
  • amino acid also includes imino acid residues such as proline and hydroxyproline.
  • the term as used herein also refers to portions of an amino acid, such as an amino acid side chain.
  • the side chains may be in either the (R) or the (S) configuration. In the preferred embodiment, the amino acids are in the (S) or L-configuration.
  • non-amino acid substituents may be used, for example to prevent or retard in vivo degradations.
  • Such non-amino acid substituents will normally include, but are not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, an aralkyl, an alkoxy, a heteroaryl, a heteroarylalkyl, or a heteroarylalkenyl.
  • alkyl is preferably of 1 to 5 carbon atoms, preferably branched, particularly isobutyl.
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl.
  • Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof.
  • Aryl preferably is phenyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl and phenylethyl.
  • Alkoxy preferably is of 1 to 5 carbon atoms, preferably methoxy.
  • Acyloxy preferably is of 2 to 6 carbon atoms, preferably acetoxy.
  • Heteroaryl preferably is pyridinyl, especially 4-pyridinyl, thienyl, especially
  • heteroarylalkyl and heteroalkenyl preferably has 1 to 6 carbon atoms, especially 1 carbon atom in the alkyl or alkylene moieties thereof.
  • the heteroaryl moiety of heteroarylalkyl and heteroarylakylene preferably has the significances indicated above as preferred for heteroaryl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl.
  • the specific amino acids comprising the targeting group are initially determined by the rules governing substrate specificity in cysteine proteases.
  • the amino acid side chain of the targeting group closest to the alkene bond generally referred to herein as "Y”
  • the amino acid side chain of the targeting group is the P 1 residue of the inhibitor.
  • the amino acid side chain of the targeting group second from the alkene bond generally referred to herein as "X”
  • X will occupy the S 2 position of the enzyme's substrate binding site when the inhibitor is bound to the enzyme, and thus is the P 2 residue. If present, additional amino acid side chains of the inhibitor will occupy the P 3 , P 4 , etc. positions.
  • additional targeting residues or specificity-enhancing residues are attached to the EWG, to occupy the S 1 ' , S 2 ' , etc. position of the enzyme's substrate binding site.
  • additional targeting groups are considered the P 1 ' , P 2 ' etc. residues of the inhibitor.
  • the additional targeting residues are chosen to confer increased specificity on the inhibitor for the particular cysteine protease to be inhibited.
  • the choice of the amino acid side chains of the targeting group and of the additional targeting residues will be done using the available information about the substrate specificity of the protease, and is routine to those skilled in the art using commercially available substrates.
  • interleukin-1 ⁇ converting enzyme displays the greatest specificity demonstrated for a cysteine protease toward a substrate, requiring an aspartyl side chain in the P 1 position.
  • the papain superfamily of cysteine proteases have an extended specificity site containing five to seven significant subsites, with the dominant one being S 2 , which is a hydrophobic pocket that binds phenylalanyl-like sidechains very well.
  • Cathepsin B similar to papain, accepts a phenylalanine side chain in S 2 , as well as an arginyl sidechain.
  • Cathepsin B similar to papain, accepts a phenylalanine side chain in S 2 , as well as an arginyl sidechain.
  • Proteinase Inhibitors in Reasearch Monographs in Cell and Tissue Physiology (1986), ed. Barrett et al., Vol. 12, Chapter 4: Inhibitors of Cysteine Proteinases, Daniel Rich, Elsevier, New York, hereby expressly incorporated by reference.
  • ICE interleukin 1 ⁇ converting enzyme
  • the targeting group of the cysteine protease inhibitor may also contain additional functional groups, as shown in Formula 1, above.
  • the "P” group of Formula 1 may be a hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group, or a label.
  • the "P” group may also be a label, such as a fluorescent label.
  • peptide amino end blocking group herein is meant, for example, groups including, but not limited to, an
  • alkoxy- ⁇ -oxoalkanoyl of 2 to 10 carbon atoms alkoxycarbonyl of overall 2 to 10 carbon atoms, alkanoyl of overall 2 to 10 carbon atoms,
  • cycloalkylcarbonyl of overall 4 to 8 carbon atoms, carbamoyl,
  • cycloalkylaminocarbonyl or oxacycloalkylaminocarbonyl of overall 4 to 8 atoms in the ring particularly 4-morpholinecarbonyl (Mu).
  • amino acids, or peptide residues are normally linked via a peptide bond or linkage, i.e. a peptidic carbamoyl group, i.e. -CONH-.
  • peptidomimetic bonds are also included, such as CH 2 -NH, CO-CH 2 , azapeptide and retro-inverso bonds.
  • alkene bond or grammatical equivalents, herein is meant a carbon-carbon double bond. It is to be understood that the alkene bonds of the cysteine protease inhibitors confer Michael acceptor functionality to the cysteine protease inhibitors. In a preferred embodiment, the carbon to which the "Y" amino acid side chain is attached is directly attached to the carbon-carbon double bond.
  • the targeting group is linked to one of the carbons of the carbon-carbon double bond, and the EWG is linked to the other carbon of the carbon-carbon double bond.
  • linked or grammatical equivalents herein is meant a covalent attachment.
  • the linkage may be direct, such that the carbon to which the "Y" amino acid side chain is attached is attached to one of the carbons of the carbon-carbon double bond.
  • the linkage between the alkene bond and the EWG is such that the electron withdrawing properties of the EWG are exerted on the alkene bond, to allow nucleophilic attack by a cysteine protease on the alkene bond.
  • the targeting group and the EWG are attached by the alkene bond in trans configuration.
  • the targeting group and the EWG are attached in cis configuration.
  • ⁇ , ⁇ -unsaturated compounds in the cis (Z) configuration, as opposed to the trans (E) configuration are made by using phosphonates bearing the highly electrophilic ⁇ -trifluoroethoxy groups at the phsophorus atom (Still et al., Tetrahedron Lett. 24:4405 (1983)) in place of phosphonates bearing dialkyl groups such as diethyl.
  • EWG electron withdrawing group
  • an EWG is conjugated with the alkene bond, such that the electron withdrawing properties of the EWG serve to allow nucleophilic attack by a cysteine protease at the alkene bond, i.e. the alkene bond and the EWG are electronically conjugated.
  • the linkage between the alkene bond and the EWG is a direct one, without intervening moieties that would prevent the electron withdrawing properties of the EWG from being exerted on the alkene bond.
  • an EWG comprises an electron withdrawing moiety, EWM, as defined below.
  • an EWG comprises a ring (e.g.
  • a five or six membered aromatic ring that is substituted with at least one EWM, a meta directing moiety or group (MDG), or a deactivating group (DG), as defined below.
  • EWM meta directing moiety or group
  • DG deactivating group
  • the EWG comprises a homocyclic six membered aromatic ring or a heterocyclic five or six membered aromatic ring, which is substituted with an EWM, MDG or DG.
  • the ring must be aromatic, that is, it must conform to Hückel's rule for the number of delocalized ⁇ electrons.
  • the ring is a six membered homocyclic ring, i.e. containing only carbon, it is substituted, with a substitution group, in such a manner that the substituted ring, when linked to the alkene bond of a cysteine protease inhibitor, allows nucleophilic attack by the protease at the alkene bond.
  • the substituted homocyclic ring is an EWG.
  • the substitution group may be an EWM, MDG, or DG.
  • a homocyclic ring may have at least one EWM, as defined below as useful in the Wadsworth-Emmons reaction, substituted at any of the carbons of the ring, to confer electron withdrawing properties on the EWG.
  • Alternative embodiments have more than one EWM substituted on the ring, with up to five substitution groups on a six membered aromatic ring.
  • the substitution group may or may not be an EWM, as defined below, but instead is considered meta directing in respect to electrophilic aromatic substitution. That is, that the electron withdrawing properties of the substitution group, when present on an aromatic ring, direct further addition of groups to the ring to a meta position, relative to the original substitution group.
  • Meta directing groups or moieties in respect to electrophilic aromatic substitution, are well known in the art.
  • meta directing moieties are the quaternary ammonium salts, NR 3 +, where R may be for example an aryl, alkyl or an aralkyl group, among others, as well as such meta directing groups as NO 2 , SO 3 H, SO 2 R, SOR, SO 2 NH 2 ,
  • the substitution group is a deactivating group.
  • Deactivating group means a group or moiety which is deactivating in respect to electrophilic aromatic substitution, by virtue of their electronegativity, as is well known in the art. That is, a substitution group that is deactivating renders the substituted aromatic ring to be less reactive than the non-substituted ring.
  • suitable deactivating groups are all halogen atoms, such as F, Cl, Br, I, and At; for example, F 5 , CF 3 , and (CF 3 ) n.
  • substitution may be either in the para, ortho or meta position, relative to the ring carbon that is attached to one of the carbons of the carbon-carbon double bond of the cysteine protease inhibitor.
  • the ring may be heterocyclic aromatic rings, that is, contain more than one kind of atom.
  • five membered rings that contain at least one nitrogen, oxygen, phosphorus, arsenic or sulfur atom, and six membered rings that contain at least one nitrogen or phosphorus atom may be used as outlined below.
  • the rings may contain more than one of the atoms, as well as combinations of atoms.
  • the heterocyclic five membered rings may be substituted, as outlined above, with a group that is an EWM as defined below.
  • the six membered rings may be substituted with a group that is either an EWM as defined below, a MDG or a DG, as defined above.
  • heterocyclic aromatic rings examples include pyrrole, furan, thiophene, pyridine, thiazole, pyrimidine, phosphole, and arsole.
  • Particularly useful substitution groups for these rings are quaternary pyridinium salts, such as NR 3 +, where R is, for example, an aralkyl or alkyl group.
  • EWGs containing five or six membered aromatic substituted rings useful in the present invention are determined by their ability to be used in the Wittig reaction.
  • the Wittig reaction is a well known method of synthesizing alkenes from carbonyl compounds, wherein the carbonyl oxygen is replaced by a carbon atom, in a reaction with a phosphonium ylide or phosphine oxide. The reaction proceeds if the phosphonium ylide or phosphine oxide contains an electron withdrawing group. Thus an electron withdrawing group that will function in the Wittig reaction can be an EWG in the present invention.
  • This reaction is well characterized and one skilled in the art will be able to choose and assay likely EWG candidates, using routine techniques.
  • the EWG comprises an EWM.
  • the EWM group is attached to or conjugated directly with one of the carbons of the carbon-carbon double bond.
  • electron withdrawing moiety or “EWM” or grammatical equivalents herein is meant any functional group that can be used in the Wadsworth-Emmons modification of the Wittig reaction in olefin synthesis.
  • the ability of a functional group to form ⁇ , ⁇ unsaturated hydrocarbons in the Wadsworth-Emmons reaction will confer the required level of electron withdrawing to function as an EWG in a cysteine protease inhibitor.
  • the EWGs of the present invention are vinylogous moieties, that is, they are attached to the carbon-carbon double bond of the cysteine protease inhibitor.
  • the term "vinylogous EWG” means an EWG linked to the alkene bond of the inhibitor; that is, the alkene bond is not part of the EWG.
  • vinylogous compounds that are useful in the present invention include, but are not limited to, vinylogous esters, vinylogous sulfones, vinylogous carboxylates, vinylogous amides, vinylogous phosphonates, vinylogous ketones, vinylogous nitriles, vinylogous sulfoxides, vinylogous sulfonamides, vinylogous sulfinamides, vinylogous nitro compounds, vinylogous sulfonates and vinylogous sulfoximines.
  • vinylogous esters vinylogous sulfones, vinylogous carboxylates, vinylogous amides, vinylogous phosphonates, vinylogous ketones, vinylogous nitriles, vinylogous sulfoxides, vinylogous sulfonamides, vinylogous sulfinamides, vinylogous nitro compounds, vinylogous
  • the cysteine protease inhibitor includes a vinylogous ester moiety as the EWG, as shown in Formula 2:
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • R is an ester moiety
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • ester moiety herein is meant a group including, but not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, an aryl, or an aralkyl.
  • alkyl is preferably of 1 to 5 carbon atoms, especially ethyl.
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl moieties thereof.
  • Aryl preferably is phenyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where
  • R 1 groups include C1-C5 alkyl, especially ethyl; C3-C7 cycloalkyl, especially cyclopentyl or cyclohexyl; C3-C7 (cycloalkyl)-Cl-C5 alkyl, especially C5-C6(cycloalkyl)-methyl; phenyl; C7-C12 phenylalkyl, especially benzyl; aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy, amino, chlorine, bromine or fluorine being particularly preferred.
  • aryl or aralkyl substituted by one or two groups of halogen-substituted C1-C5 alkyl, especially trifluoromethyl; nitro; sulfonyl; or arylsulfonyl, in protected form where appropriate.
  • cysteine protease inhibitors containing vinylogous esters as EWGs are (1) ethyl (S)-(E)-4-(4-morpholine-carbonylphenylalanyl)-amino-6-phenyl-2-hexenoate, abbreviated herein as Mu-Phe-HphVEOEt, (2) ethyl (S)-(E)-7-guanidino-4- (4-morpholinecarbonylphenylalanyl)amino-2-heptenoate hydrobromide, abbreviated herein as
  • Mu-Phe-ArgVEOEt.HBr (3) (S)-(E)-Ethyl 8-(benzyloxycarbonyl)amino-4-(4-morpholinecarbonylphenyl-alanyl)amino-2-octenoate, abbreviated herein as Mu-Phe-Lys(z)VEOEt; and (4) (S)-(E)-Ethyl 8-amino-4-(4-morpholinecarbonylphenylalanyl)amino-2-octenoate hydrobromide, abbreviated herein as Mu-Phe-LysVEOEt-HBr.
  • the cysteine protease inhibitor includes a vinylogous sulfone moiety as the EWG, as shown in Formula 3:
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • R 2 is a side chain moiety
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • the S-R 2 bond is a sulfur-carbon link where R 2 is a side chain moiety.
  • the R 2 side chain moiety may be a group including, but not limited to, an alkyl, a substituted alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl.
  • alkyl is preferably of 1 to 5 carbon atoms, especially methyl.
  • Substituted alkyl is preferably of 1 to 5 carbon atoms, bearing substitutions of alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl.
  • Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof.
  • Aryl preferably is phenyl, pentafluorophenyl or naphthyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or
  • halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl.
  • R 2 groups include (1) C1-C5 alkyl, especially methyl; (2) C3-C7 cycloalkyl, preferably cyclopentyl or cycolhexyl; (3) C3-C7(cycloalkyl) - C1-C5 alkyl, preferably C5-C6(cycloalkyl)methyl; (4) C3- C7(cycloalkylalkenyl)-C1-C5 alkyl, preferably C5-C6(cycloalkylalkenyl)-methyl; (5) phenyl, preferably pentafluorophenyl or naphtyl; (6) C7-C12 phenylalkyl, preferably benzyl; (7) C1-C5 alkyl substituted by C1-C5 alkyoxy, halogen, hydroxy or amino, with C1-C5 alkyl preferably substituted by one or two groups selected from methyl, methoxy, chlorine, bromine, fluorine,
  • Preferred cysteine protease inhibitors with vinylogous sulfones as the EWG include: (1) (S)-(E)-5-(4-morpholinecarbonylphenylalanyl)amino-7-phenyl-2-thia-3-heptene 2,2-dioxide, abbreviated herein as
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • a cysteine protease inhibitor with a vinylogous carboxylate as the EWG is (S)-(E)-4-(4-morpholinecarbonylphenylalanyl)-amino-6- phenyl-2-hexenoic acid, abbreviated herein as Mu-Phe-HphVA, and (S)-(E)-Benzyl 4-(4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenamide, abbreviated herein as Mu-Phe-HphVAMbzl.
  • the cysteine protease inhibitor includes a vinylogous phosphonate as the EWG, as shown in Formula 5: wherein
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • R 3 is an ester moiety
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • the R 3 groups are ester moieties, and may be groups including, but not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl.
  • alkyl is preferably of 1 to 5 carbon atoms, especially ethyl.
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl.
  • Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof.
  • Aryl preferably is phenyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or
  • halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl.
  • perfluoro groups such as perfluoro alkyl, aryl and aralkyl groups.
  • C1-C5 alkyl especially ethyl
  • C3-C7 cycloalkyl preferably cyclopentyl or cycolhexyl
  • C3-C7(cycloalkyl) -C1-C5 alkyl preferably C5-C6(cycloalkyl)methyl
  • C3-C7(cycloalkylalkenyl)-C1-C5 alkyl preferably C5-C6(cycloalkylalkenyl)methyl
  • aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy, amino, chlorine, bromine or fluorine being
  • a cysteine protease inhibitor with a vinylogous phosphonate as the EWG is diethyl (S)-(E)-4-(4-morpholinecarbonylphenylalanyl)amino-6- phenyl-2-hexenephosphonate, abbreviated herein as Mu-Phe-HphVPEt.
  • the cysteine protease inhibitors of the present invention include vinylogous amides as the EWG, as shown in Formula 6:
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X, Y and Z are amino acid side chains, with either (R) or (S) stereochemical configuration,
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • amide moiety as used with regard to Q is meant a group including, but not limited to, an NH2, or an NH-alkyl, an NH-cycloalkyl, an
  • N-dicycloalkyl an N-dicycloalkylalkyl, an N-diaryl, or an N-diaralkyl.
  • alkyl is preferably of 1 to 5 carbon atoms, especially ethyl.
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl moieties thereof.
  • Aryl preferably is phenyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where
  • NH-(C1-C5) alkyl especially NH-ethyl
  • NH-(C3-C7)cycloalkyl preferably cyclopentyl or cyclohexyl
  • HN- (C3-C7)cycloalkyl-(C1-C5) alkyl preferably NH-(C5-C6)cycloalkyl-methyl
  • NH-aryl preferably NH-phenyl
  • aryl or aralkyl with one group selected from hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsufonyl, or halogen-substituted (c1-C5)alkyl, especially trifluoromethyl.
  • the ester as used with regard to Q may be an oxygen linked with the ester moieties defined for vinylogous esters and phosphonates to form esters.
  • cysteine protease inhibitors that contain vinylogous amides as the EWG: (S)-(E)-(N-leucylproline methylester)-4-(4-morpholinecarbonylphenyl-alanyl)amino-6-phenyl- 2-hexenamide, abbreviated herein as
  • Mu-Phe-HphVAM-Leu-ProOMe (S)-(E)-(N-phenylalanine)-4-(4-morpholine carbonylphenylalanyl)amino-6- phenyl-2-hexenamide, abbreviated herein as Mu-Phe-HphVAM-PheOH; (S)-(E)-3-(4-morpholinecarbonyl-phenylalanylamino)-6-phenyl-2-hexenamide, abbreviated Mu-Phe-HphVAM; and (S)-(E)-Benzyl 4-(4-morpholine-carbonylphenylalanyl)amino-6-phenyl-2-hexenamide, abbreviated Mu-Phe-HphVAMBzl.
  • the cysteine protease inhibitor includes a vinylogous ketone as the EWG, as shown in Formula 7:
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • R 4 ketone moiety
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • ketone moiety as used with regard to R 4 herein is meant groups including, but not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl.
  • alkyl is preferably of 1 to 5 carbon atoms, especially ethyl.
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl.
  • Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof.
  • Aryl preferably is phenyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl. Also included are perfluoro groups, such as perfluoro alkyl, aryl, and aralkyl.
  • (C1-C5)alkyl preferably ethyl
  • (C3-C7)cycloalkyl preferably cyclopentyl or cyclohexyl
  • cysteine protease inhibitors of the present invention include a nitrile group as the EWG, as shown in Formula 8:
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • the cysteine protease inhibitors of the present invention contain a vinylogous sulfoxide as the EWG, as shown in Formula 9:
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • R 5 sulfoxide moiety
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • sulfoxide moiety as used with regard to R 5 herein is meant groups including, but are not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl.
  • alkyl is preferably of 1 to 5 carbon atoms, especially ethyl.
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl.
  • Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof.
  • Aryl preferably is phenyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl. Also included are perfluoro groups such as perfluoro alkyl, aryl, and aralkyl.
  • R 5 Particularly preferred for R 5 are:(1) (c1-C5)alkyl, preferably ethyl; (2) (C3-C7)cycloalkyl, preferably cyclohexyl or cyclopentyl; (3) (C3-C7)cycloalkyl-(C1-C5)alkyl, preferably (C5-C60cyclalkyl-C1alkyl; (4) (C3-C7)cycloalkyl- (C1-C5)alkenyl, preferably (C5-C6)cycloalkyl-C1alkenyl; (5) phenyl; (6) (C7-C12)phenylalkyl, preferably benzyl; (7) aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy
  • the EWG of the cysteine protease inhibitor includes a vinylogous sulfonamide as the EWG, as shown in Formula 10:
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X, Y and Z are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • Q hydrogen, an ester, a peptide residue or an amide moiety; and the A-B linkage is a peptide residue or an isosteric form thereof.
  • amide moiety as used with regard to Q is meant a group including, but not limited to, an NH2, or an NH-alkyl, an NH-cycloalkyl, an NH-cycloalkylalkyl, an NH-aryl, or an NH-aralkyl, or an N-dialkyl,
  • N-dicycloalkyl an N-dicycloalkylalkyl, an N-diaryl, or an N-diaralkyl.
  • alkyl is preferably of 1 to 5 carbon atoms, especially ethyl.
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl moieties thereof.
  • Aryl preferably is phenyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where
  • ester as regards to Q means an oxygen attached to the ester moities previously defined, to form an ester.
  • cysteine protease inhibitors of the present invention include a vinylogous sulfoximine as the EWG, as shown in
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • R 6 and R 7 are sulfoximine moieties
  • the A-B linkage is a peptide residue or an isosteric form thereof.
  • sulfoximine moieties as used with regard to R 6 and R 7 is meant identical or different groups including, but not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl.
  • alkyl is preferably of 1 to 5 carbon atoms, especially ethyl.
  • Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl.
  • Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to
  • Aryl preferably is phenyl.
  • Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl.
  • the optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl.
  • perfluoro groups such as perfluoro aryl, alkyl, and aralkyl groups.
  • R 6 and R 7 are: (1) (C1-C5)alkyl, preferably ethyl; (2) (C3-C7)cycloalkyl, preferably cyclohexyl or cyclopentyl; (3) (C3-C7)cycloalkyl-(C1-C5)alkyl, preferably (C5-C60cyclalkyl-C1alkyl; (4) (C3-C7)cycloalkyl-(C1-C5)alkenyl, preferably (C5-C6)cycloalkyl-C1alkenyl; (5) phenyl; (6) (C7-C12)phenylalkyl, preferably benzyl; (7) aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino,
  • cysteine protease inhibitors of the present invention have the structure shown in Formula 12:
  • R 8 the five or six membered homo- or heterocyclic aromatic rings with at least one substituted EWM, MDG, or DG;
  • R 9 a suitable group as defined below.
  • the R 8 group is an EWG group. It may be a five or six membered homocyclic aromatic ring with at least one substitution group.
  • the substituted group may be an EWM, as defined above, in the case of five membered rings, or an EWM, MDG, or DG as defined above.
  • EWMs that may be substituted onto a five or six membered ring that are preferred are esters, sulfones, carboxylates, amides, phosphonates, ketones, nitriles, nitro compounds, sulfonates, sulfoxides, sulfonamides, sulfinamides, and sulfoximines, as are defined above.
  • MDGs that may be used are the quaternary ammonium salts, NR 3 +, where R may be for example an aryl, alkyl or aralkyl, as well as such meta directing groups as NO 2 , SO 3 H, SO 2 R, SOR, SO 2 NH 2 , SO 2 NHR, SO 2 NHR 2 , SONH 2 , SONHR, SONR 2 , CN, PO 3 H, P(O)(OR) 2 , P(O)OR, OH, COOH, COR, and COOR'.
  • DGs that may be substituted onto a six membered ring are all the halogen atoms, such as F,
  • the R 9 group may be a wide variety of groups. In the preferred embodiment,
  • the R 9 group is a hydrogen atom, or other functionally neutral groups such as methyl groups.
  • the R 9 group is a peptide, such that additional targeting or specificity-enhancing residues are added to the cysteine protease inhibitor.
  • cysteine protease inhibitors of the present invention have a vinylogous five membered heterocyclic aromatic ring with a substituted EWM, as the EWG, as shown in Formula 13:
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • the A-B linkage is a peptide residue or an isosteric form thereof
  • D an oxygen, sulfur, nitrogen, phosphorus or arsenic atom
  • EWM an electron withdrawing moiety
  • the EWM may be any of the electron withdrawing groups as previously defined.
  • cysteine protease inhibitors of the present invention have a vinylogous six membered homocyclic aromatic ring with a substituted EWM, MDG or DG as the EWG, as shown in Formula 14:
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration; the A-B linkage is a peptide residue or an isosteric form thereof;
  • EWM an electron withdrawing moiety
  • MDG a meta directing group
  • cysteine protease inhibitors of the present invention have a vinylogous six membered heterocyclic aromatic ring with a substituted EWM as the EWG, as shown in Formula 15:
  • P hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • the A-B linkage is a peptide residue or an isosteric form thereof
  • T a nitrogen or phosphorus atom
  • EWM an electron withdrawing moiety
  • the EWM may also be attached to the "T" heteroatom.
  • the targeting group and the EWG are linked by a diene bond.
  • diene bond herein is meant a chain of four carbon atoms (C1, C2, C3, and C4) in which C1 and C2 are connected by a double bond, C3 and C4 are connected by a double bond, and C2 and C3 are connected by a single bond.
  • the targeting group is linked to the first carbon of the first carbon-carbon double bond (C1)
  • the EWG is linked to the last carbon of the second carbon-carbon double bond (C4).
  • the two double bonds of the diene are in (E)-(E) configuration, although alternative embodiments utilize (E)-(Z), (Z)-(E), or (E)-(E) configurations.
  • the second order rate constant for inhibition of a cysteine protease with the diene bond cysteine protease inhibitor is at least about 1000 M -1 sec -1 , with alterative embodiments having second order rate constants at least about 10,000 M -1 sec -1 , with the most preferred rate constant being at least about 100,000 M -1 sec -1 .
  • the targeting group and EWG are defined as above.
  • the cysteine protease inhibitor comprises a compound with the formula:
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • A-B is a peptide linkage
  • EWG is an electron withdrawing group.
  • the cysteine protease inhibitors of the present invention comprise a targeting group linked via an alkene bond to two EWGs.
  • the targeting group is linked to one of the carbons of the carbon-carbon double bond, and the two EWGs are linked to the other carbon of the carbon-carbon double bond.
  • the linkage of the targeting group to the alkene bond is as described above for the single EWG embodiment.
  • the linkage of the two EWGs to the alkene bond is similar as for one EWG; that is, the linkage is such that the electron withdrawing properties of the EWGs are exerted on the alkene bond, to allow
  • the two EWGs are different. In an alternative embodiment, the two EWGs are the same.
  • the cysteine protease inhibitor comprises a compound with the formula:
  • P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
  • X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
  • A-B is a peptide linkage
  • EWG is an electron withdrawing group.
  • cysteine protease inhibitors are comprised of a targeting group linked to an alkene bond conjugated with an electron withdrawing group (EWG).
  • EWG electron withdrawing group
  • the second order rate constant for inhibition of a cysteine protease with the inhibitor is at least about 1000 M - 1 sec - 1 .
  • second order rate constant or grammatical equivalents herein is meant the kinetic constant associated with a bimolecular reaction that is dependent on the concentration of two species.
  • the second order rate constants are defined and determined as below.
  • the reaction is divided into two processes.
  • the enzyme and the inhibitor first combine to give an enzyme-inhibitor complex, E ⁇ I.
  • This step is assumed to be rapid and reversible, with no chemical changes taking place; the enzyme and the inhibitor are held together by non-covalent forces.
  • k 1 is the second order rate constant for the formation of the E ⁇ I reversible complex.
  • k 2 is the first order rate constant for the disassociation of the reversible E ⁇ I complex.
  • the chemical processes then occur in a second step with a first order rate constant k irr , which is the constant for the inactivation of the E ⁇ I complex, which is similar to the k cat constant or turnover number.
  • K I k 2 /k 1
  • the second order rate constant of inactivation is k irr /K I .
  • the measurement of the first order rate constant k irr and the equilibrium constant K I proceeds according to techniques well known in the art, as described in the examples. For example, assays are run in the presence of inhibitor and substrate, generally using synthetic chromogenic substrates. Inhibition progress curve analysis using non-linear curve fitting software widely available enables the calculation of the first order rate constant k irr and the equilibrium constant K I .
  • the second order rate constant, k irr /K I is then calculated as follows:
  • K I is a dissociation constant with units of M.
  • second order rate constants are a particularly useful way of quantifying the efficiency of an enzyme with a particular substrate or inhibitor, and are frequently used in the art as such.
  • the efficiency of an inhibitor depends on the second order rate constant and not on either the K I value alone or the k irr value alone.
  • the cysteine protease inhibitors of the present invention have second order rate constants, expressed as k irr /K I , of at least about 1000 M -1 sec -1 .
  • Preferred embodiments have inhibitors that exhibit second order rate constants of at least about 10,000 M -1 sec -1 , with the most preferred embodiments having second order rate constants of at least about 100,000 M -1 sec -1 .
  • the second order rate constants of the preferred embodiment do not exceed the diffusion limit of about 1 ⁇ 10 8 M -1 sec -1.
  • the cysteine protease inhibitors are chiral.
  • the chiral cysteine protease inhibitor is comprised of a targeting group linked to an alkene bond conjugated with an EWG.
  • chiral or grammatical equivalents herein is meant a compound that exhibits dissymetry. That is, the chiral compound is not identical with its mirror image.
  • the compounds of the present invention are pure epimers. Chiral compounds, and particularly chiral cysteine protease inhibitors, are useful in the present invention because biological systems, and enzymes in particular, are stereospecific, preferring the (S) or L-form of amino acids.
  • the chiral cysteine protease inhibitors of the present invention will have amino acid side chains in the (S) or L-configuration, although some inhibitors may utilize amino acid side chains in the (R) or D-configuration.
  • compositions of the present invention are not pure epimers, but are mixtures that contain more than 50% of one epimer. Preferred embodiments have greater than about 70% of one epimer, and the most preferred embodiment has at least about 90% of one epimer.
  • the synthesis of the cysteine protease inhibitors of the present invention proceeds as follows. In general, preparation of the inhibitors described herein requires first that the amino acids from which the inhibitory functionalities are derived, i.e. the targeting amino acids, be converted into t-butoxycarbonyl-protected a-aminoaldehydes, also called N-protected ⁇ -amino aldehydes, as shown in Equation 5 (for example by the method of
  • R an amino acid side chain: alkyl, aryl, aminoalkyl, etc.
  • C is hydrogen or a peptide amino end blocking group
  • Y is any amino acid side chain except glycine (hydrogen), or, when the
  • EWG is a vinylogous ester, phenylalanine (benzyl).
  • EWG is an electron withdrawing group.
  • Boc-AspVSPh may be used as an inhibitor of ICE without further addition of amino acid side chain targeting groups.
  • additional targeting groups in the form of amino acid side chains, are added to the vinylogous cysteine protease inhibitors to form the structure depicted in Formula 1, above.
  • this is done by deprotecting the "P” group and coupling an additional N-protected amino acid, as is well known in the art.
  • the cysteine protease inhibitors of the present invention that contain vinylogous esters as the EWG can be generated by the sequence of reactions shown in Scheme I below:
  • N,O-dimethylhydroxylamine hydrochloride in the presence of triethylamine and dicyclohexylcarbodiimide in dichloromethane.
  • Alternative embodiments treat the Boc-protected amino acids in the presence of triethylamine and the coupling reagent benzotriazol-1-yloxytris
  • N-protected amino acids to form pseudopeptidyl vinylogous esters the cysteine protease inhibitors of this embodiment. Coupling is acheived via mixed anhydride or other peptide coupling reaction sequences known to those skilled in the art.
  • cysteine protease inhibitors of the present invention that contain vinylogous sulfones as the EWG can be generated by the sequence of reactions shown in Scheme II below:
  • the preferred embodiment utilizes Boc-a-amino aldehydes, prepared according to the method of Fehrentz, J-A. and Castro, B.
  • methanephosphonates are synthesized by coupling of the alkali metal anion of sulfones such as methyl phenyl sulfone with diethyl chlorophosphate.
  • sulfones such as methyl phenyl sulfone
  • diethyl chlorophosphate diethyl chlorophosphate
  • Alternative embodiments utilize m-chloroperbenzoic acid oxidation of commercially available sulfides such as diethylphosphonomethyl methyl sulfide (Aldrich Chemical Co.).
  • the vinylogous sulfones are then deprotected with hydrogen chloride in dioxane, and are coupled with N-protected amino acids to form pseudopeptidyl vinylogous sulfones, using techniques well known in the art.
  • cysteine protease inhibitors of the present invention that contain vinylogous phosphonates as the EWG may be synthesized by the sequence of reactions shown in Scheme IV:
  • Boc-a-amino aldehydes prepared according to the method of Fehrentz, J-A. and Castro, B. (Synthesis, (1983), with the sodium anion of
  • methylenediphosphonates for example tetraethyl methylenediphosphonate.
  • the vinylogous phosphonate derivatives are then deprotected with hydrogen chloride in dioxane, and coupled with N-protected amino acids to form pseudopeptidyl vinylogous phosphonates using techniques known to those skilled in the art.
  • the vinylogous amides and peptide derivatives of this invention can be generated by the sequence of reactions shown in Scheme V.
  • Boc-protected a-amino aldehyde Further elongation of the peptide sequence is concluded with fluoride-assisted deprotection of the SET moiety to afford the vinylogous amide.
  • the fluoride-cleavable silyethyl (SET) esters are used.
  • saponification conditions which cause product mixtures resulting from both ester hydrolysis and 1,4-addition of hydroxide to the vinylogous amide at high pH, are avoided.
  • the SET protection scheme therefore permits clean, smooth preparation of peptide sequences prior to the key
  • cysteine protease inhibitors of the present invention that contain vinylogous ketones, nitriles, sulfoxides, sulfonamides, sulfinamides, sulfonates and sulfoximines as the EWG may be synthesized as follows using the general scheme outlined in Scheme VI:
  • the aldehyde portion is synthesized as outlined above.
  • the phosphonate is synthesized by treatment of the enolate anion of methyl or substituted methyl ketones, such as acetone or acetophenone, with diethyl chlorophosphonate.
  • the enolate anion is generated, for example, by treatment of a tetrahydrofuran solution of diisopropylamine with butyllithium, followed by addition of the ketone to the lithium diisopropylamide (LDA) solution (H.O. House, Modern Synthetic
  • Synthesis of ⁇ , ⁇ -unsaturated sulfoxides is performed by means of the Wadsworth-Emmons reaction between Boc- ⁇ -amino aldehydes and the appropriate phosphonate.
  • the aldehyde portion is synthesized as outlined above.
  • the phosphonate is synthesized by treatment of the anion of methyl sulfoxides with diethyl chlorophosphate. The anion is generated by addition of BuLi to diisopropylamine, followed by addition of the methyl sulfoxide.
  • Synthesis of ⁇ , ⁇ -unsaturated sulfonamides is performed by means of the Wadsworth-Emmons reaction between Boc- ⁇ -amino aldehydes and the appropriate phosphonate.
  • the aldehyde portion is synthesized as outlined above.
  • the phosphonate is synthesized, for instances, by a method such as the following: a) diethylphosphoryl methanesulfonates, as prepared by the method of Carretero and Ghosez (Tetrahedron Lett., 28:1104-1108 (1987)), are converted to sulf onyl chlorides by treatment with phosphorus pentachloride (M. Quaedvlieg, in "Methoden der Organische Chemic
  • Synthesis of ⁇ , ⁇ -unsaturated sulfinamides is performed by means of the Wadsworth-Emmons reaction between Boc- ⁇ -amino aldehydes and the appropriate phosphonate.
  • the aldehyde portion is synthesized as outlined above.
  • the phosphonate may be synthesized using one of the following methods. Treatment of methyl dialkyl phosphonates such as the commercially available methyl diethyl phosphonate (Aldrich), with thionyl chloride in the presence of aluminum chloride gives the dialkylphosphoryl methanesulfinyl chloride (Vennstra et al., Synthesis (1975) 519. See also
  • Synthesis of ⁇ , ⁇ -unsaturated sulfoximines is performed by means of the Wadsworth-Emmons reaction between Boc- ⁇ -amino aldehydes and the appropriate phosphonate.
  • the aldehyde portion is synthesized as outlined above.
  • the phosphonate may be synthesized in several ways. For example, N-alkyl or N-aryl phenyl methyl sulfoximines are made by the methods described by Johnson, in "Comprehensive Organic Chemistry (Pergamon Press), supra, Chapter 11.11.
  • the lithium anion of compounds such as N-alkyl phenyl methyl sulfoximine is prepared by the treatment of the neutral compound with buthyl lithium in THF (Cram et al., J. Amer. Chem. Soc. 92:7369 (1970)). Reaction of this lithium anion with dialkyl chlorophosphates such as the commercially available diethyl chlorophosphate (Aldrich) results in the Wadsworth-Emmons reagent necessary for synthesis of the sulfoximine compounds.
  • ⁇ , ⁇ -unsaturated sulfonates is performed by means of the Wadsworth-Emmons reaction between Boc- ⁇ -amino aldehydes and the appropriate phosphonate, for instance diethylphosphoryl methanesulfonate.
  • the phosphonate may be synthesized as follows. The anion of methyl dialkyl phosphonates such as the commercially available methyl diethyl phosphonate (Aldrich) is generated by treatment of said phosphonate with a strong base such as LDA.
  • the resulting anion is sulfonated with sulfur trioxide/trimethylamine complex (Carreto et al., Tetrahedron Lett., 28:1104-1108 (1987)) to form diethylphosphoryl methanesulfonate, which is capable of reacting in the Wadsworth-Emmons procedure with aldehydes to form ⁇ , ⁇ -unsaturated sulfonates.
  • Synthesis of ⁇ , ⁇ -unsaturated nitro compounds is performed by means of the Wadsworth-Emmons reaction between Boc- ⁇ -amino aldehydes and the appropriate prosphonate.
  • the phosphonate is synthesized by treatment of the enolate anion of nitromethane with diethyl chlorophosphate.
  • the enolate anion is generated, for example, by treatment of a tetrahydrofuran solution of d ⁇ sopropylamine with butyllithium, followed by addition of nitromethane to the lithium diisopropylamide (LDA) solution (House, supra). Following formation of the enolate, diethyl chlorophosphate is added.
  • the Wadsworth-Emmons reagent forms as a consequence of coupling of the nitromethane anion with diethyl chlorophosphate.
  • R 8 the five or six homo- or heterocyclic aromatic rings with at least one substituted EWM, MDG, or DG;
  • R 9 a suitable group as defined above.
  • the chloride compounds containing R 8 and R 9 groups are generally made using commercially available reagents and products using techniques well known in the art.
  • the reaction generally produces a mixture of cis and trans configurations.
  • Cysteine protease inhibitors containing a diene bond instead of a single alkene bond are made using the same general synthetic scheme as outlined above, by repeating the reaction, as shown below in Scheme VIII:
  • the cysteine protease inhibitors which contain two EWGs linked to one of the carbons of the alkene bond may be synthesized using, for example, the methods disclosed in Brillon et al., J. Org. Chem. 57:1838-1842 (1992), hereby expressly incorporated by reference.
  • the cysteine protease inhibitors of the present invention are further purified if necessary after synthesis, for example to remove unreacted materials.
  • the cysteine protease inhibitors of the present invention may be crystallized, or passed through silica
  • cysteine protease inhibitors of the present invention synthesized through the use of the Wittig reaction may be further purified to isolate either the cis or trans configuration.
  • the techniques outlined above may be used.
  • cysteine protease inhibitors of the present invention may be easily screened for their inhibitory effect.
  • the inhibitor is first tested against the cysteine protease for that the targeting group of the inhibitor was chosen, as outlined above.
  • many cysteine proteases and their corresponding chromogenic substrates are commercially available. Thus, a variety of cysteine proteases are routinely assayed with synthetic
  • chromogenic substrates in the presence and absence of the cysteine protease inhibitor to confirm the inhibitory action of the compound, using techniques well known in the art.
  • the effective inhibitors are then subjected to kinetic analysis to calculate the k irr and K I values, and the second order rate constants determined. This is done using techniques well known in the art; for example, progress curve analysis using non-linear curve fitting software can be done to determine the first order rate constants.
  • Such software is sold under such tradenames as Sigma Plot (Jandel Scientific Corp .) and Statview (Abacus Concepts, Inc.).
  • a compound inhibits at least one cysteine protease, it is a cysteine protease inhibitor for the purposes of the invention.
  • Preferred embodiments have inhibitors that exhibit the correct kinetic parameters against at least the targeted cysteine protease.
  • cysteine protease is not commercially available in a purified form.
  • the cysteine protease inhibitors of the present invention may also be assayed for efficacy using biological assays.
  • the inhibitors may be added to cells or tissues that contain cysteine proteases, and the biological effects measured.
  • the cysteine protease inhibitors of the present invention are synthesized or modified such that the in vivo and in vitro proteolytic degradation of the inhibitors is reduced or prevented. Generally, this is done through the incorporation of synthetic amino acids, derivatives, or substituents into the cysteine protease inhibitor. Preferably, only one non-naturally occurring amino acid or amino acid side chain is incorporated into the cysteine protease inhibitor, such that the targeting of the inhibitor to the enzyme is not significantly affected. However, some embodiments that use longer cysteine protease inhibitors containing a number of targeting residues may tolerate more than one synthetic derivative.
  • non-naturally occurring amino acid substituents may be designed to mimic the binding of the naturally occurring side chain to the enzyme, such that more than one synthetic substituent is tolerated.
  • the resistance of the modified cysteine protease inhibitors may be tested against a variety of known commercially available proteases in vitro to determine their proteolytic stability. Promising candidates may then be routinely screened in animal models, for example using labelled inhibitors, to determine the in vivo stability and efficacy.
  • the cysteine protease inhibitors of the present invention are labelled.
  • a labelled cysteine protease inhibitor herein is meant a cysteine protease inhibitor that has at least one element, isotope or chemical compound attached to enable the detection of the cysteine protease inhibitor or the cysteine protease inhibitor irreversible bound to a cysteine protease.
  • labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes.
  • the labels may be incorporated into the cysteine protease inhibitor at any position.
  • a label may be attached as the "P" group in Formula 1.
  • useful labels include 14 C, 3 H, biotin, and fluorescent labels as are well known in the art.
  • phosphonates are provided. These chiral vinylogous phosphonates are derived from ⁇ -amino acids; that is, ⁇ -amino acids are used to generate the ⁇ -amino aldehydes used in the synthesis.
  • This novel class of compounds may be used in a preferred embodiment as cysteine protease inhibitors.
  • compositions comprising chirally pure vinylogous sulfones derived from ⁇ -amino acids are provided. This novel class of compounds may be used in a preferred embodiment as cysteine protease inhibitors.
  • cysteine protease inhibitors of the present invention are irreversibly bound to a cysteine protease. This is accomplished using ordinary techniques, and will normally require contacting or adding the cysteine protease inhibitor to the sample of the cysteine protease to be inhibited.
  • the cysteine protease inhibitors of the present invention are stoichiometric inhibitors; that is, a single inhibitor molecule will inhibit a single enzyme molecule. Thus in the preferred embodiment, an excess of inhibitor is added to ensure that all or most of the protease is inhibited.
  • cysteine protease inhibitor is labelled, such that the presence of a cysteine protease is detected after the excess inhibitor is removed. This may be done for example in a diagnostic assay for the detection or quantification of cysteine proteases in a sample, for example, in blood, lymph, saliva, skin or other tissue samples, in addition to bacterial, fungal, plant, yeast, viral or mammalian cell cultures.
  • cysteine protease inhibitors of the present invention are administered to a patient to treat cysteine protease-associated disorders.
  • cysteine protease-associated disorders or grammatical equivalents herein is meant pathological conditions associated with cysteine proteases.
  • the condition is associated with increased levels of cysteine proteases; for example, arthritis, muscular dystrophy, inflammation, tumor invasion, and glomerulonephritis are all associated with increased levels of cysteine proteases.
  • the condition is associated with the appearance of an extracellular cysteine protease activity that is not present in normal tissue.
  • a cysteine protease is associated with the ability of a pathogen, such as a virus, to infect or replicate in the host organism.
  • cysteine protease associated disorders or conditions include, but are not limited to, arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, Alzheimer's disease, disorders associated with autoimmune system breakdowns, periodontal disease, cancer metastasis, trauma, inflammation, gingivitis, leishmaniasis, filariasis, and other bacterial and parasite-borne infections, and others outlined above.
  • ICE interleukin 1 ⁇ converting enzyme
  • a therapeutically effective dose of a cysteine protease inhibitor is administered to a patient.
  • therapeutically effective dose herein is meant a dose that produces the effects for that it is administered. The exact dose will depend on the disorder to be treated and the amount of cysteine protease to be inhibited, and will be ascertainable by one skilled in the art using known techniques.
  • the cysteine protease inhibitors of the present invention are administered at about 1 to about 1000 mg per day. For example, as outlined above, some disorders are associated with increased levels of cysteine proteases. Due to the 1:1 stoichiometry of the inhibition reaction, the dose to be administered will be directly related to the amount of the excess cysteine protease.
  • a "patient” for the purposes of the present invention includes both humans and other animals and organisms.
  • the methods are applicable to both human therapy and veterinary applications.
  • the veterinary applications include, but are not limited to, canine, bovine, feline, porcine, equine, and ovine animals, as well as other domesticated animals including reptiles, such as iguanas, turtles and snakes, birds such as finches and members of the parrot family, rabbits, rodents such as rats, mice, guinea pigs and hamsters, amphibians, and fish.
  • Valuable non-domesticated animals such as zoo animals, may also be treated.
  • the patient is a mammal, and in the most preferred embodiment the patient is human.
  • cysteine protease inhibitors of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally,
  • cysteine protease inhibitors may be directly applied as a solution or spray.
  • compositions of the present invention comprise a cysteine protease inhibitor in a form suitable for administration to a patient.
  • the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
  • organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid,
  • “Pharmaceutically acceptable base addition salts” include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
  • compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.
  • carrier proteins such as serum albumin
  • buffers such as buffers
  • fillers such as microcrystalline cellulose, lactose, corn and other starches
  • binding agents such as microcrystalline cellulose, lactose, corn
  • Xaa 1 amino acid at P1 position relative to active site of the enzyme
  • Xaa 2 amino acid at P2 position relative to active site of the enzyme
  • Xaa 1 amino acid at P1' position relative to active site of the enzyme
  • VSMe vinyl sulfone with methyl terminus
  • VAM-Xaa 1 vinyl amide coupled to amino acid 3;
  • VEOEt vinyl ethyl ester
  • VPEt vinyl phosphonate
  • VSPh vinyl sulfone with phenyl terminus
  • Hph homophenylalanine
  • Xaa 2 Phe (phenylalanine)
  • Xaa 1 Lys(Z) (lysine, protected as its carbobenzyloxy urethane), transformed to the phenyl vinyl sulfone according to the procedure described in Example 5 and depicted in Scheme 2.
  • Morpholinecarbonylphenylalanine (2.74 g, 9.82 mmol, prepared according to the method described in Esser, R. et.al, Arthritis & Rheumatism (1994), 0000) was dissolved in THF (50 mL) at -10°C. 4-methylmorpholine (1.08 mL, 9.82 mmol) was added, followed by isobutyl chloroformate (1.27 mL, 9.82 mmol).
  • NMR spectra were recorded on a Varian Gemini 300 MHz instrument. All 1 H NMR data of this and subsequent examples are reported as delta values in parts per million relative to internal tetramethylsilane, peak assignments in boldface. The following abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; br, broad. An asterisk (*) implies that a signal is obscured or buried under another resonance.
  • Boc-Arg(Mtr)H according to the method of Fehrentz and Lauda, supra.
  • THF triethyl phosphonoacetate
  • NaH 0.145 g of a 60% mineral oil dispersion, 3.61 mmol
  • a solution of Boc-Arg(Mtr)H (1.5 g, 3.29 mmol) in THF (5 mL) was added.
  • the mixture was stirred for 45 minutes. 1H HCl (30 mL) was added.
  • Boc-HphH (1.72 g, 6.51 mmol) in THF (10 mL) was added. The mixture was stirred for 1 hour. 1M HCl (30 mL) was added. The product was extracted into ethyl acetate (50 mL), washed with saturated aqueous
  • Termini (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-1-butene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene, and (S)-(E)-3-(tert-butoxycarbonylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene were made as above, and tested against various cysteine proteases as shown below.
  • Boc-valinal (0.876 g, 4.35 mmol) prepared according to the method of Fehrentz and Castro, supra), was added as a solution in THF (5 mL). The mixture was stirred for 30 minutes. 1M HCl (30 mL) was added. The product was extracted with ethyl acetate (50 mL), washed with saturated aqueous NaHCO 3 (30 mL), brine (20 mL), dried over MgSO 4 , filtered, and evaporated to dryness to afford the product in quantitative yield.
  • the melting point of the Boc-ValVSPh was 101-103°C.
  • Mu-Phe-HphVSPh -5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Phe-HphVSPh, was as follows. To a solution of PSMP (1.94 g, 6.64 mmol) in THF (30 mL) at 0oC was added sodium hydride (0.27 g of a 60% mineral oil dispersion, 6.64 mmol). After 15 minutes, a solution of Boc-HphH (1.59 g, 8.94 mmol) in THF (5 mL) was added. The mixture was stirred for 30 minutes. 1M HCl (20 mL) was added.
  • Boc-HphH of (S)-(E)-3-amino-5-phenyl-1-phenylsulfonyl-1-pentene hydrochloride (HCl.HphVSPh).
  • Mu-Phe-HphVA Synthesis of (S)-(E)-4-(4-morpholinecarbonyl-phenylalanyl)amino-6-phenyl-2-hexenoic acid, abbreviated Mu-Phe-HphVA, was as follows. To a solution of Mu-Phe-VEOEt (see Example 1; 1.96 g, 4.15 mmol) in ethanol (7 mL) was added 1M NaOH (9.5 mL) over 3 hours. The solvents were evaporated. Water (30 mL) was added.
  • Mu-Phe-HphVPEt was as follows. To a solution of tetraethyl
  • the melting point of the product was determined to be 53-55°C.
  • Mu-Phe-HphVAM-Leu-ProOMe was as follows. Leucylproline methyl ester hydrochloride (HCl.Leu-Pro-OMe) was prepared by mixed anhydride coupling of Boc-leucine and proline methyl ester hydrochloride, followed by Hcl-mediated deprotection of the N-terminal Boc group. Mu-Phe-HphVA (from Example 6, 1.42 g, 3.21 mmol) was dissolved in THF (15 mL) and cooled to -10°C. To this solution was added 4-methylmorpholine (0.354 mL, 3.21 mmol), followed by isobutyl chloroformate (0.417 mL, 3.21 mmol). The mixed anhydride was stirred for 5 minutes, whereupon
  • the melting point of the product was determined to be 97-100°C.
  • Mu-Phe-HphVAM-PheOH proceeded as follows. Boc-PheOH (5.00 g, 18.85 mmol), trimethylsilylethanol (2.70 mL, 18.85 mmol), and
  • Boc-PheOSET tert-butoxycarbonylphenylalanine, silylethyl ester
  • Boc-PheOSET from the previous step. The mixture was stirred for 90 minutes. The solvents were evaporated, giving a waxy solid, phenylalanine silylethyl ester hydrochloride (HCl.PheOSET).
  • Diethyl phosphonoacetic acid was prepared in quantitative yield by saponification of triethyl phosphonoacetate in ethanol, in the presence of 1.1 equivalents of 1M NaOH. To a solution of DEPA (1.62 g, 8.28 mmol),
  • the melting point was determined to be 95-98°C.
  • TsOH.Asp(Ot-Bu)VSMe vinylogous sulfone (S)-(E)-3-amino-4-tert-butoxycarbonyl-1-methylsulfonyl-1-butene
  • TsOH.Asp(Ot-Bu)VSMe was synthesized as follows. A solution of anhydrous p-toluenesulfonic acid (0.95 g, 5.58 mmol) (commercially available as the hydrate from Aldrich) in 1 ml ether was added to a solution of Boc-Asp(Ot-Bu)VSME (0.41 g, 1.17 mmol) in 1:1 dichloromethane/ether (4 ml). The mixture was stirred at room temperature overnight.
  • Boc-Asp(Ot-Bu)-VSPh was as follows. Sodium hydride (0.489 g of a 60% mineral oil dispersion, 12.23 mmol) was added to a solution of PMSP (3.58 g, 12.23 mmol) in 50 mL of THF at 0°C. The mixture was stirred for 15 minutes. A solution of Boc-AspH( ⁇ -Ot-Bu), prepared as described above (3.04 gm, 11.12 mmol) in 10 mls THF was added.
  • HCl.AspVSPh (S)-(E)-3-amino-4-hycroxylcarbonyl-1-phenylsulfonyl-1-butene-p-toluenesulfonate, abbreviated HCl.AspVSPh was as follows. To a solution fo Boc-Asp(Ot-Bu)VSPh (0.32g, 0.778 mmol) in 2 mls ether was added 2 mis of 4.Q M HCl in dioxane (Aldrich). The mixture was stirred at room temperature overnight. 50 mls ether was added.
  • ⁇ , ⁇ -unsaturated sulfones [EWG'S] can be prepared as ICE inhibitors bearing Asp as the P, active site side chain moiety.
  • Mu-Leu-HphVSPh (S)-(E)-3-(4-morpholine-carbonylleucyl) amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Leu-HphVSPh, was as follows. Preparation of Mu-Leu-Hph was achieved by coupling of HCl.HphVSPh (described in the preparation of Mu-Phe-HphVSPh) with leucine morpholine urea (Mu-LeuOH).
  • Mu-LeuOH was prepared in two steps, namely by treating the leucine benzyl ester p-toluenesulfonate (Bachem) with 4-morpholine chloride (Aldrich) in the presence of triethylamine (Aldrich) to give Mu-LeuOBzl in 99% yield. Hydrogenolysis over 5%
  • Cathepsin B from human placenta obtained from Sigma, was approximately 10 nM in the assay.
  • the assay buffer contained 50 mM phosphate at pH 6.2, 2.5 mM dithiothreitol (DTT), and 2.5 mM ethylenediaminetetraacetic acid (EDTA).
  • the substrate for cathepsin B was 50 ⁇ M Z-Arg-Arg-AMC (carbobenzyloxyarginylarginylaminomethylcoumarin).
  • the assays were initiated at 25°C by addition of enzyme to 2 mL of assay buffer containing the substrate and the various inhibitors (30-0.001 ( ⁇ M).
  • the assay buffer contained 50 mM phosphate at pH 6.2, 2.5 mM dithiothreitol (DTT), and 2.5 mM ethylenediaminetetraacetic acid (EDTA).
  • the substrate for cathepsin L was 5 ⁇ M Z-Phe-Arg-AMC (carbobenzyloxy phenylalanylarginylaminomethylcoumarin).
  • the assays were initiated at 25°C by addition of enzyme to 2 mL of assay buffer containing the substrate and the various inhibitors (30-0.001 ⁇ M).
  • the substrate for cathepsin S was 10 ⁇ M Z-Val-Val-Arg- AMC (carbobenzyloxyvalinylvalinylarginylaminomethylcoumarin).
  • the assays were initiated at 25°C by addition of enzyme to 2 mL of assay buffer containing the substrate and the various inhibitors (30-0.001 ⁇ M).
  • the increase in fluorescence at 460 nm with excitation at 380 nm was followed with time.
  • Inactivation of cathepsin S was indicated by a downward curve in the increase in fluorescence with time.
  • the enzymatic production of free AMC was linear throughout the time course of inactivation examined. Data points were collected over at least 3 half-times of inactivation.
  • the inhibition progress curves were analyzed using non-linear curve fitting software to compute the k obs values. Approximate second-order inactivation constants (k obs /[I]) were calculated for all compounds. For selected inhibitors, plots of 1/[I] vs. 1/k obs yielded the true constants k irr , K I , and k irr /K I , and were corrected for the presence of substrate by dividing K I (app.) by ⁇ 1+[S]/Km ⁇ .
  • Boc-Phe-Hph-VNS Synthesis of Boc-phenylalanyl-homophenylalanyl-p-nitrostyryl, abbreviated herein as Boc-Phe-Hph-VNS, was as follows. Triphenylphoshine (10 gm, 38.1 mmmol) and 4-chloro-p-nitrophenyl (6.54 g, 38.1 mmol) were dissolved in 200 ml of THF and heated at reflux for 2 days. The white solid was filtered and washed with 200 ml diethyl ether and placed in vacuo for 16 hours.
  • Boc-homophenylalanyl-p-nitrostyryl was dissolved in 10 ml of HCl in dioxane (4 M) and left to stir under a drying tube for 30 minutes and then concentrated to a yellow foam.
  • 0.29 g (0.98 mmol) Boc-phenylalanine was dissolved in 50 ml of THF and
  • the reaction was then concentrated and then diluted with 200 ml of CH 2 Cl 2 and washed with 200 ml of 1 M HCl and 200 ml of saturated aqueous NaHCO 3 , dried over K 2 CO 3 , filtered and concentrated to dryness.
  • the product was dissolved in 10 ml EtOAc and diluted with 20 ml of diethyl ether, and a white solid was filtered and dried in vacuo.
  • the cysteine protease inhibitor made in Example 15 Boc-phyenylalanylhomophenylalanylvinyl-p-nitrostyryl, was tested against cathepsin S, as outlined in Example 12.
  • the inhibitor showed a k obs /[I] value of 40,100 M- 1 sec -1 .
  • N-fluorodiphenylsulfonimide (8.73 g, 27.69 mmol) was added as a solid. The mixture was stirred at room temperature overnight.
  • the fluorinated Wadsworth-Emmons reagent, diethylphosphonylphenylsulfonylfluoromethane (PSMP-F) was isolated by partitioning between ethyl acetate (100 mL) and 1M HCl (100 mL). The organic phase was washed with saturated aqueous sodium bicarbonate (100 mL), brine (50 mL), dried over MgSO 4 , filtered, and the solvent was removed under reduced pressure.
  • the following table summarizes the comparative IC 50 values for selected cysteine protease inhibitors against the human malarial parasite Plasmodium falciparum and the mouse malarial parasite Plasmodium vinckei.
  • the substrate used to measure in vitro protease activity was Z-Phe-Arg-AMC.
  • mice Female Lewis rats (5/group), 5 weeks old, were given intradermal injection into the base of the tail of Mycobacterium butyricum in 0.1 ml of light mineral oil.
  • the animals were provided Teklad (4%) rat chow mixed with (treated groups) or without compound (control group) and water ad libilum.
  • the compounds used were Mu-Phe-HphVSPh, Mu-Leu-HphVSPh, Mu-Tyr-HphVSPh, Mu-Phe-Lys( ⁇ -Z)VSPh,Mu-Phe-LysVSPh•HBr.
  • the compounds were given to three groups at 3, 10, and 30 mg/kg/day, respectively.
  • Mu-Phe-HphVSPh showed a dose dependent beneficial effect on all scores.
  • the high dose of Mu-Leu-HphVSPh also showed a reduction in bone and cartilage destruction.
  • Mu-Leu-HphVSPh and Mu-Phe-LysVSPh•HBr were evaluated for their effects on the growth of P. carinii in vitro, according to the procedure of M. S. Bartlett et al. [ Antimicrotubule Benzimidazoles Inhibit In Vitro Growth of P. carinii,
  • Mu-Leu-HphVSPh and Mu-Phe-LysVSPh•HBr (10 mM each) inhibited the growth of P. carinii 64% and 50% respectively.
  • Irradiated J774 cells were infected with T. cruzi and simultaneously treated with 20 mM of peptidyl vinyl derivatives for 5 days; thereafter without inhibitor.
  • the primary culture HF66 cells were inhibited only 10% by these compounds at the same concentration.
  • the reaction conditions were 50 mM Tris, pH 7.5, 5 mM CaCl 2 , 2.5 mM DTT, assayed at 25°C.
  • the substrate was 100 ⁇ M Suc-Leu-Tyr-AMC. The results are shown in Table 6.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

Irreversible cysteine protease inhibitors based upon an alkene bond being conjugated to an electron withdrawing group are disclosed. The inhibitor structure also provides a targeting peptide which is specific for different cysteine proteases. The method of making the inhibitors, and methods of using the inhibitors to inhibit cysteine proteases and for therapy are disclosed.

Description

"Irreversible Cysteine Protease Inhibitors Containing Vinyl Groups Conjugated to Electron Withdrawing Groups" FIELD OF THE INVENTION
The invention relates to novel cysteine protease inhibitors. The inhibitors
are specific to cysteine proteases and do not inhibit serine, aspartyl or zinc protease.
BACKGROUND OF THE INVENTION
Cysteine or thiol proteases contain a cysteine residue at the active site
responsible for proteolysis. Since cysteine proteases have been implicated in a number of diseases, including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, and other parasite-borne
infections, methods for selectively and irreversibly inactivating them provide opportunities for new drug candidates. See, for example, Meijers, M.H.M.
et al., Agents Actions (1993), 39 (Special Conference Issue), C219;
Machleidt, W. et al, Fibrinolysis (1992), 6 Suppl. 4, 125; Sloane, B.F. et al.,
Biomed. Biochim. Acta (1991), 50, 549; Duffy, M.J., Clin. Exp. Metastasis
(1992), 10, 145; Rosenthal, P.J., Wollish, W.S., Palmer, J.T., Rasnick, D., J.
Clin. Investigations (1991), 88, 1467; Baricos, W.H. et al, Arch. Biochem.
Biophys. (1991), 288, 468; Thornberry, N.A. et al., Nature (1992), 356, 768.
Low molecular weight inhibitors of cysteine proteases have been described by Rich, Proteinase Inhibitors (Chapter 4, "Inhibitors of Cysteine Proteinases"), Elsevier Science Publishers (1986). Such inhibitors include peptide aldehydes, which form hemithioacetals with the cysteine of the protease active site. The disadvantage of aldehydes is their in vivo and chemical instabilities. Aldehydes have been transformed into α,β-unsaturated esters and sulfones by means of the Wadsworth-Emmons-Horner modification of the Wittig reaction (Wadsworth, W.S. and Emmons, W.D. (J. Am. Chem. Soc. (1961), 83, 1733: Equation 1).
Figure imgf000004_0001
where R = alkyl, aryl, etc.
EWG = COOEt, SO2Me, etc. α,β-unsaturated esters (Hanzlik et al., J. Med. Chem., 27(6):711-712 (1984), Thompson et al., J. Med. Chem. 29:104-111 (1986), Liu et al., J. Med. Chem., 35(6): 1067 (1992)) and an α,β-unsaturated sulfones (Thompson et al., supra, Liu et al., supra) were made using this method and tested as inhibitors of two cysteine proteases, papain and dipeptidyl amino-peptidase I (also called cathepsin C). However, the inhibition of papain by these α,β- unsaturated compounds showed poor inhibition, evidenced by second order rate constants from less than 1 M-1sec-1 to less than 70 M-1sec-1 for the α,β- unsaturated esters, and from less than 20 M-1sec-1 to less than 60 M-1sec-1 for the sulfone. In addition, this chemistry has not been demonstrated with derivatives of α-amino acids other than those corresponding to glycine, or in the case of the ester, phenylalanine. Thus the chirality of these compounds is non-existent for the glycine derivatives and unclear for the phenylalanine derivatives. This is significant since inhibition of an enzyme generally requires a chiral compound.
Additional methods for selectively and irreversibly inhibiting cysteine proteases have relied upon alkylation by peptide α-fluoromethyl ketones (Rasnick, D., Anal. Biochem. (1985), 149, 416), diazomethylketones (Kirschke, H., Shaw, E. Biochem. Biphys. Res. Commun. (1981), 101, 454), acyloxymethyl ketones (Krantz, A. et al., Biochemistry, (1991), 30, 4678; Krantz, A. et al., U.S. Patent 5,055,451, issued October 8, 1991), and ketosulfonium salts (Walker, B., Shaw, E., Fed. Proc. Fed. Am. Soc. Exp. Biol., (1985), 44, 1433). The proposed mechanism of inactivation relies upon irreversible inactivation of the active site thiol group via alkylation, as depicted in Equation 2.
Figure imgf000005_0001
where
PG= protecting group
R1, R2 = amino acid side chains X = Cl, F, N2, OC(O)R, (+)S(CH3)3
Other families of cysteine protease inhibitors include epoxysuccinyl peptides, including E-64 and its analogs (Hanada, K. et al., Agric. Biol. Chem (1978), 42, 523; Sumiya, S. et al., Chem. Pharm. Bull. ((1992), 40, 299 Gour-Salin, B.J. et al., J. Med. Chem., (1993), 36, 720), α-dicarbonyl compounds, reviewed by Mehdi, S., Bioorganic Chemistry, (1993), 21, 249, and
N-peptidyl-O-acyl hydroxamates (Bromme, D., Neumann, U., Kirschke, H., Demuth, H-U., Biochim. Biophys. Acta, (1993), 1202, 271.
SUMMARY OF THE INVENTION It is an object of the present invention to provide novel cysteine protease inhibitors that function irreversibly, resulting in large second order rate constants for the overall inhibition reaction. Accordingly, it is an object to provide these novel cysteine protease inhibitors that can be used to inhibit cysteine proteases selectively, and are thus useful in a variety of therapeutic applications.
In accordance with the foregoing objects, the present invention provides cysteine protease inhibitors comprising a targeting group linked to an alkene bond electronically conjugated with an electron withdrawing group (EWG). The second order rate constant for inhibition of a cysteine protease with the inhibitor, expressed as kirr/KI, preferably is at least about 1000 M-1sec-1.
An additional aspect of the present invention is to provide chiral cysteine protease inhibitors comprising a targeting group linked to an alkene bond conjugated with an EWG. Additionally provided are these chiral cysteine protease inhibitors wherein the second order rate constant for inhibition of a cysteine protease with the inhibitor, expressed as kirr/KI, is at least about 1000 M-1sec-1.
In a further aspect of the present invention, a cysteine protease inhibitor is provided with the formula:
Figure imgf000007_0001
In this formula, P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group or a label. X and Y are amino side chains, with either (R) or (S) configuration. The A-B linkage is a peptide or peptidomimetic linkage, and EWG is an electron withdrawing group. Also provided are cysteine protease inhibitors wherein the second order rate constant for inhibition of a cysteine protease with the inhibitor, expressed as kirr/KI, is at least about 1000 M-1sec"1.
Also provided are labelled cysteine protease inhibitors, and cysteine protease inhibitors that contain additional targeting groups linked to the EWG.
In a further aspect of the present invention, cysteine protease inhibitors are provided wherein the EWG is a moiety or group that will work in the Wadsworth-Emmons reaction for olefin synthesis when directly attached to a methylenephosphonate species. Thus the EWG group, when functionally included as a component of the cysteine protease inhibitor, may be selected from the group consisting of vinylogous esters, vinylogous sulfones, vinylogous carboxylates, vinylogous amides, vinylogous phosphonates, vinylogous ketones, vinylogous nitriles, vinylogous sulfoxides, vinylogous sulfonamides, vinylogous sulfinamides, vinylogous sulfonates and vinylogous sulfoximines.
An additional aspect of the present invention relates to methods for making a cysteine protease inhibitor. The method comprises: a) a protected α-amino aldehyde is coupled with a Wadsworth-Emmons reagent containing an EWG to form a cysteine protease inhibitor intermediate; b) the cysteine protease inhibitor intermediate is then deprotected at the N-terminus; and c) the deprotected cysteine protease inhibitor intermediate is then coupled to N-terminally protected amino acids.
The invention also includes a method for inhibiting a cysteine protease, comprising irreversibly binding an cysteine protease inhibitor to the protease. The invention further provides a method of treating cysteine protease-associated disorders, comprising administering a therapeutically effective dose of a cysteine protease inhibitor to a patient. Thus, pharmaceutical compositions of cysteine protease inhibitors are also provided.
Additionally, the invention provides methods of detecting a cysteine protease in a sample, comprising assaying the sample in the presence and absence of a cysteine protease inhibitor of the present invention and calculating the difference in activity due to the protease. Further provided are cysteine protease inhibitors with the formula:
Figure imgf000009_0001
In this formula, P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group, or a label. X and
Y are amino side chains, with either (R) or (S) configuration. The A-B linkage is a peptide or peptidomimetic linkage, and EWG is an electron withdrawing group.
An additional aspect of the invention provides cysteine protease inhibitors with the formula:
Figure imgf000009_0002
In this formula, P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group or a label. X and Y are amino side chains, with either (R) or (S) configuration. The A-B linkage is a peptide or peptidomimetic linkage, and EWG is an electron withdrawing group. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to novel cysteine protease inhibitors. It is believed that the inhibitors function to inactivate cysteine proteases based on the following mechanism:
Figure imgf000010_0001
It is believed that the enzyme is thus irreversibly inhibited by 1,4 conjugate addition of the nucleophilic thiol group. This mechanism is thus
distinguished from the alkylation mechanism depicted in Equation 2.
This mechanism permits specificity of the enzyme inhibitors for cysteine proteases over serine, aspartyl, and zinc proteases, by virtue of a different mechanism. The mechanisms of serine protease action have been described by Walsh, C, in "Enzymatic Reaction Mechanisms" pp. 94-97, W.H.
Freeman and Co., San Francisco, 1979. The serine at the active site reacts with the carbonyl of the substrate, forming a tetrahedral intermediate. The inhibitors of this invention have no carbonyl at the site of nucleophilic attack, and are not susceptible to attack by serine proteases.
Cysteine proteases are a family of proteases that bear a thiol group at the active site. These proteases are found in bacteria, viruses, eukaryotic microorganisms, plants, and animals. Cysteine proteases may be generally classified as belonging to one of four or more distinct superfamilies.
Examples of cysteine proteases that may be inhibited by the novel cysteine protease inhibitors of the present invention include, but are not limited to, the plant cysteine proteases such as papain, ficin, aleurain, oryzain and actinidain; mammalian cysteine proteases such as cathepsins B, H, J, L, N,
S, T and C, (cathepsin C is also known as dipeptidyl peptidase I), interleukin converting enzyme (ICE), calcium-activated neutral proteases, calpain I and II; viral cysteine proteases such as picornian 2A and 3C, aphthovirus endopeptidase, cardiovirus endopeptidase, comovirus endopeptidase, potyvirus endopeptidases I and II, adenovirus endopeptidase, the two endopeptidases from chestnut blight virus, togavirus cysteine endopeptidase, as well as cysteine proteases of the polio and rhinoviruses; and cysteine proteases known to be essential for parasite lifecycles, such as the proteases from species of Plasmodia, Entamoeba, Onchocera, Trypansoma,
Leishmania, Haemonchus, Dictyostelium, Therileria, and Schistosoma, such as those associated with malaria (P. falciparium), trypanosomes (T cruzi, the enzyme is. also known as cruzain or cruzipain), murine P. vinckei, and the C. elegans cysteine protease. For an extensive listing of cysteine proteases that may be inhibited by the cysteine protease inhibitors of the present invention, see Rawlings et al., Biochem. J. 290:205-218 (1993), hereby expressly incorporated by reference.
Accordingly, inhibitors of cysteine proteases are useful in a wide variety of applications. For example, the inhibitors of the present invention are used to quantify the amount of cysteine protease present in a sample, and thus are used in assays and diagnostic kits for the quantification of cysteine proteases in blood, lymph, saliva, or other tissue samples, in addition to bacterial, fungal, plant, yeast, viral or mammalian cell cultures. Thus in a preferred embodiment, the sample is assayed using a standard protease substrate. A cysteine protease inhibitor is added, and allowed to bind to any cysteine protease present. The protease assay is then rerun, and the loss of activity is correlated to cysteine protease activity using techniques well known to those skilled in the ait
The cysteine protease inhibitors are also useful to remove or inhibit contaminating cysteine proteases in a sample. For example, the cysteine protease inhibitors of the present invention are added to samples where proteolytic degradation by contaminating cysteine proteases is undesirable. Alternatively, the cysteine protease inhibitors of the present invention may be bound to a chromatographic support, using techniques well known in the art, to form an affinity chromatography column. A sample containing an undesirable cysteine protease is run through the column to remove the protease.
In a preferred embodiment, the cysteine protease inhibitors are useful for inhibiting cysteine proteases implicated in a number of diseases. In particular, cathepsins B, L, and S, cruzain, and interleukin 1β converting enzyme are inhibited. These enzymes are examples of lysosomal cysteine proteases implicated in a wide spectrum of diseases characterized by tissue degradation. Such diseases include, but are not limited to, arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, parasite-borne infections, Alzheimer's disease, periodontal disease, and cancer metastasis.
For example, mammalian lysosomal thiol proteases play an important role in intracellular degradation of proteins and possibly in the activation of some peptide hormones. Enzymes similar to cathepsins B and L are released from tumors and may be involved in tumor metastasis. Cathepsin L is present in diseased human synovial fluid and transformed tissues. Similarly, the release of cathepsin B and other lysosomal proteases from
polymorphonuclear granulocytes and macrophages is observed in trauma and inflammation. The cysteine protease inhibitors also find application in a multitude of other diseases, including, but not limited to, gingivitis, malaria, leishmaniasis, filariasis, and other bacterial and parasite-borne infections. The compounds also offer application in viral diseases, based on the approach of inhibiting proteases necessary for viral replication. For example, many picornoviruses including poliovirus, foot and mouth disease virus, and rhinovirus encode for cysteine proteases that are essential for cleavage of viral polyproteins.
Additionally, these compounds offer application in disorders involving interleukin-1β converting enzyme (ICE), a cysteine protease responsible for processing interleukin 1β; for example, in the treatment of inflammation and immune based disorders of the lung, airways, central nervous system and surrounding membranes, eyes, ears, joints, bones, connective tissues, cardiovascular system including the pericardium, gastrointestinal and urogenital systems, the skin and the mucosal membranes. These conditions include infectious diseases where active infection exists at any body site, such as meningitis and salpingitis; complications of infections including septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome; acute or chronic inflammation due to antigen, antibody and/or complement deposition; inflammatory conditions including arthritis, chalangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury and vasculitis.
Immune-based diseases include but are not limited to conditions involving T-cells and/or macrophages such as acute and delayed hypersensitivity, graft rejection, and graft- versus-host disease; auto-immune diseases including Type I diabetes mellitus and multiple sclerosis. Bone and cartilage reabsorption as well as diseases resulting in excessive deposition of extracellular matrix such as interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, and keloid formation may also be treated with the inhibitors of the present invention. The inhibitors may also be useful in the treatment of certain tumors that produce IL 1 as an autocrine growth factor and in preventing the cachexia associated with certain tumors. Apoptosis and cell death are also associated with ICE and may be treated with the inhibitors of the present invention. Furthermore, the cysteine protease inhibitors of the present invention find use in drug potentiation applications. For example, therapeutic agents such as antibiotics or antitumor drugs can be inactivated through proteolysis by endogeneous cysteine proteases, thus rendering the administered drug less effective or inactive. For example, it has been shown that bleomycin, an antitumor drug, can be hydrolyzed by bleomycin hydrolase, a cysteine protease (see Sebti et al., Cancer Res. January 1991, pages 227-232).
Accordingly, the cysteine protease inhibitors of the invention may be administered to a patient in conjunction with a therapeutic agent in order to potentiate or increase the activity of the drug. This co-administration may be by simultaneous administration, such as a mixture of the cysteine protease inhibitor and the drug, or by separate simultaneous or sequential
administration.
In addition, cysteine protease inhibitors have been shown to inhibit the growth of bacteria, particularly human pathogenic bacteria (see Bjorck et al., Nature 337:385 (1989)). Accordingly, the cysteine protease inhibitors of the present invention may be used as antibacterial agents to retard or inhibit the growth of certain bacteria.
The cysteine protease inhibitors of the invention also find use as agents to reduce the damage of bacterial cysteine proteases to host organisms. For example, staphylococcus produces a very active extracellular cysteine protease which degrades insoluble elastin, possibly contributing to the connective tissue destruction seen in bacterial infections such as septicemia, septic arthritis and otitis. See Potempa et al., J. Biol. Chem. 263(6):2664-2667 (1988). Accordingly, the cysteine protease inhibitors of the invention may be used to treat bacterial infections to prevent tissue damage.
The present invention generally provides new peptide-based and
peptidomimetic cysteine protease inhibitors for use as irreversible, mechanism-based cysteine protease inhibitors. In the preferred embodiment, these cysteine protease inhibitors are Michael acceptors. By the term "Michael acceptor" or grammatical equivalents herein is meant an alkene conjugated with an electron-withdrawing group, such as an α,β-unsaturated, vinylogous electron withdrawing group.
The cysteine protease inhibitors are comprised of a targeting group linked to an alkene conjugated with an EWG. A preferred embodiment exhibits the structure shown below in Formula 1:
Figure imgf000015_0001
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
A - B is a peptide linkage; and
EWG is an electron withdrawing group. By the term "targeting group", or grammatical equivalents, herein is meant a portion of a cysteine protease inhibitor that allows the binding of the inhibitor to a cysteine protease. In a preferred embodiment, the targeting group of a cysteine protease inhibitor comprises at least one amino acid side chain. In the preferred embodiment, the targeting group comprises at least two amino acids linked via a peptide bond. In a preferred embodiment, the carbon to which the "Y" amino acid side chain is attached is directly attached to the carbon-carbon double bond. The targeting group may include up to about 15 amino acids, although cysteine protease inhibitors are generally from 1 to 7 amino acids, since smaller inhibitors are usually desired in therapeutic applications.
The targeting group may comprise naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures. Thus "amino acid", or "peptide residue", as used herein means both naturally occurring and synthetic amino acids, although preferably a single cysteine protease inhibitor does not contain more than one non-naturally occurring amino acid side chain. For example, homo-phenylalanine, citrulline and noreleucine are considered amino acids for the purposes of the invention. "Amino acid" also includes imino acid residues such as proline and hydroxyproline. The term as used herein also refers to portions of an amino acid, such as an amino acid side chain. The side chains may be in either the (R) or the (S) configuration. In the preferred embodiment, the amino acids are in the (S) or L-configuration.
If non-naturally occurring side chains are used, non-amino acid substituents may be used, for example to prevent or retard in vivo degradations. Such non-amino acid substituents will normally include, but are not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, an aralkyl, an alkoxy, a heteroaryl, a heteroarylalkyl, or a heteroarylalkenyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, preferably branched, particularly isobutyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof. Aryl preferably is phenyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl and phenylethyl. Alkoxy preferably is of 1 to 5 carbon atoms, preferably methoxy. Acyloxy preferably is of 2 to 6 carbon atoms, preferably acetoxy. Heteroaryl preferably is pyridinyl, especially 4-pyridinyl, thienyl, especially
2-thienyl, or furyl, especially 2-furyl. Heteroarylalkyl and heteroalkenyl preferably has 1 to 6 carbon atoms, especially 1 carbon atom in the alkyl or alkylene moieties thereof. The heteroaryl moiety of heteroarylalkyl and heteroarylakylene preferably has the significances indicated above as preferred for heteroaryl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl.
The specific amino acids comprising the targeting group are initially determined by the rules governing substrate specificity in cysteine proteases.
That is, combinations of amino acids that confer specificity to the enzyme to be inhibited will be used.
It is to be understood that the order of the amino acid side chains within the inhibitor is significant in conferring inhibitor targeting. Thus, as is well known for substrates, the amino acid side chain of the targeting group closest to the alkene bond, generally referred to herein as "Y", will occupy the S1 position of the enzyme's substrate binding site when the inhibitor is bound to the enzyme. That is, the "Y" amino acid side chain of the targeting group is the P1 residue of the inhibitor. Similarly, the amino acid side chain of the targeting group second from the alkene bond, generally referred to herein as "X", will occupy the S2 position of the enzyme's substrate binding site when the inhibitor is bound to the enzyme, and thus is the P2 residue. If present, additional amino acid side chains of the inhibitor will occupy the P3, P4, etc. positions.
In a preferred embodiment, additional targeting residues or specificity-enhancing residues are attached to the EWG, to occupy the S1 ', S2 ', etc. position of the enzyme's substrate binding site. These additional targeting groups are considered the P1 ', P2 ' etc. residues of the inhibitor. As for the targeting group, the additional targeting residues are chosen to confer increased specificity on the inhibitor for the particular cysteine protease to be inhibited.
The choice of the amino acid side chains of the targeting group and of the additional targeting residues will be done using the available information about the substrate specificity of the protease, and is routine to those skilled in the art using commercially available substrates. For example, interleukin-1β converting enzyme displays the greatest specificity demonstrated for a cysteine protease toward a substrate, requiring an aspartyl side chain in the P1 position. The papain superfamily of cysteine proteases have an extended specificity site containing five to seven significant subsites, with the dominant one being S2, which is a hydrophobic pocket that binds phenylalanyl-like sidechains very well. Cathepsin B, similar to papain, accepts a phenylalanine side chain in S2, as well as an arginyl sidechain. For a general review, see "Proteinase Inhibitors", in Reasearch Monographs in Cell and Tissue Physiology (1986), ed. Barrett et al., Vol. 12, Chapter 4: Inhibitors of Cysteine Proteinases, Daniel Rich, Elsevier, New York, hereby expressly incorporated by reference. In addition, the specificity of the interleukin 1β converting enzyme (ICE), was explored in Thornberry et al., supra, also expressly incorporated by reference herein. Table 1 lists some of the favored amino acid side chains for the "X" (P2), "Y" (P1), etc. positions for a number of cysteine proteases.
Figure imgf000019_0001
The targeting group of the cysteine protease inhibitor may also contain additional functional groups, as shown in Formula 1, above. Thus, the "P" group of Formula 1 may be a hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group, or a label. In some embodiments, the "P" group may also be a label, such as a fluorescent label. By the term "peptide amino end blocking group" herein is meant, for example, groups including, but not limited to, an
alkoxy-ω-oxoalkanoyl of 2 to 10 carbon atoms, alkoxycarbonyl of overall 2 to 10 carbon atoms, alkanoyl of overall 2 to 10 carbon atoms,
cycloalkylcarbonyl of overall 4 to 8 carbon atoms, carbamoyl,
alkylcarbamoyl, or dialkylcarbamoyl, a benzoyl, an alkylsulfonyl of overall 1 to 10 carbon atoms, especially alkoxycarbonyl of overall 4 to 8 carbon atoms, particularly tert-butoxycarbonyl (BOC) or benzyloxycarbonyl (CBZ,
Z), especially cycloalkylaminocarbonyl or oxacycloalkylaminocarbonyl of overall 4 to 8 atoms in the ring, particularly 4-morpholinecarbonyl (Mu).
The amino acids, or peptide residues, are normally linked via a peptide bond or linkage, i.e. a peptidic carbamoyl group, i.e. -CONH-. Thus, in Formula 1, A = CO and B = NH. However, peptidomimetic bonds are also included, such as CH2-NH, CO-CH2, azapeptide and retro-inverso bonds.
By the term "alkene bond", or grammatical equivalents, herein is meant a carbon-carbon double bond. It is to be understood that the alkene bonds of the cysteine protease inhibitors confer Michael acceptor functionality to the cysteine protease inhibitors. In a preferred embodiment, the carbon to which the "Y" amino acid side chain is attached is directly attached to the carbon-carbon double bond.
In a preferred embodiment, the targeting group is linked to one of the carbons of the carbon-carbon double bond, and the EWG is linked to the other carbon of the carbon-carbon double bond. By the term "linked" or grammatical equivalents herein is meant a covalent attachment. For the targeting group linkage to the alkene bond, the linkage may be direct, such that the carbon to which the "Y" amino acid side chain is attached is attached to one of the carbons of the carbon-carbon double bond.
Alternatively, there may be other groups between the targeting group and the alkene bond that do not substantially diminish the ability of the targeting group to target an enzyme. In the case of the linkage between the alkene bond and the EWG, the linkage is such that the electron withdrawing properties of the EWG are exerted on the alkene bond, to allow nucleophilic attack by a cysteine protease on the alkene bond.
In a preferred embodiment, the targeting group and the EWG are attached by the alkene bond in trans configuration. In alternative embodiments, the targeting group and the EWG are attached in cis configuration. α,β-unsaturated compounds in the cis (Z) configuration, as opposed to the trans (E) configuration, are made by using phosphonates bearing the highly electrophilic β-trifluoroethoxy groups at the phsophorus atom (Still et al., Tetrahedron Lett. 24:4405 (1983)) in place of phosphonates bearing dialkyl groups such as diethyl.
By the term "electron withdrawing group" or "EWG" or grammatical equivalents herein is meant a functional group that allows nucleophilic attack by the thiol-group of a cysteine protease at the alkene bond of the inhibitor as a result of the electron withdrawing properties of the EWG. Thus the
EWG is conjugated with the alkene bond, such that the electron withdrawing properties of the EWG serve to allow nucleophilic attack by a cysteine protease at the alkene bond, i.e. the alkene bond and the EWG are electronically conjugated. Thus, preferably the linkage between the alkene bond and the EWG is a direct one, without intervening moieties that would prevent the electron withdrawing properties of the EWG from being exerted on the alkene bond. In some embodiments, an EWG comprises an electron withdrawing moiety, EWM, as defined below. In alternative embodiments, an EWG comprises a ring (e.g. a five or six membered aromatic ring) that is substituted with at least one EWM, a meta directing moiety or group (MDG), or a deactivating group (DG), as defined below. It is to be understood, as will be described more fully below, that an EWG that contains structures such as five or six membered rings between a functional EWM, MDG or DG, and the alkene bond, is permissible as long as the ability of the EWM, MDG or DG to exert an electron withdrawing force on the double bond is not substantially diminished; i.e. that nucleophilic attack by the cysteine protease at the alkene bond may still occur.
In one embodiment, the EWG comprises a homocyclic six membered aromatic ring or a heterocyclic five or six membered aromatic ring, which is substituted with an EWM, MDG or DG. The ring must be aromatic, that is, it must conform to Hückel's rule for the number of delocalized π electrons.
If the ring is a six membered homocyclic ring, i.e. containing only carbon, it is substituted, with a substitution group, in such a manner that the substituted ring, when linked to the alkene bond of a cysteine protease inhibitor, allows nucleophilic attack by the protease at the alkene bond. Thus the substituted homocyclic ring is an EWG. The substitution group may be an EWM, MDG, or DG.
In one embodiment, a homocyclic ring may have at least one EWM, as defined below as useful in the Wadsworth-Emmons reaction, substituted at any of the carbons of the ring, to confer electron withdrawing properties on the EWG. Alternative embodiments have more than one EWM substituted on the ring, with up to five substitution groups on a six membered aromatic ring. In alternative embodiments, the substitution group may or may not be an EWM, as defined below, but instead is considered meta directing in respect to electrophilic aromatic substitution. That is, that the electron withdrawing properties of the substitution group, when present on an aromatic ring, direct further addition of groups to the ring to a meta position, relative to the original substitution group. Meta directing groups or moieties, in respect to electrophilic aromatic substitution, are well known in the art. Examples of meta directing moieties are the quaternary ammonium salts, NR3+, where R may be for example an aryl, alkyl or an aralkyl group, among others, as well as such meta directing groups as NO2, SO3H, SO2R, SOR, SO2NH2,
SO2NHR, SO2NHR2, SONH2, SONHR, SONR2, CN, PO3H, P(O)(OR)2, P(O)OR, COOH, COR, and COOR'.
In one embodiment, the substitution group is a deactivating group.
"Deactivating group" (DG) or grammatical equivalents, means a group or moiety which is deactivating in respect to electrophilic aromatic substitution, by virtue of their electronegativity, as is well known in the art. That is, a substitution group that is deactivating renders the substituted aromatic ring to be less reactive than the non-substituted ring. In this embodiment, examples of suitable deactivating groups are all halogen atoms, such as F, Cl, Br, I, and At; for example, F5, CF3, and (CF3)n.
The substitution may be either in the para, ortho or meta position, relative to the ring carbon that is attached to one of the carbons of the carbon-carbon double bond of the cysteine protease inhibitor.
Alternatively, the ring may be heterocyclic aromatic rings, that is, contain more than one kind of atom. Thus five membered rings that contain at least one nitrogen, oxygen, phosphorus, arsenic or sulfur atom, and six membered rings that contain at least one nitrogen or phosphorus atom, may be used as outlined below. The rings may contain more than one of the atoms, as well as combinations of atoms. In addition, in the preferred embodiment, the heterocyclic five membered rings may be substituted, as outlined above, with a group that is an EWM as defined below. The six membered rings may be substituted with a group that is either an EWM as defined below, a MDG or a DG, as defined above.
Examples of suitable heterocyclic aromatic rings are pyrrole, furan, thiophene, pyridine, thiazole, pyrimidine, phosphole, and arsole. Particularly useful substitution groups for these rings are quaternary pyridinium salts, such as NR3+, where R is, for example, an aralkyl or alkyl group.
EWGs containing five or six membered aromatic substituted rings useful in the present invention are determined by their ability to be used in the Wittig reaction. The Wittig reaction is a well known method of synthesizing alkenes from carbonyl compounds, wherein the carbonyl oxygen is replaced by a carbon atom, in a reaction with a phosphonium ylide or phosphine oxide. The reaction proceeds if the phosphonium ylide or phosphine oxide contains an electron withdrawing group. Thus an electron withdrawing group that will function in the Wittig reaction can be an EWG in the present invention. This reaction is well characterized and one skilled in the art will be able to choose and assay likely EWG candidates, using routine techniques.
In a preferred embodiment, the EWG comprises an EWM. In this
embodiment, the EWM group is attached to or conjugated directly with one of the carbons of the carbon-carbon double bond. By the term "electron withdrawing moiety" or "EWM" or grammatical equivalents herein is meant any functional group that can be used in the Wadsworth-Emmons modification of the Wittig reaction in olefin synthesis. Thus, the ability of a functional group to form α,β unsaturated hydrocarbons in the Wadsworth-Emmons reaction will confer the required level of electron withdrawing to function as an EWG in a cysteine protease inhibitor.
One skilled in the art will be able to routinely test the electron-withdrawing properties of a functional group using the Wadsworth-Emmons modification of the Wittig reaction (see Wadsworth et al., J. Am. Chem. Soc. 83:1733, (1961)). For example, the alkali metal anion of (RO)2P(O)CH2-EWG will react with an aldehyde to form the α,β unsaturated alkene.
Preferably, the EWGs of the present invention are vinylogous moieties, that is, they are attached to the carbon-carbon double bond of the cysteine protease inhibitor. As used herein, the term "vinylogous EWG" means an EWG linked to the alkene bond of the inhibitor; that is, the alkene bond is not part of the EWG. Some of the vinylogous compounds that are useful in the present invention include, but are not limited to, vinylogous esters, vinylogous sulfones, vinylogous carboxylates, vinylogous amides, vinylogous phosphonates, vinylogous ketones, vinylogous nitriles, vinylogous sulfoxides, vinylogous sulfonamides, vinylogous sulfinamides, vinylogous nitro compounds, vinylogous sulfonates and vinylogous sulfoximines.
In a preferred embodiment, the cysteine protease inhibitor includes a vinylogous ester moiety as the EWG, as shown in Formula 2:
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid residue with or without an amino end blocking group or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
R, is an ester moiety; and
the A-B linkage is a peptide residue or an isosteric form thereof.
By the term "ester moiety" herein is meant a group including, but not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, an aryl, or an aralkyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, especially ethyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl moieties thereof. Aryl preferably is phenyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where
appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl. Particularly preferred R1 groups include C1-C5 alkyl, especially ethyl; C3-C7 cycloalkyl, especially cyclopentyl or cyclohexyl; C3-C7 (cycloalkyl)-Cl-C5 alkyl, especially C5-C6(cycloalkyl)-methyl; phenyl; C7-C12 phenylalkyl, especially benzyl; aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy, amino, chlorine, bromine or fluorine being particularly preferred. Also preferred are aryl or aralkyl substituted by one or two groups of halogen-substituted C1-C5 alkyl, especially trifluoromethyl; nitro; sulfonyl; or arylsulfonyl, in protected form where appropriate.
In a specific preferred embodiment, cysteine protease inhibitors containing vinylogous esters as EWGs are (1) ethyl (S)-(E)-4-(4-morpholine-carbonylphenylalanyl)-amino-6-phenyl-2-hexenoate, abbreviated herein as Mu-Phe-HphVEOEt, (2) ethyl (S)-(E)-7-guanidino-4- (4-morpholinecarbonylphenylalanyl)amino-2-heptenoate hydrobromide, abbreviated herein as
Mu-Phe-ArgVEOEt.HBr; (3) (S)-(E)-Ethyl 8-(benzyloxycarbonyl)amino-4-(4-morpholinecarbonylphenyl-alanyl)amino-2-octenoate, abbreviated herein as Mu-Phe-Lys(z)VEOEt; and (4) (S)-(E)-Ethyl 8-amino-4-(4-morpholinecarbonylphenylalanyl)amino-2-octenoate hydrobromide, abbreviated herein as Mu-Phe-LysVEOEt-HBr.
In an additional preferred embodiment, the cysteine protease inhibitor includes a vinylogous sulfone moiety as the EWG, as shown in Formula 3:
Figure imgf000027_0001
wherein P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
R2 is a side chain moiety; and
the A-B linkage is a peptide residue or an isosteric form thereof.
The S-R2 bond is a sulfur-carbon link where R2 is a side chain moiety. The R2 side chain moiety may be a group including, but not limited to, an alkyl, a substituted alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, especially methyl. Substituted alkyl is preferably of 1 to 5 carbon atoms, bearing substitutions of alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or
halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof. Aryl preferably is phenyl, pentafluorophenyl or naphthyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or
halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl.
Particularly preferred R2 groups include (1) C1-C5 alkyl, especially methyl; (2) C3-C7 cycloalkyl, preferably cyclopentyl or cycolhexyl; (3) C3-C7(cycloalkyl) - C1-C5 alkyl, preferably C5-C6(cycloalkyl)methyl; (4) C3- C7(cycloalkylalkenyl)-C1-C5 alkyl, preferably C5-C6(cycloalkylalkenyl)-methyl; (5) phenyl, preferably pentafluorophenyl or naphtyl; (6) C7-C12 phenylalkyl, preferably benzyl; (7) C1-C5 alkyl substituted by C1-C5 alkyoxy, halogen, hydroxy or amino, with C1-C5 alkyl preferably substituted by one or two groups selected from methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, with hydroxy, amino, chlorine, bromine or fluorine being most preferred; (8) C1-C5 alkyl substituted with nitro, alkyl or arylsufonyl, optionally protected where appropriate; (9) C1-C5 alkyl substituted with halogen, preferably trifluoromethyl; (10) aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy, amino, chlorine, bromine or fluorine being particularly preferred; (11) aryl or aralkyl substituted by one or two groups of halogen-substituted C1-C5 alkyl, especially trifluoromethyl; nitro; sulfonyl; or arylsulfonyl, in protected form where appropriate.
Preferred cysteine protease inhibitors with vinylogous sulfones as the EWG include: (1) (S)-(E)-5-(4-morpholinecarbonylphenylalanyl)amino-7-phenyl-2-thia-3-heptene 2,2-dioxide, abbreviated herein as
Mu-Phe-HphVSMe; (2) (S)(E)-3-tert-butoxycarbonylamino-4-methyl-1 -phenylsulfonyl-1-pentene, abbreviated herein as Boc-ValVSPh; (3) (S)-(E)-3-(4-morpholinecarbonyl-phenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated herein as Mu-Phe-HphVSPh; (4) (S)- (E)-3-tert-butoxycarbonylamino-4-tert-butoxycarbonyl-1-methylsulfonyl-1-butene, abbreviated herein as (Boc-Asp(Ot-Bu)VSMe; (5) (S)-(E)-3-amino-4-tert-butoxycarbonyl-1-methylsulfonyl-1-butene, abbreviated TsOH.Asp(Ot-Bu)VSMe; (6) (S)-(E)-3-tert-butoxycarbonylamino-4-tert-butoxycarbonyl-1-phenylsulfonyl-1-butene, abbreviated Boc-Asp(Ot-Bu)-VSPh; (7) (S)-(E)-3-amino-4-tert-butoxycarbonyl-1-phenylsulfonyl-1-butene-p-toluenesulfonate, abbreviated TsOH.Asp(Ot-Bu)VSPh; (8) (S)-(E)-3-amino-4-hycroxylcarbonyl-1-phenylsulfonyl-1-butene-p-toluenesulfonate, abbreviated HCl.AspVSPh; (9) (E)-3-acetyltyrosylvalylalanylamino-4-tert-butoxycarbonyl-1-phenylsulfonyl-1-butene, abbreviated Ac-Tyr-Val-Ala-Asp(Ot-Bu)VSPh; (10)
(e)-3-acetyltyrosylvalylalanylamino-4-hydroxycarbonyl-1-phenylsulfonyl-1-butene (Ac-Tyr-Val-Ala-AspVSPh; (11) (S)-(E)-3-(4-morpholinecarbonylleucyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Leu-HphVSPh, ( 12) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-6-guanidino-1-phenylsulfonyl-1-hexene hydrobromide, abbreviated Mu-Phe- ArgVSPh.HBr; (13) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Phe-HphVSPh; (14) (S)-(E)-3-glycylamino-4-phenyl-1-phenylsulfonyl-1-butene hydrochloride, abbreviated Gly-PheVSPh.HCl; (15) (S)-(E)-7-(benzyloxycarbonyl)amino-3-(4-morpholinecarbonylphenylalanyl)-amino-1-phenylsulfonyl-1-heptene, abbreviated Mu-Phe-Lys(Z)VSPh; (16) (S)-(E)-7-amino-3-(4-morpholinecarbonylphenylalanyl)amino-1-phenylsulfonyl-1-heptene hydrobromide, abbreviated Mu-Phe-LysVSPh.HBr; (17) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-4-methyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Phe-ValVSPh; (18) (S)-(E)-3-amino-4-phenyl-1-phenylsulfonyl-1-butene hydrochloride, abbreviated PheVSPh.HCl; (19) (S)-(E)-3-(4-morpholinecarbonylvalyl)amino-4-phenyl-1-phenylsulfonyl-1-butene, abbreviated Mu-Val-PheVSPh; (20) (S)-(E)-3-(4-morpholinecarbonylarginyl)amino-6-guanidino-1-phenylsulfonyl-1-hexene dihydrobromide, abbreviated Mu-ARg-Arg-VSPh.2HBr; (21) (S)-(E)-3-(4- morpholinecarbonylphenylalanyl)amino-4-benzyloxy-1-phenylsulfonyl-1-butene, abbreviated Mu-Phe-SEr(OBzl)VSPh; (22) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-7-benzoylamino -1-phenylsulfonyl-1-heptene, abbreviated Mu-Phe-Lys(Bz)VSPh; (23) (R)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Phe-D-HphVSPh; (24) (S)-(E)-3-[4-morpholinecarbonyl-(3,5-diiodotyrosyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Tyr(I2)-HphVSPh; (25) (S)-(E)-3-[4-tert-butoxycarbonyl-(3,5-diiodotyrosyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Boc-Tyr(I2)-HphVSPh; (26) (S,S)-(E)-3-[4-morpholinecarbonyl-(1,2,3,4-tetrahydro-3-isoquinoline-carbonyl)]amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Tic-HphVSPh; (27) (S,S)-(E)-3-[tert-butoxycarbonyl-(1,2,3,4-tetrahydro-3-isoquinolinecarbonyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Boc-Tic-HphVSPh; (28) (S)-(E)-3-(4-morpholinecarbonylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene, abbreviated Mu-Leu-HphVSPh; (29) (S)-(E)-3-amino-5-phenyl-1-phenylsulfonyl-1-pentene hydrochloride, abbreviated HphVSPh-HCl; (30) (S)-(E)-3-[(4-morpholinecarbonyl-(R,S)-α-methylphenylalanyl]amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-DL-Fam-HphVSPh; (31) (S)-(E)-3-(benzyloxycarbonylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene, abbreviated Z-Leu-Leu-TyrVSPh; (32) (S)-(E)-3-(4-morpholinecarbonyltyrosyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Tyr-HphVSPh; (33) (S)-(E)-3-(tert-butoxycarbonyl-2-naphthylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Boc-Np-HphVSPh; (34) (S)-(E)-3-(4-morpholinecarbonyl-2-naphthylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Np-HphVSPh; (35) (S)-(E)-3-(4-morpholinecarbonyl-4-biphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Bip-HphVSPh; (36) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-phenylsulfonyl-1-heptene, abbreviated Mu-Phe-NleVSPh; (37) (S)-(E)-3-(4- morpholinecarbonylphenylalanyl)amino-1-phenylsulfonyl-6-thia-1-heptene, abbreviated Mu-Phe-MetVSPh; (38) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-methylsulfonyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Phe-Met(O2)VSPh; (39) (S)-(E)-3-(acetylleucylleucyl)amino-1-phenylsulfonyl-1-heptene, abbreviated Ac-Leu-Leu-NleVSPh; (40) (S)-(E)- 3-(acetylleucylleucyl)amino-1-phenylsulfonyl-6-thia-1-heptene, abbreviated Ac-Leu-Leu-MetVSPh; (41) (S)-(E)-3-(acetylleucylleucyl)amino-5-methylsulfonyl-1-phenylsulfonyl-1-pentene, abbreviated Ac-Leu-Leu-Met(O2)VSPh; (42) (S)-(E)-3-(carbomethoxypropionylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated MeOSuc-Phe-HphVSPh;
(43) (S)-7-(benzyloxycarbonyl)amino-3-(4-morpholinecarbonylphenylalanyl)-amino-1-fluoro-1-phenylsulfonyl-1-heptene, abbreviated Mu-Phe-Lys(Z)fVSPh; (44) (S)-(E)-3-(acetylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene, abbreviated Ac-Leu-Leu-TyrVSPh; (45) (S)-(E)-3-(dimethylsulfamoylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated DimSam-Phe-HphVSPh; (46) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-(4-bromophenylsulfonyl)-5-phenyl-1-pentene, abbreviated Mu-Phe-HphVSPhBr; (47) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-(2-napthylsulfonyl)-5-phenyl-1-pentene, abbreviated Mu-Phe-HphVSNp; (48) (S)-(E)-3-(4-morpholinecarbonyl-2-naphthylalanyl)amino-1-(2-napthylsulfonyl)-5-phenyl-1-pentene, abbreviated Mu-Np-HphVSNp; (49) (S)-(E)-3-(4-morpholinecarbonyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-HphVSPh; (50) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-1-butene, abbreviated Mu-Phe-AlaVSMe; (51) (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene, abbreviated Mu-Phe-PheVSMe; and (52) (S)-(E)-3-(tert-2butoxycarbonylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene, abbreviated Boc-Ala-PheVSMe. In one embodiment, the cysteine protease inhibitors of the present invention include a vinylogous carboxylate as the EWG, as shown in Formula 4:
Figure imgf000033_0001
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration; and
the A-B linkage is a peptide residue or an isosteric form thereof.
In the preferred embodiment, a cysteine protease inhibitor with a vinylogous carboxylate as the EWG is (S)-(E)-4-(4-morpholinecarbonylphenylalanyl)-amino-6- phenyl-2-hexenoic acid, abbreviated herein as Mu-Phe-HphVA, and (S)-(E)-Benzyl 4-(4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenamide, abbreviated herein as Mu-Phe-HphVAMbzl.
In a preferred embodiment, the cysteine protease inhibitor includes a vinylogous phosphonate as the EWG, as shown in Formula 5:
Figure imgf000034_0001
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
R3 is an ester moiety; and
the A-B linkage is a peptide residue or an isosteric form thereof. The R3 groups are ester moieties, and may be groups including, but not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, especially ethyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof. Aryl preferably is phenyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or
halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl. Also included are perfluoro groups, such as perfluoro alkyl, aryl and aralkyl groups.
Particularly preferred are: (1) C1-C5 alkyl, especially ethyl; (2) C3-C7 cycloalkyl, preferably cyclopentyl or cycolhexyl; (3) C3-C7(cycloalkyl) -C1-C5 alkyl, preferably C5-C6(cycloalkyl)methyl; (4) C3-C7(cycloalkylalkenyl)-C1-C5 alkyl, preferably C5-C6(cycloalkylalkenyl)methyl; (5) phenyl; (6) C7-C12 phenylalkyl, preferably benzyl; (7) C1-C5 alkyl substituted by C1-C5 alkyoxy, halogen, hydroxy or amino, with C1-C5 alkyl preferably substituted by one or two groups selected from methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, with hydroxy, amino, chlorine, bromine or fluorine being most preferred; (8) C1-C5 alkyl substituted with nitro, alkyl or arylsufonyl, optionally protected where appropriate; (9) C1-C5 alkyl substituted with halogen, preferably
trifluoromethyl; (10) aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy, amino, chlorine, bromine or fluorine being
particularly preferred; (11) aryl or aralkyl substituted by one or two groups of halogen-substituted C1-C5 alkyl, especially trifluoromethyl; nitro;
sulfonyl; or arylsulfonyl, in protected form where appropriate.
In a preferred embodiment, a cysteine protease inhibitor with a vinylogous phosphonate as the EWG is diethyl (S)-(E)-4-(4-morpholinecarbonylphenylalanyl)amino-6- phenyl-2-hexenephosphonate, abbreviated herein as Mu-Phe-HphVPEt. In another preferred embodiment, the cysteine protease inhibitors of the present invention include vinylogous amides as the EWG, as shown in Formula 6:
Figure imgf000036_0001
wherein
P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X, Y and Z are amino acid side chains, with either (R) or (S) stereochemical configuration,
Q = hydrogen, an ester, a peptide residue, or an amide moiety; and
The A-B linkage is a peptide residue or an isosteric form thereof.
By "amide moiety" as used with regard to Q is meant a group including, but not limited to, an NH2, or an NH-alkyl, an NH-cycloalkyl, an
NH-cycloalkylalkyl, an NH-aryl, or an NH-aralkyl, or an N-dialkyl,
N-dicycloalkyl, an N-dicycloalkylalkyl, an N-diaryl, or an N-diaralkyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, especially ethyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl moieties thereof. Aryl preferably is phenyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where
appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl.
Particularly preferred for Q are: (1) NH-(C1-C5) alkyl, especially NH-ethyl; (2) NH-(C3-C7)cycloalkyl, preferably cyclopentyl or cyclohexyl; (3) HN- (C3-C7)cycloalkyl-(C1-C5) alkyl, preferably NH-(C5-C6)cycloalkyl-methyl; (4) NH-aryl, preferably NH-phenyl; (5) NH-(C-C12)phenylalkyl, preferably benzyl; (6) aryl or aralkyl substituted by one or two groups of (C1-C5) alkyl, (preferably methyl), (C1-C5)alkyoxy, (preferably methoxy), or halogen, (preferably chlorine.bromine, fluorine, hydroxy, or amino).
Especially preferred is to substitue the aryl or aralkyl with one group selected from hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsufonyl, or halogen-substituted (c1-C5)alkyl, especially trifluoromethyl. The ester as used with regard to Q may be an oxygen linked with the ester moieties defined for vinylogous esters and phosphonates to form esters.
Specific preferred embodiments, include the following cysteine protease inhibitors that contain vinylogous amides as the EWG: (S)-(E)-(N-leucylproline methylester)-4-(4-morpholinecarbonylphenyl-alanyl)amino-6-phenyl- 2-hexenamide, abbreviated herein as
Mu-Phe-HphVAM-Leu-ProOMe; (S)-(E)-(N-phenylalanine)-4-(4-morpholine carbonylphenylalanyl)amino-6- phenyl-2-hexenamide, abbreviated herein as Mu-Phe-HphVAM-PheOH; (S)-(E)-3-(4-morpholinecarbonyl-phenylalanylamino)-6-phenyl-2-hexenamide, abbreviated Mu-Phe-HphVAM; and (S)-(E)-Benzyl 4-(4-morpholine-carbonylphenylalanyl)amino-6-phenyl-2-hexenamide, abbreviated Mu-Phe-HphVAMBzl.
Although not preferred, in one embodiment, the cysteine protease inhibitor includes a vinylogous ketone as the EWG, as shown in Formula 7:
Figure imgf000038_0001
wherein
P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
R4 = ketone moiety; and
the A-B linkage is a peptide residue or an isosteric form thereof.
By "ketone moiety" as used with regard to R4 herein is meant groups including, but not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, especially ethyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof. Aryl preferably is phenyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl. Also included are perfluoro groups, such as perfluoro alkyl, aryl, and aralkyl.
Particularly preferred are: (1) (C1-C5)alkyl, preferably ethyl; (2) (C3-C7)cycloalkyl, preferably cyclopentyl or cyclohexyl; (3) (C3-C7)cycloalkyl- (C1-C5)alkyl, especially (C5-C6)cycloalkyl-methyl; (4) (C3-C7)cycloalkyl-(C1-C5)alkenyl, especially (C5-C6)cycloalkyl-methylene; (5) phenyl; (6) (C7-C12)penylalkyl, especially benzyl; (7) aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy, amino, chlorine, bromine or fluorine being particularly preferred; (11) aryl or aralkyl substituted by one or two groups of halogen-substituted C1-C5 alkyl, especially trifluoromethyl; nitro; sulfonyl; or arylsulfonyl, in protected form where appropriate; (12) perfluoro groups, such as perfluoro alkyl, aryl, and aralkyl.
In another preferred embodiment, the cysteine protease inhibitors of the present invention include a nitrile group as the EWG, as shown in Formula 8:
Figure imgf000040_0001
wherein
P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
the C=N group is a nitrile; and
the A-B linkage is a peptide residue or an isosteric form thereof. In another preferred embodiment, the cysteine protease inhibitors of the present invention contain a vinylogous sulfoxide as the EWG, as shown in Formula 9:
Figure imgf000040_0002
wherein P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
R5 = sulfoxide moiety; and
the A-B linkage is a peptide residue or an isosteric form thereof.
By "sulfoxide moiety" as used with regard to R5 herein is meant groups including, but are not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, especially ethyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl.
Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof. Aryl preferably is phenyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl. Also included are perfluoro groups such as perfluoro alkyl, aryl, and aralkyl.
Particularly preferred for R5 are:(1) (c1-C5)alkyl, preferably ethyl; (2) (C3-C7)cycloalkyl, preferably cyclohexyl or cyclopentyl; (3) (C3-C7)cycloalkyl-(C1-C5)alkyl, preferably (C5-C60cyclalkyl-C1alkyl; (4) (C3-C7)cycloalkyl- (C1-C5)alkenyl, preferably (C5-C6)cycloalkyl-C1alkenyl; (5) phenyl; (6) (C7-C12)phenylalkyl, preferably benzyl; (7) aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy, amino, chlorine, bromine or fluorine being particularly preferred;or (8) aryl or aralkyl substituted by one or two groups of halogen-substituted C1-C5 alkyl, especially trifluoromethyl.
In a preferred embodiment, the EWG of the cysteine protease inhibitor includes a vinylogous sulfonamide as the EWG, as shown in Formula 10:
Figure imgf000042_0001
wherein
P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X, Y and Z are amino acid side chains, with either (R) or (S) stereochemical configuration;
Q = hydrogen, an ester, a peptide residue or an amide moiety; and the A-B linkage is a peptide residue or an isosteric form thereof. By "amide moiety" as used with regard to Q is meant a group including, but not limited to, an NH2, or an NH-alkyl, an NH-cycloalkyl, an NH-cycloalkylalkyl, an NH-aryl, or an NH-aralkyl, or an N-dialkyl,
N-dicycloalkyl, an N-dicycloalkylalkyl, an N-diaryl, or an N-diaralkyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, especially ethyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to 5 carbon atoms, particularly 1 carbon atom, in the alkyl moieties thereof. Aryl preferably is phenyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where
appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl.
By "ester" as regards to Q means an oxygen attached to the ester moities previously defined, to form an ester.
In a preferred embodiment, the cysteine protease inhibitors of the present invention include a vinylogous sulfoximine as the EWG, as shown in
Formula 11:
Figure imgf000043_0001
wherein
P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
R6 and R7 are sulfoximine moieties; and
the A-B linkage is a peptide residue or an isosteric form thereof.
By "sulfoximine moieties" as used with regard to R6 and R7 is meant identical or different groups including, but not limited to, an alkyl, a cycloalkyl, a cycloalkylalkyl, a cycloalkylalkenyl, an aryl, or an aralkyl. In such an instance, alkyl is preferably of 1 to 5 carbon atoms, especially ethyl. Cycloalkyl preferably is of 3 to 7 carbon atoms, preferably cyclopentyl or cyclohexyl. Cycloalkylalkyl or cycloalkylalkenyl preferably is of 3 to 7 carbon atoms in the cycloalkyl, particularly 5 or 6 carbon atoms, and of 1 to
5 carbon atoms, particularly 1 carbon atom, in the alkyl or alkylene moieties thereof. Aryl preferably is phenyl. Aralkyl preferably is phenylalkyl of 7 to 12 carbon atoms, particularly benzyl. The optional substituents of an aryl or aralkyl moiety preferably are one or two groups alkyl of 1 to 5 carbon atoms, alkoxy of 1 to 5 carbon atoms, halogen of atomic number of from 9 to 35, hydroxy and/or amino, preferably one or two groups methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino, particularly one hydroxy, amino, chlorine, bromine, or fluorine, optionally in protected form where appropriate, nitro, alkyl or arylsulfonyl, or halogen-substituted alkyl of 1 to 5 carbon atoms, particularly trifluoromethyl. Also included are perfluoro groups, such as perfluoro aryl, alkyl, and aralkyl groups. Particularly preferred for R6 and R7 are: (1) (C1-C5)alkyl, preferably ethyl; (2) (C3-C7)cycloalkyl, preferably cyclohexyl or cyclopentyl; (3) (C3-C7)cycloalkyl-(C1-C5)alkyl, preferably (C5-C60cyclalkyl-C1alkyl; (4) (C3-C7)cycloalkyl-(C1-C5)alkenyl, preferably (C5-C6)cycloalkyl-C1alkenyl; (5) phenyl; (6) (C7-C12)phenylalkyl, preferably benzyl; (7) aryl or aralkyl substituted by one or two groups of C1-C5 alkyl, C1-C5 alkoxy, halogen, hydroxy or amino, with one or two groups of methyl, methoxy, chlorine, bromine, fluorine, hydroxy or amino being preferred and hydroxy, amino, chlorine, bromine or fluorine being particularly preferred;or (8) aryl or aralkyl substituted by one or two groups of halogen-substituted C1-C5 alkyl, especially trifluoromethyl.
In one embodiment, the cysteine protease inhibitors of the present invention have the structure shown in Formula 12:
Figure imgf000045_0001
Wherein
R8 = the five or six membered homo- or heterocyclic aromatic rings with at least one substituted EWM, MDG, or DG; and
R9 = a suitable group as defined below.
The R8 group is an EWG group. It may be a five or six membered homocyclic aromatic ring with at least one substitution group. The substituted group may be an EWM, as defined above, in the case of five membered rings, or an EWM, MDG, or DG as defined above. EWMs that may be substituted onto a five or six membered ring that are preferred are esters, sulfones, carboxylates, amides, phosphonates, ketones, nitriles, nitro compounds, sulfonates, sulfoxides, sulfonamides, sulfinamides, and sulfoximines, as are defined above. MDGs that may be used are the quaternary ammonium salts, NR3+, where R may be for example an aryl, alkyl or aralkyl, as well as such meta directing groups as NO2, SO3H, SO2R, SOR, SO2NH2, SO2NHR, SO2NHR2, SONH2, SONHR, SONR2, CN, PO3H, P(O)(OR)2, P(O)OR, OH, COOH, COR, and COOR'. DGs that may be substituted onto a six membered ring are all the halogen atoms, such as F,
Cl, Br, I, and At; for example, F5, CF3, and (CF3)n
The R9 group may be a wide variety of groups. In the preferred
embodiment, the R9 group is a hydrogen atom, or other functionally neutral groups such as methyl groups. In alternative embodiments, the R9 group is a peptide, such that additional targeting or specificity-enhancing residues are added to the cysteine protease inhibitor.
In a preferred embodiment, the cysteine protease inhibitors of the present invention have a vinylogous five membered heterocyclic aromatic ring with a substituted EWM, as the EWG, as shown in Formula 13:
Figure imgf000046_0001
wherein P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
the A-B linkage is a peptide residue or an isosteric form thereof;
D = an oxygen, sulfur, nitrogen, phosphorus or arsenic atom; and
EWM = an electron withdrawing moiety.
The EWM may be any of the electron withdrawing groups as previously defined.
In a preferred embodiment, the cysteine protease inhibitors of the present invention have a vinylogous six membered homocyclic aromatic ring with a substituted EWM, MDG or DG as the EWG, as shown in Formula 14:
Figure imgf000047_0001
wherein
P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration; the A-B linkage is a peptide residue or an isosteric form thereof;
EWM = an electron withdrawing moiety;
MDG = a meta directing group; and
DG = a deactivating group. In a preferred embodiment, the cysteine protease inhibitors of the present invention have a vinylogous six membered heterocyclic aromatic ring with a substituted EWM as the EWG, as shown in Formula 15:
Figure imgf000048_0001
wherein
P = hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
the A-B linkage is a peptide residue or an isosteric form thereof;
T = a nitrogen or phosphorus atom; and
EWM = an electron withdrawing moiety.
The EWM may also be attached to the "T" heteroatom.
In a further embodiment, the targeting group and the EWG are linked by a diene bond. By "diene bond" herein is meant a chain of four carbon atoms (C1, C2, C3, and C4) in which C1 and C2 are connected by a double bond, C3 and C4 are connected by a double bond, and C2 and C3 are connected by a single bond. In this embodiment, the targeting group is linked to the first carbon of the first carbon-carbon double bond (C1), and the EWG is linked to the last carbon of the second carbon-carbon double bond (C4). In a preferred embodiment, the two double bonds of the diene are in (E)-(E) configuration, although alternative embodiments utilize (E)-(Z), (Z)-(E), or (E)-(E) configurations.
In a preferred embodiment, the second order rate constant for inhibition of a cysteine protease with the diene bond cysteine protease inhibitor, expressed as kirr/KI, is at least about 1000 M-1sec-1, with alterative embodiments having second order rate constants at least about 10,000 M-1sec-1, with the most preferred rate constant being at least about 100,000 M-1sec-1 .
In this embodiment, the targeting group and EWG are defined as above. In a preferred embodiment, the cysteine protease inhibitor comprises a compound with the formula:
Figure imgf000049_0001
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label; X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
A-B is a peptide linkage; and
EWG is an electron withdrawing group.
In an additional embodiment, the cysteine protease inhibitors of the present invention comprise a targeting group linked via an alkene bond to two EWGs. In this embodiment, the targeting group is linked to one of the carbons of the carbon-carbon double bond, and the two EWGs are linked to the other carbon of the carbon-carbon double bond. The linkage of the targeting group to the alkene bond is as described above for the single EWG embodiment. The linkage of the two EWGs to the alkene bond is similar as for one EWG; that is, the linkage is such that the electron withdrawing properties of the EWGs are exerted on the alkene bond, to allow
nucleophilic attack by a cysteine protease on the alkene bond. In this embodiment, preferably the two EWGs are different. In an alternative embodiment, the two EWGs are the same.
In a preferred embodiment, the cysteine protease inhibitor comprises a compound with the formula:
Figure imgf000050_0001
wherein P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains, with either (R) or (S) stereochemical configuration;
A-B is a peptide linkage; and
EWG is an electron withdrawing group.
In one embodiment, the cysteine protease inhibitors are comprised of a targeting group linked to an alkene bond conjugated with an electron withdrawing group (EWG).
In this embodiment, the second order rate constant for inhibition of a cysteine protease with the inhibitor, expressed as kirrKI, is at least about 1000 M- 1sec- 1.
By the term "second order rate constant" or grammatical equivalents herein is meant the kinetic constant associated with a bimolecular reaction that is dependent on the concentration of two species. The second order rate constants are defined and determined as below.
The determination of second order rate constants is known in the art. For example, for irreversible inhibition reactions such as those of the present invention, the reaction scheme is as follows:
Figure imgf000052_0001
The reaction is divided into two processes. The enzyme and the inhibitor first combine to give an enzyme-inhibitor complex, E·I. This step is assumed to be rapid and reversible, with no chemical changes taking place; the enzyme and the inhibitor are held together by non-covalent forces. In this reaction, k1 is the second order rate constant for the formation of the E·I reversible complex. k2 is the first order rate constant for the disassociation of the reversible E·I complex. The chemical processes then occur in a second step with a first order rate constant kirr, which is the constant for the inactivation of the E·I complex, which is similar to the kcat constant or turnover number. In this reaction, KI = k2/k1, and the second order rate constant of inactivation is kirr/KI.
The measurement of the first order rate constant kirr and the equilibrium constant KI proceeds according to techniques well known in the art, as described in the examples. For example, assays are run in the presence of inhibitor and substrate, generally using synthetic chromogenic substrates. Inhibition progress curve analysis using non-linear curve fitting software widely available enables the calculation of the first order rate constant kirr and the equilibrium constant KI. The second order rate constant, kirr/KI, is then calculated as follows:
At equilibrium, k1[E][I] = k2[E·I]
or
Figure imgf000053_0001
where KI is a dissociation constant with units of M.
For the inactivation of E,
Figure imgf000053_0002
Eliminating [E]:
Figure imgf000053_0003
Using KI as a common denominator gives:
Figure imgf000053_0004
and:
Figure imgf000053_0005
kirr is the first order rate constant of inactivation of E. When [I] « KI, the rate equation reduces to
Figure imgf000054_0001
that is the pseudo-second order rate expression where kirr/KI represents the pseudo-second order rate constant with units of M-1sec-1.
It is to be understood that second order rate constants are a particularly useful way of quantifying the efficiency of an enzyme with a particular substrate or inhibitor, and are frequently used in the art as such. The efficiency of an inhibitor depends on the second order rate constant and not on either the KI value alone or the kirr value alone. Thus even if an inhibitor exhibits a very low KI, or alternatively a very high kirr, it may not be a efficient inhibitor if the second order rate constant is low. Accordingly, the cysteine protease inhibitors of the present invention have second order rate constants, expressed as kirr/KI, of at least about 1000 M-1sec-1.
Preferred embodiments have inhibitors that exhibit second order rate constants of at least about 10,000 M-1sec-1, with the most preferred embodiments having second order rate constants of at least about 100,000 M-1sec-1. In addition, the second order rate constants of the preferred embodiment do not exceed the diffusion limit of about 1 × 108 M-1sec-1.
In the preferred embodiment, the cysteine protease inhibitors are chiral. In this embodiment, the chiral cysteine protease inhibitor is comprised of a targeting group linked to an alkene bond conjugated with an EWG. By the term "chiral" or grammatical equivalents herein is meant a compound that exhibits dissymetry. That is, the chiral compound is not identical with its mirror image. Thus in the preferred embodiment, the compounds of the present invention are pure epimers. Chiral compounds, and particularly chiral cysteine protease inhibitors, are useful in the present invention because biological systems, and enzymes in particular, are stereospecific, preferring the (S) or L-form of amino acids. Thus in the preferred embodiment, the chiral cysteine protease inhibitors of the present invention will have amino acid side chains in the (S) or L-configuration, although some inhibitors may utilize amino acid side chains in the (R) or D-configuration.
In alternative embodiments, the compositions of the present invention are not pure epimers, but are mixtures that contain more than 50% of one epimer. Preferred embodiments have greater than about 70% of one epimer, and the most preferred embodiment has at least about 90% of one epimer. The synthesis of the cysteine protease inhibitors of the present invention proceeds as follows. In general, preparation of the inhibitors described herein requires first that the amino acids from which the inhibitory functionalities are derived, i.e. the targeting amino acids, be converted into t-butoxycarbonyl-protected a-aminoaldehydes, also called N-protected α-amino aldehydes, as shown in Equation 5 (for example by the method of
Fehrentz, J-A. and Castro, B. (Synthesis, (1983), 676 (Equation 5)).
Figure imgf000055_0001
wherein
R = an amino acid side chain: alkyl, aryl, aminoalkyl, etc.;
a) Cl-H2N+(Me)OMe, dicyclohexylcarbodiimide, triethylamine; and b) lithium aluminum hydride. The resulting aldehydes are transformed into vinylogous compounds using the Wadsworth-Emmons-Horner modification of the Wittig reaction to make cysteine protease inhibitor intermediates (Wadsworth et al., J. Amer. Chem. Soc. 83:1733 (1961); Equation 1). In one embodiment, the vinylogous compounds, as cysteine protease inhibitor intermediates, may be used as cysteine protease inhibitors without further chemical addition, i.e. the inhibitors have only a single amino acid side chain, as depicted in Formula 16:
Figure imgf000056_0001
wherein
C is hydrogen or a peptide amino end blocking group;
"Y" is any amino acid side chain except glycine (hydrogen), or, when the
EWG is a vinylogous ester, phenylalanine (benzyl); and
EWG is an electron withdrawing group. For example, Boc-AspVSPh may be used as an inhibitor of ICE without further addition of amino acid side chain targeting groups.
In a preferred embodiment, additional targeting groups, in the form of amino acid side chains, are added to the vinylogous cysteine protease inhibitors to form the structure depicted in Formula 1, above. Generally, this is done by deprotecting the "P" group and coupling an additional N-protected amino acid, as is well known in the art. Specifically, the cysteine protease inhibitors of the present invention that contain vinylogous esters as the EWG can be generated by the sequence of reactions shown in Scheme I below:
Figure imgf000057_0001
a) Cl-NH2+(CH3)OCH3, dicyclohexylcarboiimide, Et3N/CH2Cl2;
b) LiAlH4/THF;
c) NaH/THF;
d) HCl/dioxane/CH2Cl2; and
e) 4-methylmorpholine, isobutyl chloroformate/THF. A preferred embodiment treats Boc-protected amino acids such as homophenylalanine, depicted as the example of Scheme 1, with
N,O-dimethylhydroxylamine hydrochloride, in the presence of triethylamine and dicyclohexylcarbodiimide in dichloromethane. Alternative embodiments treat the Boc-protected amino acids in the presence of triethylamine and the coupling reagent benzotriazol-1-yloxytris
(dimethylamino)-phosphonium hexafluorophosphate (BOP). Subsequent reduction with lithium aluminum hydride results in Boc-a-amino aldehydes, for example using the method of Fehrentz, J-A. and Castro, B. (Synthesis, (1983), 676-678). The resulting aldehydes are then treated with the sodium anion of triethyl phosphonoacetate, in the manner of Wadsworth, W.S. and Emmons, W.D. (J. Am. Chem. Soc. (1961), 83, 1733, to produce the vinylogous esters of the present invention. These vinylogous esters are then deprotected with hydrogen chloride in dioxane, and coupled with
N-protected amino acids to form pseudopeptidyl vinylogous esters, the cysteine protease inhibitors of this embodiment. Coupling is acheived via mixed anhydride or other peptide coupling reaction sequences known to those skilled in the art.
In a preferred embodiment, the cysteine protease inhibitors of the present invention that contain vinylogous sulfones as the EWG can be generated by the sequence of reactions shown in Scheme II below:
Figure imgf000059_0001
Generally, the preferred embodiment utilizes Boc-a-amino aldehydes, prepared according to the method of Fehrentz, J-A. and Castro, B.
(Synthesis, (1983). Treatment of these aldehydes with the sodium anion of sulfonylmethanephosphonates, for example diethyl phenylsulfonylmethanephosphonate, results in the corresponding vinylogous sulfone derivatives, in the manner of Wadsworth, W.S. and Emmons, W.D. (J. Am. Chem. Soc. (1961), 83, 1733. In one embodiment, sulfonyl
methanephosphonates are synthesized by coupling of the alkali metal anion of sulfones such as methyl phenyl sulfone with diethyl chlorophosphate. Alternative embodiments utilize m-chloroperbenzoic acid oxidation of commercially available sulfides such as diethylphosphonomethyl methyl sulfide (Aldrich Chemical Co.). The vinylogous sulfones are then deprotected with hydrogen chloride in dioxane, and are coupled with N-protected amino acids to form pseudopeptidyl vinylogous sulfones, using techniques well known in the art.
The vinylogous carboxylates of this embodiment are made using the sequence of reactions shown in Scheme III below:
Figure imgf000060_0001
Generally, saponification of the ester functionality of the vinylogous esters, described above, results in carboxylates. Acidification, as is known in the art, gives the corresponding carboxylic acids.
The cysteine protease inhibitors of the present invention that contain vinylogous phosphonates as the EWG may be synthesized by the sequence of reactions shown in Scheme IV:
Figure imgf000061_0001
a) NaH/THF;
b) HCl/dioxane; and
c) Mu-PheOH, 4-methylmorpholine, isobutyl chloroformate/THF. Generally, vinylogous phosphonate derivatives are made by treating
Boc-a-amino aldehydes, prepared according to the method of Fehrentz, J-A. and Castro, B. (Synthesis, (1983), with the sodium anion of
methylenediphosphonates, for example tetraethyl methylenediphosphonate. The vinylogous phosphonate derivatives are then deprotected with hydrogen chloride in dioxane, and coupled with N-protected amino acids to form pseudopeptidyl vinylogous phosphonates using techniques known to those skilled in the art. The vinylogous amides and peptide derivatives of this invention can be generated by the sequence of reactions shown in Scheme V.
Figure imgf000062_0001
a) (CH3)3SiCH2CH2OH, dicyclohexylcarbodiimide (DCC), (C2H5)3N, 4-dimethylamino-pyridine, CH2Cl2;
b) HCl/dioxane;
c) NaOH/C2H5OH;
d) PheOSET, DCC, (C2H5)3N, CH2Cl2;
e) NaH, EPAc-PheOSET, THF;
f) Mu-PheOH, 4-methylmorpholine, isobutyl chloroformate, THF; and g) (n-C4H9)4N+F-, 3Å molecular sieves, THF.
The N-Boc amino acid, protected as its silylethyl (SET) ester, is
N-deprotected, then coupled with the saponification product of triethyl phosphonoacetate. The diethyl phosphonoacetyl amino acid derivative is then coupled, in Wadsworth-Emmons fashion, with the appropriate
Boc-protected a-amino aldehyde. Further elongation of the peptide sequence is concluded with fluoride-assisted deprotection of the SET moiety to afford the vinylogous amide.
Generally, to ensure that the double bond remains intact during the preparation of the vinylogous amides bound to peptide chains in that the C-terminus is to be converted to the free carboxylate or carboxylic acid group, the fluoride-cleavable silyethyl (SET) esters are used. Thus saponification conditions, which cause product mixtures resulting from both ester hydrolysis and 1,4-addition of hydroxide to the vinylogous amide at high pH, are avoided. The SET protection scheme therefore permits clean, smooth preparation of peptide sequences prior to the key
Wadsworth-Emmons coupling with an eye to carboxylate formation if the C-terminus is to be a free acid.
The cysteine protease inhibitors of the present invention that contain vinylogous ketones, nitriles, sulfoxides, sulfonamides, sulfinamides, sulfonates and sulfoximines as the EWG may be synthesized as follows using the general scheme outlined in Scheme VI:
Figure imgf000064_0001
wherein
a) Cl-H2N+(Me)OMe, dicyclohexylcarboniimide, triethylamine; and b) lithium aluminum hydride.
Structure (I - VIII) are as follows. For the synthesis of cysteine protease inhibitors with vinylogous ketones as the EWG, structure I is used:
Figure imgf000064_0002
Synthesis of α,β-unsaturated ketones is performed by means of the
Wadsworth-Emmons reaction between Boc-α-amino aldehydes and the appropriate phosphonate. Generally, the aldehyde portion is synthesized as outlined above. The phosphonate is synthesized by treatment of the enolate anion of methyl or substituted methyl ketones, such as acetone or acetophenone, with diethyl chlorophosphonate. The enolate anion is generated, for example, by treatment of a tetrahydrofuran solution of diisopropylamine with butyllithium, followed by addition of the ketone to the lithium diisopropylamide (LDA) solution (H.O. House, Modern Synthetic
Reactions, 2nd Ed. (W. Benjamin, Inc., Menlo Park, CA, Chapter 9).
Following formation of the enolate, diethyl chlorophosphonate is added. The Wadsworth-Emmons reagent forms as a consequence of coupling of the enolate with diethyl chlorophosphate. For the synthesis of cysteine protease inhibitors with vinylogous nitriles as the EWG, structure II is used:
Figure imgf000065_0001
Synthesis of α,β-unsaturated nitriles is performed by means of the
Wadsworth-Emmons reaction between Boc-α-amino aldehydes and the appropriate phosphonate. Generally, the aldehyde portion is synthesized as outlined above. The phosphonate is commercially available.
For the synthesis of cysteine protease inhibitors with vinylogous sulfoxides as the EWG, structure III is used:
Figure imgf000066_0001
Synthesis of α,β-unsaturated sulfoxides is performed by means of the Wadsworth-Emmons reaction between Boc-α-amino aldehydes and the appropriate phosphonate. Generally, the aldehyde portion is synthesized as outlined above. The phosphonate is synthesized by treatment of the anion of methyl sulfoxides with diethyl chlorophosphate. The anion is generated by addition of BuLi to diisopropylamine, followed by addition of the methyl sulfoxide.
For the synthesis of cysteine protease inhibitors with vinylogous
sulfonamides as the EWG, structure IV is used:
Figure imgf000066_0002
Synthesis of α,β-unsaturated sulfonamides is performed by means of the Wadsworth-Emmons reaction between Boc-α-amino aldehydes and the appropriate phosphonate. Generally, the aldehyde portion is synthesized as outlined above. The phosphonate is synthesized, for instances, by a method such as the following: a) diethylphosphoryl methanesulfonates, as prepared by the method of Carretero and Ghosez (Tetrahedron Lett., 28:1104-1108 (1987)), are converted to sulf onyl chlorides by treatment with phosphorus pentachloride (M. Quaedvlieg, in "Methoden der Organische Chemic
(Houben-Weyl)", ed. E. Muller, Thieme Verlag, Stuttgart, 4th Ed., 1955, Vol. IX, Chapter 14); or b) treatment of the sulfonyl chloride with an amine, such as ammonia, a primary amine (including an amino acid derivative), or a secondary amine, that results in the formation of the sulfonamide
(Quaedvlieg, supra, Chapter 19). The sulfonamide-phosphonate is then reacted with Boc-α-aminoaldehydes to form the target compounds as per the Wadsworth-Emmons reaction. For the synthesis of cysteine protease inhibitors with vinylogous
sulfinamides as the EWG, structure V is used:
Figure imgf000067_0001
Synthesis of α,β-unsaturated sulfinamides is performed by means of the Wadsworth-Emmons reaction between Boc-α-amino aldehydes and the appropriate phosphonate. Generally, the aldehyde portion is synthesized as outlined above. The phosphonate may be synthesized using one of the following methods. Treatment of methyl dialkyl phosphonates such as the commercially available methyl diethyl phosphonate (Aldrich), with thionyl chloride in the presence of aluminum chloride gives the dialkylphosphoryl methanesulfinyl chloride (Vennstra et al., Synthesis (1975) 519. See also
Anderson, "Comprehensive. Organic Chemistry (Pergamon Press)", Vol. 3, Chapter 11.18, (1979). Alternatively, treatment of the dialkyl phosphoryl sulfinyl chloride with amines (Stirling, Internat. J. Sulfur Chem. (B) 6:277 (1971)), yields the dialkyl phosphoryl sulfinamide.
For the synthesis of cysteine protease inhibitors with vinylogous
sulfoximines as the EWG, structure VI is used:
Figure imgf000068_0001
Synthesis of α,β-unsaturated sulfoximines is performed by means of the Wadsworth-Emmons reaction between Boc-α-amino aldehydes and the appropriate phosphonate. Generally, the aldehyde portion is synthesized as outlined above. The phosphonate may be synthesized in several ways. For example, N-alkyl or N-aryl phenyl methyl sulfoximines are made by the methods described by Johnson, in "Comprehensive Organic Chemistry (Pergamon Press), supra, Chapter 11.11. Alternatively, the lithium anion of compounds such as N-alkyl phenyl methyl sulfoximine is prepared by the treatment of the neutral compound with buthyl lithium in THF (Cram et al., J. Amer. Chem. Soc. 92:7369 (1970)). Reaction of this lithium anion with dialkyl chlorophosphates such as the commercially available diethyl chlorophosphate (Aldrich) results in the Wadsworth-Emmons reagent necessary for synthesis of the sulfoximine compounds.
For the synthesis of cysteine protease inhibitors with vinylogous sulfonates as the EWG, structure VII is used:
Figure imgf000069_0001
Synthesis of α,β-unsaturated sulfonates is performed by means of the Wadsworth-Emmons reaction between Boc-α-amino aldehydes and the appropriate phosphonate, for instance diethylphosphoryl methanesulfonate. The phosphonate may be synthesized as follows. The anion of methyl dialkyl phosphonates such as the commercially available methyl diethyl phosphonate (Aldrich) is generated by treatment of said phosphonate with a strong base such as LDA. The resulting anion is sulfonated with sulfur trioxide/trimethylamine complex (Carreto et al., Tetrahedron Lett., 28:1104-1108 (1987)) to form diethylphosphoryl methanesulfonate, which is capable of reacting in the Wadsworth-Emmons procedure with aldehydes to form α,β-unsaturated sulfonates.
For the synthesis of cysteine protease inhibitors with vinylogous nitro compoundss as the EWG, structure VIII is used:
Figure imgf000069_0002
Synthesis of α,β-unsaturated nitro compounds is performed by means of the Wadsworth-Emmons reaction between Boc-α-amino aldehydes and the appropriate prosphonate. The phosphonate is synthesized by treatment of the enolate anion of nitromethane with diethyl chlorophosphate. The enolate anion is generated, for example, by treatment of a tetrahydrofuran solution of dϋsopropylamine with butyllithium, followed by addition of nitromethane to the lithium diisopropylamide (LDA) solution (House, supra). Following formation of the enolate, diethyl chlorophosphate is added. The Wadsworth-Emmons reagent forms as a consequence of coupling of the nitromethane anion with diethyl chlorophosphate.
For the synthesis of cysteine protease inhibitors with EWGs comprising five or six homo- or heterocyclic aromatic rings with at least one substituted
EWG group, scheme VII is used:
Figure imgf000071_0001
Wherein
a) heat at reflux; b) solvent;
c) H2O/NaOH;
d) organic extraction; e) mix;
f) HCl/dioxane 4M; g) couple;
h) base; and
R8 = the five or six homo- or heterocyclic aromatic rings with at least one substituted EWM, MDG, or DG; and
R9 = a suitable group as defined above.
The chloride compounds containing R8 and R9 groups are generally made using commercially available reagents and products using techniques well known in the art. The reaction generally produces a mixture of cis and trans configurations. Cysteine protease inhibitors containing a diene bond instead of a single alkene bond are made using the same general synthetic scheme as outlined above, by repeating the reaction, as shown below in Scheme VIII:
Figure imgf000073_0001
The cysteine protease inhibitors which contain two EWGs linked to one of the carbons of the alkene bond may be synthesized using, for example, the methods disclosed in Brillon et al., J. Org. Chem. 57:1838-1842 (1992), hereby expressly incorporated by reference. In one embodiment, the cysteine protease inhibitors of the present invention are further purified if necessary after synthesis, for example to remove unreacted materials. For example, the cysteine protease inhibitors of the present invention may be crystallized, or passed through silica
chromatography columns using solvent mixtures to elute the pure inhibitors. In particular, the cysteine protease inhibitors of the present invention synthesized through the use of the Wittig reaction may be further purified to isolate either the cis or trans configuration. For example, the techniques outlined above may be used.
Once produced, the cysteine protease inhibitors of the present invention may be easily screened for their inhibitory effect. The inhibitor is first tested against the cysteine protease for that the targeting group of the inhibitor was chosen, as outlined above. Alternatively, many cysteine proteases and their corresponding chromogenic substrates are commercially available. Thus, a variety of cysteine proteases are routinely assayed with synthetic
chromogenic substrates in the presence and absence of the cysteine protease inhibitor, to confirm the inhibitory action of the compound, using techniques well known in the art. The effective inhibitors are then subjected to kinetic analysis to calculate the kirr and KI values, and the second order rate constants determined. This is done using techniques well known in the art; for example, progress curve analysis using non-linear curve fitting software can be done to determine the first order rate constants. Such software is sold under such tradenames as Sigma Plot (Jandel Scientific Corp .) and Statview (Abacus Concepts, Inc.).
If a compound inhibits at least one cysteine protease, it is a cysteine protease inhibitor for the purposes of the invention. Preferred embodiments have inhibitors that exhibit the correct kinetic parameters against at least the targeted cysteine protease.
In some cases, the cysteine protease is not commercially available in a purified form. The cysteine protease inhibitors of the present invention may also be assayed for efficacy using biological assays. For example, the inhibitors may be added to cells or tissues that contain cysteine proteases, and the biological effects measured.
In one embodiment, the cysteine protease inhibitors of the present invention are synthesized or modified such that the in vivo and in vitro proteolytic degradation of the inhibitors is reduced or prevented. Generally, this is done through the incorporation of synthetic amino acids, derivatives, or substituents into the cysteine protease inhibitor. Preferably, only one non-naturally occurring amino acid or amino acid side chain is incorporated into the cysteine protease inhibitor, such that the targeting of the inhibitor to the enzyme is not significantly affected. However, some embodiments that use longer cysteine protease inhibitors containing a number of targeting residues may tolerate more than one synthetic derivative. In addition, non-naturally occurring amino acid substituents may be designed to mimic the binding of the naturally occurring side chain to the enzyme, such that more than one synthetic substituent is tolerated. In this embodiment, the resistance of the modified cysteine protease inhibitors may be tested against a variety of known commercially available proteases in vitro to determine their proteolytic stability. Promising candidates may then be routinely screened in animal models, for example using labelled inhibitors, to determine the in vivo stability and efficacy.
In one embodiment, the cysteine protease inhibitors of the present invention are labelled. By a "labelled cysteine protease inhibitor" herein is meant a cysteine protease inhibitor that has at least one element, isotope or chemical compound attached to enable the detection of the cysteine protease inhibitor or the cysteine protease inhibitor irreversible bound to a cysteine protease. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the cysteine protease inhibitor at any position. For example, a label may be attached as the "P" group in Formula 1. Examples of useful labels include 14C, 3H, biotin, and fluorescent labels as are well known in the art. In one embodiment, compositions comprising chiral vinylogous
phosphonates are provided. These chiral vinylogous phosphonates are derived from α-amino acids; that is, α-amino acids are used to generate the α-amino aldehydes used in the synthesis. This novel class of compounds may be used in a preferred embodiment as cysteine protease inhibitors. In one embodiment, compositions comprising chirally pure vinylogous sulfones derived from α-amino acids are provided. This novel class of compounds may be used in a preferred embodiment as cysteine protease inhibitors.
Also provided are methods for inhibiting cysteine proteases using the cysteine protease inhibitors of the present invention. In the preferred embodiment, a cysteine protease inhibitor is irreversibly bound to a cysteine protease. This is accomplished using ordinary techniques, and will normally require contacting or adding the cysteine protease inhibitor to the sample of the cysteine protease to be inhibited. The cysteine protease inhibitors of the present invention are stoichiometric inhibitors; that is, a single inhibitor molecule will inhibit a single enzyme molecule. Thus in the preferred embodiment, an excess of inhibitor is added to ensure that all or most of the protease is inhibited. In alternative embodiments, only a portion of the protease activity is inhibited. In some embodiments, the cysteine protease inhibitor is labelled, such that the presence of a cysteine protease is detected after the excess inhibitor is removed. This may be done for example in a diagnostic assay for the detection or quantification of cysteine proteases in a sample, for example, in blood, lymph, saliva, skin or other tissue samples, in addition to bacterial, fungal, plant, yeast, viral or mammalian cell cultures.
In the preferred embodiment, the cysteine protease inhibitors of the present invention are administered to a patient to treat cysteine protease-associated disorders. By "cysteine protease-associated disorders" or grammatical equivalents herein is meant pathological conditions associated with cysteine proteases. In some disorders, the condition is associated with increased levels of cysteine proteases; for example, arthritis, muscular dystrophy, inflammation, tumor invasion, and glomerulonephritis are all associated with increased levels of cysteine proteases. In other disorders or diseases, the condition is associated with the appearance of an extracellular cysteine protease activity that is not present in normal tissue. In other embodiments, a cysteine protease is associated with the ability of a pathogen, such as a virus, to infect or replicate in the host organism.
Specific examples of cysteine protease associated disorders or conditions include, but are not limited to, arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, malaria, Alzheimer's disease, disorders associated with autoimmune system breakdowns, periodontal disease, cancer metastasis, trauma, inflammation, gingivitis, leishmaniasis, filariasis, and other bacterial and parasite-borne infections, and others outlined above.
In particular, disorders associated with interleukin 1β converting enzyme (ICE) are included, as outlined above.
In this embodiment, a therapeutically effective dose of a cysteine protease inhibitor is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces the effects for that it is administered. The exact dose will depend on the disorder to be treated and the amount of cysteine protease to be inhibited, and will be ascertainable by one skilled in the art using known techniques. In general, the cysteine protease inhibitors of the present invention are administered at about 1 to about 1000 mg per day. For example, as outlined above, some disorders are associated with increased levels of cysteine proteases. Due to the 1:1 stoichiometry of the inhibition reaction, the dose to be administered will be directly related to the amount of the excess cysteine protease. In addition, as is known in the art, adjustments for inhibitor degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the disease may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.
A "patient" for the purposes of the present invention includes both humans and other animals and organisms. Thus the methods are applicable to both human therapy and veterinary applications. For example, the veterinary applications include, but are not limited to, canine, bovine, feline, porcine, equine, and ovine animals, as well as other domesticated animals including reptiles, such as iguanas, turtles and snakes, birds such as finches and members of the parrot family, rabbits, rodents such as rats, mice, guinea pigs and hamsters, amphibians, and fish. Valuable non-domesticated animals, such as zoo animals, may also be treated. In the preferred embodiment the patient is a mammal, and in the most preferred embodiment the patient is human.
The administration of the cysteine protease inhibitors of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally,
intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the cysteine protease inhibitors may be directly applied as a solution or spray.
The pharmaceutical compositions of the present invention comprise a cysteine protease inhibitor in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts.
"Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. Additives are well known in the art, and are used in a variety of formulations.
The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes
contemplated for carrying out various aspects of the invention. It is understood that these examples in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All references cited herein are expressly incorporated by reference. EXAMPLES
The following abbreviation conventions have been used to simplify the examples.
Mu = morpholine urea
Xaa1 = amino acid at P1 position relative to active site of the enzyme Xaa2 = amino acid at P2 position relative to active site of the enzyme Xaa1,= amino acid at P1' position relative to active site of the enzyme
VSMe = vinyl sulfone with methyl terminus
VA = vinyl carboxylate
VAM-Xaa1,= vinyl amide coupled to amino acid 3;
VEOEt = vinyl ethyl ester
VPEt = vinyl phosphonate
VSPh = vinyl sulfone with phenyl terminus
Hph = homophenylalanine For instance, Mu-Phe-Lys(Z)VSPh, where Xaa2 = Phe (phenylalanine) and
Xaa1 = Lys(Z) (lysine, protected as its carbobenzyloxy urethane), transformed to the phenyl vinyl sulfone according to the procedure described in Example 5 and depicted in Scheme 2.
Example 1
Synthesis of Cysteine Protease Inhibitor
Containing a Vinylogous Ethyl Ester
Unless otherwise indicated, all reactions were performed under an inert atmosphere of argon or nitrogen at room temperature. THF was distilled from sodium benzophenone ketyl. All other solvents and commercially available reagents were used without further purification.
Synthesis of Ethyl (S)-(E)-4-(4-morpholinecarbonyl-phenylalanyl)-amino-6-phenyl-2-hexenoate, abbreviated Mu-Phe-Hph VEOEt, was as follows. Unless otherwise noted, all reagents were obtained from Aldrich, Inc. 0.393 g of a 60% mineral oil dispersion (9.82 mmol) of sodium hydride was added to a solution of triethyl phosphonoacetate (2.20 g, 9.82 mmol) in THF (50 mL) at -10°C. The mixture was stirred for 15 minutes, whereupon a solution of Boc-homophenylalaninal (Boc-HphH) (2.35 g, 9.82 mmol, prepared by conversion of Boc-homophenylalanine (Synthetech) to its N,O-dimethylhydroxamide, using the Fehrentz method, followed by lithium aluminum hydride reduction) in THF (20 mL) was added. The mixture was stirred for 45 minutes. 1M HCl (30 mL) was added. The product was extracted with ethyl acetate (50 mL), washed with saturated aqueous NaHCO3 (30 mL) dried over MgSO4, filtered, and evaporated to dryness. The dried material was dissolved in CH2Cl2 (10 mL), and a 4.0 M solution of HCl in dioxane (20 mL) was added. The mixture was stirred for 30 minutes. The solvents were removed under reduced pressure and the residue, ethyl (S)-4-amino-6-phenyl-2-hexenoate hydrochloride, was pumped dry.
Morpholinecarbonylphenylalanine (2.74 g, 9.82 mmol, prepared according to the method described in Esser, R. et.al, Arthritis & Rheumatism (1994), 0000) was dissolved in THF (50 mL) at -10°C. 4-methylmorpholine (1.08 mL, 9.82 mmol) was added, followed by isobutyl chloroformate (1.27 mL, 9.82 mmol). The mixed anhydride was stirred for 10 minutes, whereupon a solution of ethyl (S)-4-amino-6-phenyl-2-hexenoate hydrochloride from the previous step in DMF (10 mL) was added, followed by 4-mefhylmorpholine (1.08 mL, 9.82 mmol). The mixture was stirred for 1 hour. 1M HCl (50 mL) was added. The product was extracted with ethyl acetate (100 mL), washed with saturated aqueous NaHCO3 (50 mL), dried over MgSO4 and decolorizing charcoal (DARCO), filtered, and evaporated to dryness, giving 3.80 g (80% yield from Boc-homophenylalaninal). Thin-layer chromatography (TLC) was done. Unless otherwise noted, all data for this and subsequent examples used 10% MeOH/CH2Cl2.
Visualization was accomplished by means of UV light at 254 nm, followed by ninhydrin, bromocresol green, or p-anisaldehyde stain. The retention factor (Rf) of the Mu-Phe-Hph VEOEt was 0.55.
NMR spectra were recorded on a Varian Gemini 300 MHz instrument. All 1H NMR data of this and subsequent examples are reported as delta values in parts per million relative to internal tetramethylsilane, peak assignments in boldface. The following abbreviations are used: s, singlet; d, doublet; t, triplet; q, quartet; br, broad. An asterisk (*) implies that a signal is obscured or buried under another resonance.
1H NMR (CDCl3): 1.28 (3H, t, J=6Hz, CH3); 1.7-1.95 (m, 2H, CH2CH2Ph); 2.59 (2H, CH2CH2Ph); 2.99-3.17 (2H, 2×dd, J=7,15Hz and 5,15Hz, PhCH2 of Phe residue); 3.26 (4H, m, 2×CH2O (morpholine)); 3.61 (4H, m, 2×CH2N (morpholine)); 4.39 (q, J=6Hz, CH2 (ester)); 4.47-4.6 (2H, m*, 2×CHNH); 5.06 (1H, d, J=7Hz, NHCH), 5.65 (1H, d, J=15Hz, trans COCH=CH,); 6.15 (1H, d, J=7Hz, NHCH); 6.67 (1H, dd, J=5,15Hz, trans CH=CHCO);
7.09-7.36 (10H, m, aromatic).
Mass spectral data were obtained from M-Scan, Inc., West Chester, PA. FAB, high-resolution: calculated for C28H35N3O5, (m+H) = 494.2655, found, 494.2638.
Indication of approximately a 7:1 ratio of (S) to (R) epimers was evidenced by the appearance of a doublet at 5.82 ppm (J=15Hz) coupled to a doublet of doublets at 6.79 (J=5,15Hz). This phenomenon is possibly due to isomerically impure commercial material.
Example 2
Synthesis of Cysteine Protease Inhibitor Containing a Vinylogous Ethyl Ester Ethyl (S)-(E)-7-guanidino-4-(4-morpholinecarbonylphenylalanyl)amino-2-heptenoate hydrobromide, abbreviated
Mu-Phe-ArgVEOEt.HBr, was made as follows.
Boc-N -4-methoxy-2,3,6-trimethylbenzenesulfonylarginine
(Boc-Arg(Mtr)OH) was converted to its aldehyde, abbreviated as
Boc-Arg(Mtr)H according to the method of Fehrentz and Castro, supra. To a solution of triethyl phosphonoacetate (0.916 mL, 3.61 mmol) in THF (20 mL) was added NaH (0.145 g of a 60% mineral oil dispersion, 3.61 mmol). The solution was stirred for 15 minutes. A solution of Boc-Arg(Mtr)H (1.5 g, 3.29 mmol) in THF (5 mL) was added. The mixture was stirred for 45 minutes. 1H HCl (30 mL) was added. The product was extracted into ethyl acetate (50 mL), washed with saturated aqueous NaHCO3 (30 mL), dried over MgSO4, filtered, and evaporated to dryness. The residue was precipitated from CH2Cl2/ether/hexane to give 1.55 g (89%) of product, ethyl (S)-(E)-4-tert-butoxycarbonylamino-7-(4-methoxy-2,3,6-trimethylbenzenesulfonylguanidino)-2-heptenoate.
This material was treated immediately with 5 mL of 30% hydrogen bromide in acetic acid for 5 hours. The orange oil was dissolved in methanol (8 mL), and poured into ether (300 mL). The oil that separated was dried in vacuo, giving 0.81 g (67%) of ethyl (S)-4-amino-7- guanidino-2-heptenoate dihydrobromide (ArgVEOEt.2HBr) as an orange foamy solid.
To a solution of Mu-PheOH (0.55 g, 1.98 mmol) in DMF (8 mL) at -lOoC were added 4-methylmorpholine (0.217 mL, 1.98 mmol), followed by isobutyl chloroformate (0.256 mL, 1.98 mmol). The mixed anhydride was stirred for 15 minutes, whereupon a solution of ArgVEOEt.2HBr (0.81 g, 1.98 mmol) in DMF (2 mL) was added, followed by 4-methylmorpholine (0.217 mL, 1.98 mmol). The mixture was stirred for 1 hour. The solvent was removed in vacuo. Butanol (30 mL) was added. The solution was washed with saturated aqueous NaHCO3 (15 mL), filtered through glass wool, and the solvent was removed under reduced pressure. The residue was dissolved in methanol (5 mL) and filtered through a pad of Celite. The filtrate was poured into 1:1 ether/ethyl acetate (300 mL), filtered, and the solids were dried overnight, giving 0.77 g of product (68%: 41% from Boc-Arg(Mtr)H).
Melting points for this and subsequent examples were recorded on a Mel-Temp II. The melting point of theArgVEOEt.HBr was 138-142°C (dec). The NMR results, as defined in Example 1, were as follows. NMR
(DMSO-d6): 1.2 (3H, t, J=6Hz, CH3); 1.4-1.65 (4H, m,
CH2CH2CH2-guanidinium); 2.82-2.95 (2H, m, CH2Ph); 3.0-3.15 (2H, m*, CH2-guanidinium); 3.1 (4H, m, 2×CH2N (morpholine)); 3.45 (4H, m, 2×CH2O (morpholine)); 4.1 (2H, q, J=6Hz, CH2 (ester)); 4.18 (1H, m, CHNH); 4.43 (1H, m, CHNH); 5.75 (1H, d, J=15Hz, trans COCH=CH);
6.67 (1H, d, J=7Hz, NHCH); 6.75 (1H, dd, J=5,15Hz, trans CH=CHCO); 7.1-7.3 (9H, m*, aromatic and guanidinium); 7.81 (1H, m, NH); 8.15 (1H, d, J=7Hz, NHCH).
Example 3
Additional Cysteine Protease Inhibitors with
Vinylogous Ethyl Esters
(S)-(E)-Ethyl 8-(benzyloxycarbonyl)amino-4-(4-morpholinecarbonylphenylalanyl)amino-2-octenoate and (S)-(E)-Ethyl 8-amino-4-(4-morpholinecarbonylphenylalanyl)amino-2-octenoate hydrobromide were made as per Examples 1 and 2, and tested against a variety of cysteine proteases as shown below. Example 4
Synthesis of a Cysteine Protease Inhibitor with a Vinylogous Sulfone with Methyl terminus
Synthesis of (S)-(E)-5-(4-morpholinecarbonyl-phenylalanyl)amino
-7-phenyl-2-thia-3-heptene 2,2-dioxide, abbreviated Mu-Phe-HphVSMe, was as follows. Diethyl(methylsulfonylmethyl) phosphonate (MSMP) was prepared by m-chloroperbenzoic acid oxidation of commercially available diethyl(methylthiomethyl) phosphonate. To a solution of MSMP (1.5 g, 6.51 mmol) in THF (25 mL) at 0°C was added sodium hydride (0.26 g of a 60% mineral oil dispersion). The mixture was stirred for 15 minutes. A solution of Boc-HphH (1.72 g, 6.51 mmol) in THF (10 mL) was added. The mixture was stirred for 1 hour. 1M HCl (30 mL) was added. The product was extracted into ethyl acetate (50 mL), washed with saturated aqueous
NaHCO3 (30 mL), dried over MgSO4, filtered, and the solvents were removed under reduced pressure, giving 1.90 g of a white solid.
This material was dissolved in CH2Cl2 (5 mL), and was treated with 10 mL of a 4.0 M solution of HCl in dioxane. The mixture was stirred for 2 hours. Ether (200 mL) was added to the white suspension. The mixture was stirred vigorously for 5 minutes, filtered, and pumped dry to give 1.40 g of (S)-(E)-5-amino-7-phenyl-2- thia-3-heptene 2,2-dioxide (HCl.HphVSMe).
To a solution of Mu-PheOH (0.71 g, 2.54 mmol) in THF (10 mL) at -10°C were added 4-methylmorpholine (0.28 mL, 2.54 mmol) and isobutyl chloroformate (0.329 mL, 2.54 mmol). The mixed anhydride was stirred for 10 minutes, whereupon a solution of HCl.HphVSMe (0.70 g, 2.54 mmol) in DMF (2 mL) was added, followed by 4-methylmorpholine (0.28 mL, 2.54 mmol). The mixture was stirred for 45 minutes. 1M HCl (30 mL) was added. The product was extracted into ethyl acetate (50 mL), washed with saturated aqueous NaHCO3 (30 mL), dried over MgSO4, filtered, and evaporated to dryness. The residue was crystallized from
CH2Cl2/ether/hexane (1:10:5) to give a total of 0.57 g (45% yield, 35% from Boc-HphH). The retention factor on TLC: (10% MeOH/CH2Cl2) was 0.69.
1H NMR (CDCl3): 1.7-1.97 (2H, m, CH2CH2Ph); 2.31 (2H, m, CH2CH2Ph); 2.86 (3H, s, CH3SO2); 3.08 (2H, br. d, PhCH2); 3.48 (4H, m, 2×CH2N (morpholine)); 3.62 (4H, m, 2×CH2O, (morpholine)); 4.52 (1H, q, J=7Hz, CHNH (Phe)); 4.61 (1H, m, CHNH); 4.95 (1H, d, J=7Hz, NHCH); 6.10 (1H, dd, J=2,15Hz, trans SO2CH=CH); 6.43 (1H, d, J=7Hz, NHCH); 6.70 (1H, dd, J=5,15Hz, trans CH=CHSO2); 7.08-7.38 (10H, m, aromatic.)
Indication of approximately an 8:1 ratio of (S) to (R) epimers was evidenced by the presence in the spectrum of Mu-Phe-HphVSMe of a doublet of doublets at 6.95 ppm (J=5,15Hz), along with a singlet at 2.87 ppm. This phenomenon is possibly due to isomerically impure commercial material.
Example 5
Synthesis of additional Cysteine Protease
Inhibitors with Vinylogous Sulfones with Methyl
Termini (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-1-butene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene, and (S)-(E)-3-(tert-butoxycarbonylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene were made as above, and tested against various cysteine proteases as shown below. Example 6
Synthesis of a Cysteine Protease Inhibitor with a Vinylogous Sulfone with Phenyl terminus
Synthesis of (S)-(E)-3-tert-butoxycarbonylamino-4-methyl-1-phenylsulfonyl-1-pentene, abbreviated Boc-ValVSPh, was as follows. To a solution of diethyl phenylsulfonylmethylenephosphonate (PSMP), (1.40 g, 4.79 mmol, prepared by treatment of the lithium anion of methyl phenyl sulfone with diethyl chlorophosphate) in THF (20 mL) at -20°C was added sodium hydride (0.192 g of a 60% mineral oil dispersion, 4.79 mmol). The mixture was warmed to 0°C over 20 minutes. Boc-valinal (0.876 g, 4.35 mmol) prepared according to the method of Fehrentz and Castro, supra), was added as a solution in THF (5 mL). The mixture was stirred for 30 minutes. 1M HCl (30 mL) was added. The product was extracted with ethyl acetate (50 mL), washed with saturated aqueous NaHCO3 (30 mL), brine (20 mL), dried over MgSO4, filtered, and evaporated to dryness to afford the product in quantitative yield.
The melting point of the Boc-ValVSPh was 101-103°C.
TLC analysis (30% ethyl acetate/pet. ether) showed a retention factor of 0.4. 1H NMR (CDCl3): 0.92 (6H, 2×d, J=6Hz, isopropyl CH3's of valine residue); 1.39 (9H, s, t-C4H9); 1.87 (1H, m, CH(CH3)2); 4.11 (1H, m, CHNH); 4.5 (1H, br d, NHCH); 6.41 (1H, d, J=15Hz, trans SO2CH=CH); 6.87 (1H, dd, J=5,15Hz, trans CH=CHSO2); 7.48-7.87 (5H, m, aromatic). Example 7
Synthesis of a Cysteine Protease Inhibitor with a Vinylogous Sulfone with Phenyl Terminus
Synthesis of (S)-(E)-3-(4-morpholinecarbonyl-phenylalanyl)amino
-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Phe-HphVSPh, was as follows. To a solution of PSMP (1.94 g, 6.64 mmol) in THF (30 mL) at 0ºC was added sodium hydride (0.27 g of a 60% mineral oil dispersion, 6.64 mmol). After 15 minutes, a solution of Boc-HphH (1.59 g, 8.94 mmol) in THF (5 mL) was added. The mixture was stirred for 30 minutes. 1M HCl (20 mL) was added. The product (Boc-HphVSPh) was extracted into ethyl acetate (80 mL), washed with saturated aqueous NaHCO3 (30 mL), dried over MgSO4, filtered, and the solvents were removed under reduced pressure to give a pale yellow oil.
This material was dissolved in CH2Cl2 (5 mL) and treated with a 4.0 M solution of HCl in dioxane (15 mL) for 30 minutes. The solvents were removed under reduced pressure, the residue was dissolved in methanol (5 mL) and the solution was poured into hexane/ether (1:1; 350 mL). The precipitate was filtered and pumped dry to give 0.77 g (38% from
Boc-HphH) of (S)-(E)-3-amino-5-phenyl-1-phenylsulfonyl-1-pentene hydrochloride (HCl.HphVSPh).
To a solution of Mu-PheOH (0.63 g, 2.28 mmol) in THF (10 mL) at -10ºC was added 4-methylmorpholine (0.251 mL, 2.28 mmol), followed by isobutyl chloroformate (0.295 mL, 2.28 mmol). The mixed anhydride was stirred for 10 minutes, whereupon a solution of HCl.HphVSPh (0.77 g, 2.28 mmol) in DMF (2 mL) was added, followed by 4-methylmorpholine (0.251 mL, 2.28 mmol). The mixture was stirred for 1 hour. 1M HCl (20 mL) was added. The product was extracted into ethyl acetate (50 mL), washed with saturated aqueous NaHCO3 (30 mL), dried over MgSO4, filtered, and evaporated to dryness, giving 0.80 g (62%) yield of product as an amorphous solid.
The melting point of the product was 85-87°C. 1H NMR (CDCl3): 1.68-1.93 (2H, m, CH2CH2Ph); 2.58 (2H, m,
CH2CH2Ph); 3.03 (2H, d, J=7Hz, PhCH2CH); 3.27 (4H, m, 2×CH2N
(morpholine)); 3.62 (4H, m, 2×CH2O (morpholine)); 4.44 (1H, q, J=7Hz, CHCH2Ph); 4.62 (1H, m, CHCH=CH); 4.93 (1H, d, J=7Hz, NHCH); 6.08 (1H, dd, J=2,15Hz, trans SO2CH=CH); 6.23 (1H, d, J=7Hz, NHCH); 6.77 (1H, dd, J=5,15Hz, trans CH=CHSO2); 7.07-7.87 (15H, m, aromatic).
Mass Spectroscopy (FAB, high resolution): calculated for C31H35N3O5S,
(m+H) = 562.2376, found 562.2362.
Example 8
Synthesis of additional cysteine protease inhibitors with vinylogous sulfones with phenyl termini The following cysteine protease inhibitors were made as per examples 6 and
7 and tested as shown below: (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-6-guanidino-1-phenylsulfonyl-1-hexene hydrobromide, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-glycylamino-4-phenyl-1-phenylsulfonyl-1-butene hydrochloride, (S)-(E)-7-(benzyloxycarbonyl)amino-3-(4-morpholinecarbonylphenylalanyl)-amino-1-phenylsulfonyl-1-heptene, (S)-(E)-7-amino-3-(4-morpholinecarbonylphenylalanyl)amino-1-phenylsulfonyl-1-heptene hydrobromide, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-4-methyl-1-phenylsulfonyl-1-butene, (S)-(E)-3-amino-4-phenyl-1-phenylsulfonyl-1-butene hydrochloride, (S)-(E)-3-(4-morpholinecarbonylvalyl)amino-4-phenyl- 1-phenylsulfonyl-1-butene, (S)-(E)-3-(4-morpholinecarbonylarginyl)amino-6- guanidino-1-phenylsulfonyl-1-hexene dihydrobromide, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-4-benzyloxy-1-phenylsulfonyl-1-butene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-7-benzoylamino-1-phenylsulfonyl-1-heptene, (R)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-[4-morpholinecarbonyl-(3,5-diiodotyrosyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-[4-tert-butoxycarbonyl-(3,5-diiodotyrosyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S,S)-(E)-3-[4-morpholinecarbonyl-(1,2,3,4-tetrahydro-3-isoquinoline-carbonyl)]amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S,S)-(E)-3-[tert-butoxycarbonyl-(1,2,3,4-tetrahydro-3-isoquinolinecarbonyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene, (S)-(E)-3-amino-5-phenyl-1-phenylsulfonyl-1-pentene hydrochloride, (S)-(E)-3-[(4-morpholinecarbonyl-(R,S)-α-methylphenylalanyl]amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)- (E)-3-(benzyloxycarbonylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene, (S)-(E)-3-(4-morpholinecarbonyltyrosyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(tert-butoxycarbonyl-2-naphthylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonyl-2-naphthylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonyl-4-biphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-phenylsulfonyl-1-heptene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-phenylsulfonyl-6-thia-1-heptene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-methylsulfonyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(acetylleucylleucyl)amino-1-phenylsulfonyl-1-heptene, (S)-(E)-3-(acetylleucylleucyl)amino-1-phenylsulfonyl-6-thia-1-heptene, (S)-(E)-3-(acetylleucylleucyl)amino-5-methylsulfonyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(carbomethoxypropionylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-7-(benzyloxycarbonyl)amino-3-(4-morpholinecarbonyl phenylalanyl)-amino-1-fluoro-1-phenylsulfonyl-1-heptene, (S)-(E)-3-(acetylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene, (S)-(E)-3-(dimethylsulfamoylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-(4-bromophenylsulfonyl)-5-phenyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-(2-napthylsulfonyl)-5-phenyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonyl-2-naphthylalanyl)amino-1-(2-napthylsulfonyl)-5-phenyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-1-butene, (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene, and (S)-(E)-3-(tert-2butoxycarbonylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene.
Example 9
Synthesis of a Cysteine Protease Inhibitor with
a Vinylogous Carboxlate
Synthesis of (S)-(E)-4-(4-morpholinecarbonyl-phenylalanyl)amino-6-phenyl-2-hexenoic acid, abbreviated Mu-Phe-HphVA, was as follows. To a solution of Mu-Phe-VEOEt (see Example 1; 1.96 g, 4.15 mmol) in ethanol (7 mL) was added 1M NaOH (9.5 mL) over 3 hours. The solvents were evaporated. Water (30 mL) was added. The solution was washed with ethyl acetate (30 mL), acidified with 1M HCl (15 mL), extracted with ethyl acetate (60 mL), dried over MgSO4, filtered, and evaporated to dryness, giving a slightly off-white foam. Yield = 1.63 g (89%). The melting point was determined to be 91-93°C. TLC analysis in 10% CH3OH/CH2Cl2 showed a retention factor of 0-0.3 (streak, staining yellow with bromocresol green, indicating presence of acidic functionality). The material was derivatized with HCl.Leu-ProOCH3 (Example 8, infra, to demonstrate retention of double bond configuration; see NMR data described therein.
Example 10
Synthesis of an additional cysteine protease inhibitor
with a vinylogous carboxylate
(S)-(E)-Benzyl 4-(4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenamide was synthesized using the techniques of example 9 and tested as shown below.
Example 11
Synthesis of a Cysteine Protease Inhibitor with
a Vinylogous Phosphonate Suynthesis of diethyl (S)-(E)-4-(4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenephosphonate, abbreviated
Mu-Phe-HphVPEt, was as follows. To a solution of tetraethyl
methylenediphosphonate (2.00 g, 6.94 mmol) in THF (30 mL) was added sodium hydride (0.278 g of a 60% mineral oil dispersion, 6.94 mmol). The mixture effervesced rapidly and then clarified. After 5 minutes, a solution of Boc-HphH (1.83 g, 6.94 mmol) in THF (5 mL) was added. The mixture was stirred for 1 hour. 1M HCl (20 mL) was added. The product was extracted into ethyl acetate (50 mL), washed with saturated aqueous
NaHCO3 (20 mL), brine (10 mL), dried over MgSO4, filtered, and evaporated to dryness, giving 2.46 g (89%) of diethyl (S)-(E)-4-tert-butoxycarbonylamino-6-phenyl-2-hexenephosphonate (Boc-HphVPEt) as a single spot on TLC (Rf=0.58, 10% CH3OH/CH2Cl2). This material was used without further purification.
To a solution of Boc-Hph-VPEt (2.46 g, 6.19 mmol) in CH2Cl2 (3 mL) was added 10 mL of a 4.0 M solution of HCl in dioxane. The mixture was stirred at room temperature for 1.5 hours. The solvents were removed under reduced pressure and the residue was dissolved in methanol (10 mL). The solution was poured into ether (400 mL). The precipitate was collected on a Buchner funnel, washed with ether (2×20 mL), and was pumped dry to give 1.25 g (60%) of product, diethyl (S)-(E)-4-amino-6-phenyl-2-hexenephosphonate hydrochloride (HCl.HphVPEt).
To a solution of Mu-PheOH (1.04 g, 3.74 mmol) in THF (15 mL) at -10ºC was added 4-methylmorpholine (0.412 mL, 3.74 mmol), followed by isobutyl chloroformate (0.486 mL, 3.74 mmol). The mixed anhydride was stirred for 5 minutes, whereupon a solution of HCl.HphVPEt (1.25 g, 3.74 mmol) in DMF (5 mL) was added, followed by 4-methylmorpholine (0.412 mL, 3.74 mmol). The mixture was stirred for 1 hour. Ethyl acetate (50 mL) was added. The solution was washed with 1M HCl (25 mL), saturated aqueous NaHCO3 (25 mL), and brine (10 mL), dried over MgSO4, filtered, and evaporated to dryness. The product, upon treatment with
CH2Cl2/ether/hexane (315 mL in a 15:200:100 ratio) formed an oil that solidified on drying in vacuo to give 1.44 g (69%) of the final product.
The melting point of the product was determined to be 53-55°C.
TLC analysis (10% CH3OH/CH2Cl2) showed a retention factor of 0.48. 1H NMR (CDCl3): 1.35 (6H, 2×t, J=7Hz, 2×CH3CH2OP); 1.68-1.87 (2H, m, CH2CH2Ph); 2.58 (2H, m, CH2CH2Ph); 3.08 (2H, d, J=7Hz, CH2Ph); 3.28 (4H, m, 2×CH2N (morpholine)); 3.62 (4H, m, 2×CH2O (morpholine));
4.0-4.13 (4H, 2×dq, J=3,7Hz, 2×CH3CH2OP, long-range H-C-O-P coupling responsible for splitting of quartet); 4.53 (1H, q*, J=7Hz, CHNHC=O); 4.56 (1H, m, CHCH=CH); 5.02 (1H, d, J=7Hz, NHCH); 5.50 (1H, ddd,
J=2,15,17Hz, P-CH=CH-CH); 6.34 (1H, d, J=7Hz, NHCH); 6.58 (1H, ddd,
5,15,20Hz, CH=CH-P); 7.08-7.34 (10H, m, aromatic).
Mass spectroscopy (FAB, high resolution): calculated for C29H40N3O6P, (m+H) = 558.2733, found 558.2775.
Example 12
Synthesis of a Cysteine Protease Inhibitor with
A Vinylogous Amide
Synthesis of (S)-(E)-(N-leucylproline methyl ester)-4-(4-morpholinecarbonylphenyl-alanyl)amino-6-phenyl-2-hexenamide, abbreviated
Mu-Phe-HphVAM-Leu-ProOMe, was as follows. Leucylproline methyl ester hydrochloride (HCl.Leu-Pro-OMe) was prepared by mixed anhydride coupling of Boc-leucine and proline methyl ester hydrochloride, followed by Hcl-mediated deprotection of the N-terminal Boc group. Mu-Phe-HphVA (from Example 6, 1.42 g, 3.21 mmol) was dissolved in THF (15 mL) and cooled to -10°C. To this solution was added 4-methylmorpholine (0.354 mL, 3.21 mmol), followed by isobutyl chloroformate (0.417 mL, 3.21 mmol). The mixed anhydride was stirred for 5 minutes, whereupon
HCl.Leu-ProOMe (0.897 g, 3.21 mmol) was added. 4-methylmorpholine (0.354 mL, 3.21 mmol) was added. The mixture was stirred for 4 hours. 1M HCl (20 mL) was added. The product was extracted into ethyl acetate (50 mL), washed with saturated aqueous NaHCO3 (20 mL), brine (20 mL, dried over MgSO4, filtered, and evaporated to dryness. The residue was dissolved in CH2Cl2 (5 mL) and was poured into 1:1 ether/pet ether (150 mL). The precipitate was collected on a Buchner funnel and pumped dry to give 1.42 g (64%) of a white solid.
The melting point of the product was determined to be 97-100°C.
TLC analysis (10% CH3OH/CH2Cl2) showed a retention factor of 0.47. 1H NMR (CDCl3): 0.93 (6H, 2xd, J=7Hz, 2×CH3 (Leu)); 1.67-2.25 (9H, m,
CH(CH3)2, CH2 (Leu), 2×CH2 (Pro), CH2CH2Ph); 2.54 (1H, br t,
PhCH2CH2); 3.04 (2H, m, CH2Ph); 3.28 (4H, m, 2×CH2N (morpholine)); 3.5-3.8 (6H, m*, 2×CH2O (morpholine), CH2N (Pro)); 3.7 (3H, s, OCH3); 4.42-4.52 (2H, m, 2×CHNH); 4.89 (1H, m, CHNH); 5.11 (1H, d, J=7Hz, NHCH); 5.43 (1H, dd, J=2,15Hz, trans NHCOCH=CH); 6.03 (1H, d, J=7Hz,
NHCH); 6.25 (1H, d, J=7Hz, NHCH); 6.55 (1H, dd, J=6,15Hz, trans CH=CHCONH); 7.03=7.36 (10H, m, aromatic).
Example 13
Synthesis of a Cysteine Protease Inhibitor
with a Vinylogous Amide
Synthesis of (S)-(E)-(N-phenylalanine)-4- (4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenamide, abbreviated
Mu-Phe-HphVAM-PheOH, proceeded as follows. Boc-PheOH (5.00 g, 18.85 mmol), trimethylsilylethanol (2.70 mL, 18.85 mmol), and
4-dimethylaminopyridine (0.23 g, 1.89 mmol) were dissolved in CH2Cl2 (70 mL). A solution of dicylcohexylcarbodiimide (DCC) (3.89 g, 18.85 mmol) in CH2Cl2 (20 mL) was added. The mixture was stirred for 1 hour. The suspension was filtered and the solvent was removed under reduced pressure. The residue was dissolved in ether (200 mL), washed with 50 mL each of 1M HCl, saturated aqueous NaHCO3, and brine, dried over MgSO4, filtered, and evaporated to dryness. The residue was dissolved in hot hexane, filtered to remove any residual dicyclohexylurea (DCU) by-product, and evaporated to give 6.7 g (98% yield) of a colorless oil,
tert-butoxycarbonylphenylalanine, silylethyl ester (Boc-PheOSET). TLC of the Boc-PheOSET (30% ethyl acetate/hexane) showed a Rf of 0.65.
30 mL of a 4.0 M solution of HCl in dioxane was added to the
Boc-PheOSET from the previous step. The mixture was stirred for 90 minutes. The solvents were evaporated, giving a waxy solid, phenylalanine silylethyl ester hydrochloride (HCl.PheOSET). 1H NMR (CDCl3): 0.02 (9H, s, (CH3)3Si); 0.89 (2H, m, CH2Si); 3.32-2.51
(2H, 2xdd, J=7,14Hz, J=5,14Hz, CH2Ph); 4.18 (2H, m, CH2CH2Si); 4.37 (1H, br q, CHNH3 +); 7.23-7.37 (5H, m, aromatic); 8.82 (3H, br s, NH3 +).
Diethyl phosphonoacetic acid (DEPA) was prepared in quantitative yield by saponification of triethyl phosphonoacetate in ethanol, in the presence of 1.1 equivalents of 1M NaOH. To a solution of DEPA (1.62 g, 8.28 mmol),
HCl.PheOSET (2.5 g, 8.28 mmol), and triethylamine (0.676 mL, 8.28 mmol) in CH2Cl2 (30 mL) was added a solution of DCC (1.71 g, 8.28 mmol) in CH2Cl2 (10 mL). The mixture was stirred at room temperature for 16 hours. The white suspension was filtered, the solvent was removed under reduced pressure, and the residue was dissolved in ethyl acetate (100 mL). The solution was washed with 1M HCl (50 mL), saturated aqueous NaHCO3 (50 mL), brine (25 mL), dried over MgSO4, filtered, and evaporated to dryness. The residue was dissolved in hot pet ether and filtered to remove any remaining DCU, and was evaporated to give a colorless oil, diethyl phosphonoacetylphenylalanine, silylethyl ester (EPAc-PheOSET) weighing
3.56 g (97% from Boc-PheOSET). TLC analysis (20% ethyl acetate/CH2Cl2) showed a retention factor of 0.22.
To a solution of EPAc-PheOSEt (1.19 g, 2.68 mmol) in THF (10 mL) at 0°C was added sodium hydride (107 mg of a 60% mineral oil dispersion). The mixture was stirred for 15 minutes while being allowed to warm to room temperature, whereupon a solution of Boc-HphH (0.707 g, 2.68 mmol) in THF (5 mL) was added. The mixture was stirred for 20 minutes. 1M HCl (15 mL) was added. The product was extracted into ethyl acetate (40 mL), washed with saturated aqueous NaHCO3 (15 mL), brine (15 mL), dried over MgSO4, filtered, and evaporated to dryness. The product, (S)-(E)-(N-phenylalanine silylethyl ester)-4-tert-butoxycarbonylamino-6-phenyl-2-hexenamide (Boc-HphVAM-PheOSET) was crystallized from CH2Cl2 and 1:1 ether/hexane. Yield = 0.78 g (53%). TLC analysis (30% ethyl acetate/hexane) showed a retention factor of 0.35.
To a solution of Boc-HphVAM-PheOSET (1.80 g, 3.25 mmol) in CH2Cl2 (1 mL) were added 8 mL of a 4.0 M solution of HCl in dioxane. The mixture was stirred for 60 minutes, whereupon the solvents were removed under reduced pressure. The residue was pumped to a pale yellow foamy solid, (S)-(E)-(N-phenylalanine silylethyl ester)-4-amino-6-phenyl-2-hexenamide (HCl.HphVAM-PheOSET). Yield = 1.40 g (88%). To a solution of Mu-PheOH (0.797 g, 2.86 mmol) in THF (10 mL) at -10ºC was added 4-methylmorpholine (0.315 mL, 2.86 mmol), followed by isobutyl chloroformate (0.371 mL, 2.86 mmol). The mixed anhydride was stirred for 5 minutes, whereupon a solution of HCl.HphVAM-PheOSET (1.40 g, 2.86 mmol) in THF (5 mL) was added. 4-methylmorpholine (0.315 mL, 2.86 mmol) was added. The mixture was stirred for 75 minutes. Ethyl acetate (40 mL) was added. The mixture was washed with 1M HCl (15 mL), saturated aqueous NaHCO3 (15 mL), brine (10 mL), dried over MgSO4, filtered, and evaporated to dryness, giving 1.9 g (93%) of the product, (S)-(E)- (N-phenylalanine silylethyl ester)-4-(4-mθrpholinecarbonylphenylalanyl)amino-6-phenyl- 2-hexenamide
(Mu-Phe-HphVAM-PheOSET). TLC analysis (50% ethyl acetate/CH2Cl2) revealed a retention factor of 0.32.
To a solution of Mu-Phe-HphVAM-PheOSET (1.59 g, 2.23 mmol) in THF (10 mL) were added ~2 g of 3Å molecular sieves, followed by 2.23 mL of a 1.0 M THF solution of tetrabutylammonium fluoride. The mixture was stirred at room temperature overnight. Ethyl acetate (50 mL) was added.
The solution was filtered through Celite, washed with 1M HCl (20 mL), brine (20 mL) dried over MgSO4, filtered, and evaporated to dryness. The residue was dissolved in CH2Cl2 (10 mL) and the solution was poured into ether (300 mL). The precipitate was collected on a Buchner funnel, washed with ether (2×20 mL), and pumped dry to give 0.84 g (61%) of
Mu-Phe-HphVAM-PheOH as a white solid.
The melting point was determined to be 95-98°C.
TLC analysis (10% CH3OH/CH2Cl2) showed a retention factor of 0.05-0.18 (yellow stain with bromocresol green indicating acidic functionality.) Mass spectroscopy (FAB, low resolution): calculated for C35H40N4O6,
(m+H) = 613, found weak probable molecular ion cluster centered at m/z = 614.
Example 14
Synthesis of a cysteine protease inhibitor
with a vinylogous sulfone Synthesis of (S)-(E)-3-tert-butoxycarbonylamino-4-tert-butoxycarbonyl-1-methylsulfonyl-1-butene, abbreviated herein as (Boc-Asp(Ot-Bu)VSMe, was as follows. The aldehpyde of Boc-Asp(Ot-Bu) was prepared in a slightly modified version of the manner of Fehrentz, supra, by the conversion to the N2O-dimethyl amide in quantitative yield. Reduction with lithium aluminum hydride (0.5 mole equivalents) reduced the amide in the presence of the tertbutyl ester in 88% yield. Sodium hydride (0.633 g of a 60% mineral oil suspension, 16.58 mmol) was added to a solution of diethyl
methylsulfonylmethylene phosphonate (3.5 g, 15.2 mmol) in THF (50 ml) at 0°C. The mixture was warmed to 25°C over 60 minutes. Boc-AspH(β-O-t- Bu) (3.78 g, 13.82 mmol) was added as a solution in THF (15 mls). The mixture was stirred for 60 minutes. 50 mls of 1 M HCl was added. The product was extracted with 100 mls of ethyl acetate, washed with 50 mls saturated aqueous NaHCO3, 50 mls of brine, dired over CaCl2, filtered, and evaporated to dryness. The residue was purified by column chromatography
(30-60% ethyl acetate in hexane, gradient elution) to afford the product, (1.88 gm, 39%), that could be crystallized from ether and hexane.
TLC (30% ethyl acetate/hexane): Rf = 0.25. 1H NMR (CDCL3): 1.43 (18H, 2xs*, t-Bu CH3's); 2.55 (2H, 2×dd, J=16,7 Hz, CH2COOt-Bu); 2.91 (3H, s, CH3); 4.69 (1H, m, CHNH); 5.38 (1H, m, NHCH); 6.50 (1H, dd, J=15,2 Hz, trans SO2CH=CH); 6.86 (1H, J=5, 15 Hz, trans CH=CHSO2).
Example 15
Synthesis of a cysteine protease inhibitor
with a vinylogous sulfone (S)-(E)-3-amino-4-tert-butoxycarbonyl-1-methylsulfonyl-1-butene, abbreviated TsOH.Asp(Ot-Bu)VSMe was synthesized as follows. A solution of anhydrous p-toluenesulfonic acid (0.95 g, 5.58 mmol) (commercially available as the hydrate from Aldrich) in 1 ml ether was added to a solution of Boc-Asp(Ot-Bu)VSME (0.41 g, 1.17 mmol) in 1:1 dichloromethane/ether (4 ml). The mixture was stirred at room temperature overnight. 15 ml of ether was added. The product, a precipitate, was filtered, washed with 20 mls ether, and dried in vacuo to give 0.49 g (99%) of the product. By using p-toluenesulfonic acid, the Boc group was selectively removed in the presence of the less labile tert-butyl ester.
Example 16
Synthesis of a cysteine protease inhibitor
with a vinylogous sulfone
Synthesis of (S)-(E)-3-tert-butoxycarbonylamino-4-tert-butoxycarbonyl-1-phenylsulfonyl-1-butene, abbreviated Boc-Asp(Ot-Bu)-VSPh was as follows. Sodium hydride (0.489 g of a 60% mineral oil dispersion, 12.23 mmol) was added to a solution of PMSP (3.58 g, 12.23 mmol) in 50 mL of THF at 0°C. The mixture was stirred for 15 minutes. A solution of Boc-AspH(β-Ot-Bu), prepared as described above (3.04 gm, 11.12 mmol) in 10 mls THF was added. The mixture was stirred for 1 hour, whereupon 30 mls of 1 M HCl was added. The product was extracted with ethyl acetate (100 ml), and washed with 50 mls of saturated aqueous NaHCO3, 30 mls brine, dired over MgSO4. filtered, and evaporated to dryness. Chromatography on silica gel
(20-30% ethyl acetate/hexane, gradient elution) afforded 2.07 g 45%) of the product.
TLC = Rf = 0.31.
Example 17
Synthesis of a cysteine protease inhibitor
with a vinylogous sulfone Synthesis of (S)-(E)-3-amino-4-tert-butoxycarbonyl-1-phenylsulfonyl-1-butene-p-toluenesulfonate, abbreviated TsOH.Asp(Ot-Bu)VSPh, was as follows. A solution of anhydrous p-toluenesulfonic acid (1.0 g, 5.87 mmol) in 2 mis ether was added to a solution of Boc-Asp(Ot-Bu)VSPh (0.72 g, 1.75 mmol) in 2 mis ether. The mixture was stirred at room temperature overnight, then diluted with ether (25 mls). The white precipitate, was filtered, washed with ether, and dried in vacuo to give 0.80 g (95%) of the product.
Example 18
Synthesis of a cysteine protease inhibitor with a vinylogous sulfone
Synthesis of (S)-(E)-3-amino-4-hycroxylcarbonyl-1-phenylsulfonyl-1-butene-p-toluenesulfonate, abbreviated HCl.AspVSPh was as follows. To a solution fo Boc-Asp(Ot-Bu)VSPh (0.32g, 0.778 mmol) in 2 mls ether was added 2 mis of 4.Q M HCl in dioxane (Aldrich). The mixture was stirred at room temperature overnight. 50 mls ether was added. The supernatant was decanted, and the residue was precipitated from methanol/ether, filtered, and dried in vacuo to give 0.2o g (88%) of product. By using HCl, both Boc and t-butyl ester groups were thus removed in one reaction. Example 19
Synthesis of a cysteine protease inhibitor with a vinylogous sulfone
Synthesis of (E)-3-acetyltyrosylvalylalanylamino-4-tert-butoxycarbonyl-1-phenylsulfonyl-1-butene, abbreviated Ac-Tyr-Val-Ala-Asp(Ot-Bu)VSPh, was as follows. Ac-Tyr-Val-AlaOH was prepared by standard peptide chemistry and coupled via mixed anhydride chemistry to TsOH.Asp(Ot-Bu)VSPh. The proton NMR spectrum (in CD8OD) indicated a singlet at 1.18 ppm, integrating to 9H (t-butyl ester), a singlet at 1.75 integrating to 3H (CH8 of acetate at N-terminus). Signals for the alkene group hydrogens are obscured by the aromatic Tyr protons at 6.6-7.2 ppm. The sulfonate aromatic protons (5H) absorbed at 7.6-7.9 ppm. The presence of the remaining residues in the NMR spectrum was clarified, in part, by removal of the t-butyl ester and spectroscopic analysis (infra).
Example 20
Synthesis of a cysteine protease inhibitor
with vinylogous sulfones
Synthesis of (E)-3-acetyltyrosylvalylalanylamino-4-hydroxycarbonyl-1-phenylsulfonyl-1-butene, abbreviated Ac-Tyr-Val-Ala-AspVSPh was as follows. Trifluoroacetic acid (0.5 mL) was added to Ac-Tyr-Val-Ala-Asp(O-t-Bu) VSPh (45 mg, 66.7 μmol). The mixture was permitted to stand at room temperature overnight. Ether (20mL) was added. The precipitate was chilled to -20°C, filtered, washed with ether (10mL), and dried in vacuo. 1H NMR (CD3OD/DMSO-d6) indicated Ala and Val residues (0.8-1.2ppm). The t-butyl group singlet at 1.18 ppm was no longer present. The presence of the vinyl sulfone group was indicated as a doublet (J=15Hz) at 6.66 ppm, partially obscured by the doublet of the Tyr-aromatic residue, and as a doublet of doublets (J=15,5Hz) at 6.91 ppm. The other Tyr-aromatic residue was seen as a doublet at 7.01 ppm. The sulfone aromatic protons (5H) were seen between 7.6 and 7.85 ppm.
The above examples demonstrate the feasibility of chemical manipulation of aspartic acid derivatives with the Asp side chain protected and deprotected.
By using toluenesulfonic acid and trifluoroacetic acid at the appropriate stages of the synthesis, α,β-unsaturated sulfones [EWG'S] can be prepared as ICE inhibitors bearing Asp as the P, active site side chain moiety.
Example 21
Synthesis of a cysteine protease inhibitor
with a vinylogous sulfone
Synthesis of (S)-(E)-3-(4-morpholine-carbonylleucyl) amino-5-phenyl-1-phenylsulfonyl-1-pentene, abbreviated Mu-Leu-HphVSPh, was as follows. Preparation of Mu-Leu-Hph was achieved by coupling of HCl.HphVSPh (described in the preparation of Mu-Phe-HphVSPh) with leucine morpholine urea (Mu-LeuOH). Mu-LeuOH was prepared in two steps, namely by treating the leucine benzyl ester p-toluenesulfonate (Bachem) with 4-morpholine chloride (Aldrich) in the presence of triethylamine (Aldrich) to give Mu-LeuOBzl in 99% yield. Hydrogenolysis over 5%
palladium/charcoal in ethyl acetate afforded the desired product in quantitative yield.
Example 22
Inhibition of Cathepsin B
Stock solutions of the various inhibitors (10 mM) were made in DMF;
dilutions were made in the same solvent. Cathepsin B from human placenta, obtained from Sigma, was approximately 10 nM in the assay. The assay buffer contained 50 mM phosphate at pH 6.2, 2.5 mM dithiothreitol (DTT), and 2.5 mM ethylenediaminetetraacetic acid (EDTA). The substrate for cathepsin B was 50 μM Z-Arg-Arg-AMC (carbobenzyloxyarginylarginylaminomethylcoumarin). The assays were initiated at 25°C by addition of enzyme to 2 mL of assay buffer containing the substrate and the various inhibitors (30-0.001 (μM). The increase in fluorescence at 460 nm with excitation at 380 nm was followed with time, and the assay was linear throughout the range observed. Inactivation of cathepsin B was indicated by a downward curve in the increase in fluorescence with time. In the absence of inhibitors, the enzymatic production of free AMC was linear throughout the time course of inactivation examined. Data points were collected over at least 3 half-times of inactivation, and in duplicate. The inhibition progress curves were analyzed using non-linear curve fitting software to compute the kobs values. Approximate second-order inactivation constants (kobs/[I]) were calculated for all compounds. For selected inhibitors, plots of 1/[I] vs.
1/kobs yielded the true constants kirr, KI, and kirr/KI, and were corrected for the presence of substrate by dividing KI(app.) by { 1+tS]/Km}.
The results are shown in Table 2.
Figure imgf000106_0001
Figure imgf000107_0001
Example 23
Inhibition of Cathepsin L
Stock solutions of the various inhibitors (10 mM) were made in DMF; dilutions were made in the same solvent. Cathepsin L from rat liver, (see
Mason et al., Biochem. J. 226:233-241 (1985)) was approximately 1 nM in the assay. The assay buffer contained 50 mM phosphate at pH 6.2, 2.5 mM dithiothreitol (DTT), and 2.5 mM ethylenediaminetetraacetic acid (EDTA). The substrate for cathepsin L was 5 μM Z-Phe-Arg-AMC (carbobenzyloxy phenylalanylarginylaminomethylcoumarin). The assays were initiated at 25°C by addition of enzyme to 2 mL of assay buffer containing the substrate and the various inhibitors (30-0.001 μM). The increase in fluorescence at 460 nm with excitation at 380 nm was followed with time. Inactivation of cathepsin L was indicated by a downward curve in the increase in fluorescence with time. In the absence of inhibitors, the enzymatic production of free AMC was linear throughout the time course of inactivation examined. Data points were collected over at least 3 half-times of inactivation. The inhibition progress curves were analyzed using non-linear curve fitting software to compute the kobs values. Approximate second-order inactivation constants (kobs/[I]) were calculated for all compounds. For selected inhibitors, plots of 1/[I] vs. 1/kobs yielded the true constants kirr, KI, and kirr/KI, and were corrected for the presence of substrate by dividing KI(app.) by { 1+[S]/Km}. The results are shown in Table 3.
Figure imgf000109_0001
Figure imgf000109_0002
Figure imgf000110_0001
Example 24
Inhibition of Cathepsin S Stock solutions of the various inhibitors (10 mM) were made in DMF; dilutions were made in the same solvent. Cloned cathepsin S, (see Brömme et al., J. Biol. Chem. 268(&): 4832-4838 (1993)) was less than 1 nM in the assay. The assay buffer contained 100 mM phosphate at pH 6.5, 0.01% Triton, 2.5 mM dithiothreitol (DTT), and 2.5 mM ethylenediaminetetraacetic acid (EDTA). The substrate for cathepsin S was 10 μM Z-Val-Val-Arg- AMC (carbobenzyloxyvalinylvalinylarginylaminomethylcoumarin). The assays were initiated at 25°C by addition of enzyme to 2 mL of assay buffer containing the substrate and the various inhibitors (30-0.001 μM). The increase in fluorescence at 460 nm with excitation at 380 nm was followed with time. Inactivation of cathepsin S was indicated by a downward curve in the increase in fluorescence with time. In the absence of inhibitors, the enzymatic production of free AMC was linear throughout the time course of inactivation examined. Data points were collected over at least 3 half-times of inactivation. The inhibition progress curves were analyzed using non-linear curve fitting software to compute the kobs values. Approximate second-order inactivation constants (kobs/[I]) were calculated for all compounds. For selected inhibitors, plots of 1/[I] vs. 1/kobs yielded the true constants kirr, KI, and kirr/KI, and were corrected for the presence of substrate by dividing KI(app.) by { 1+[S]/Km}.
The results are shown in Table 4.
Figure imgf000112_0001
Figure imgf000113_0001
Example 25
Inhibition of Cruzain
Inhibition of cruzain, from T. cruzi, (see Eakin et al., J. Biol. Chem. 268(9): 6115-6118 (1993)) proceeded exactly as for cathepsin L, outlined above, using an enzyme concentration of 1 nM.
The results are shown in Table 5.
Figure imgf000114_0001
Figure imgf000115_0001
Example 26
Stability of selected inhibitors toward glutathione The inhibitors (5 mM) were incubated with glutathione (GSH) (0.3 mM) in phosphate buffer (50 mM) at pH = 6.2 containing 15% DMF at 20ºC. Periodically, 50 μL samples were added to 1 mL of buffer and treated with 10μL of 30 mM Ellmans reagent and the absorbance measured at 412 nm.
After 24 hours there was no measurable reaction between
Mu-Phe-HphVSMe or Mu-Phe-HphVPEt with GSH. The second order rate constant for the loss of GSH was measured to be 5.5 × 10-4 M-1s-1 for Mu-Phe-LysVSPh. The vinyl ester analog Mu-Phe-Arg VEOEt was 10 times more reactive at 5.3 × 10-3 M-1s-1. However, these compounds react at a minimum of 106-109 times faster at the active sites of cysteine proteases than with GSH. Example 27
Selectivity for cysteine proteases versus
serine proteases
Boc-Ala-PheVSPh (100 μM, in 100 mM TRIS buffer at pH = 7.5) did not bind to chymotrypsin, nor did it inactivate chymotrypsin after 1 hour. The same was true for MeOSuc-Ala-Ala-Pro-ValVSPh (100 μM, in 100 mM TRIS buffer at pH = 7.5) with elastase.
Example 28
Synthesis of a Cysteine Protease Inhibitor with a 6 membered homocyclic substituted aromatic ring
as the EWG
Synthesis of Boc-phenylalanyl-homophenylalanyl-p-nitrostyryl, abbreviated herein as Boc-Phe-Hph-VNS, was as follows. Triphenylphoshine (10 gm, 38.1 mmmol) and 4-chloro-p-nitrophenyl (6.54 g, 38.1 mmol) were dissolved in 200 ml of THF and heated at reflux for 2 days. The white solid was filtered and washed with 200 ml diethyl ether and placed in vacuo for 16 hours. p-nitromethylphenyltriphenylphosponium chloride (1.20 g, 2.77 mmol) was dissolved in 50 ml H2O and 1.4 ml of 2 M, (2.77 mmol) sodium hydroxide was added. An immediate glassy red colored solid was formed, and the
H2O layer was extracted with 100 ml of toluene. The organic layer was dried over K2CO3, filtered and concentrated to dryness. The resulting red solid was dissolved in 100 ml of THF and 0.73 g (2.77 mmol) of Boc-homophenylalanyl aldehyde was added. The solution turned yellow over time. The reaction was complete after 16 hours. The reaction mixture was diluted with 250 ml of CH2Cl2 and washed with 200 ml of 1 M HCl, and 200 ml of saturated aqueous NaHCO3, dried over MgSO4, filtered and concentrated to dryness. The residue was dissolved in 20 ml of a 20% ETOAc/hexane solution and eluted down a silica gel column with 20% ETOAc/hexane solution. 25 ml fractions were collected. Fractions 6-12 were combined and concentrated to dryness. 340 mg of a 50/50 mixture of cis-trans configuration of Boc-homophenylalanyl-p-nitrostyryl was recovered.
The 340 mg (0.89 mmol) of Boc-homophenylalanyl-p-nitrostyryl was dissolved in 10 ml of HCl in dioxane (4 M) and left to stir under a drying tube for 30 minutes and then concentrated to a yellow foam. 0.29 g (0.98 mmol) Boc-phenylalanine was dissolved in 50 ml of THF and
216 μl (1.96 mmol) of N-methylmorpholine was added. The reaction was then stirred at 0°C for 5 minutes under argon and 129 μl (0.98 mmol) of isobutylcholorformate was added, and a white precipitate began to form. After 5 minutes, the HCl salt of homophenylalanyl-p-nitrostyryl (284 mg, 0.98 mmd) in 10 ml of DMF was added and the reaction was allowed to warm up to room temperature over 16 hours. The reaction was then concentrated and then diluted with 200 ml of CH2Cl2 and washed with 200 ml of 1 M HCl and 200 ml of saturated aqueous NaHCO3, dried over K2CO3, filtered and concentrated to dryness. The product was dissolved in 10 ml EtOAc and diluted with 20 ml of diethyl ether, and a white solid was filtered and dried in vacuo. 200 mgs of the resulting product, Boc-phenylalanyl-homophenylalanyl-p-nitrostyryl, was recovered as a 50/50 mixture of cis and trans configuration as determined by 1H NMR, and by TLC: 30% EtOAc/hexane, with bromo creoso green stain: Rf of the two forms, cis and trans, was .48 and .54. Example 29
Assay of a Cysteine Protease Inhibitor with a
6 membered substituted homocyclic ring as the EWG
The cysteine protease inhibitor made in Example 15, Boc-phyenylalanylhomophenylalanylvinyl-p-nitrostyryl, was tested against cathepsin S, as outlined in Example 12. The inhibitor showed a kobs/[I] value of 40,100 M-1sec-1.
Example 30
Synthesis of a cysteine protease inhibitor
with a dienylsulfone as the EWG
Synthesis of (S)-(E,E)-5-(4-morpholinecarbonylphenylalanyl)-amino-7-phenyl-1-phenylsuflonyl-1,3-heptadiene (Mu-Phe-Hph-DIESPh). a) Diethyl phosphonoacetyl N,O-dimethylhyroxamide {(EtO)2PC)CH2CON(Me)OMe} was prepared in 82% yield from diethyl phosphonoacetic acid and N,O-dimethylhydroxylamine hydrochloride in the presence of dicyclohexylcarbodiimide and triethylamine. b) To a solution of {(EtO)2POCH2CON(Me)OMe (1.13 g, 4.71 mmol) in THF (25 mL) at 0°C was added sodium hydride (0.188 g, 4.71 mmol as a 60% mineral oil dispersion. After 15 minutes, a solution of Boc-homophenylalaninal (1.24 g, 4.71 mmol) in THF (5 mL) was added. The mixture was stirred for 30 minutes. 1M HCl
(50 mL) was added. The intermediate, (S)-(E)-4-tert-butoxycarbonylamino-6-phenyl-2-hexenoyl N,O-dimethylhydroxamide (Boc-HphVAMN(Me)OMe) was extracted with ethyl acetate (50 mL), washed with saturated aqueous sodium bicarbonate (50 mL) and brine (50 mL), dried over MgSO4, filtered, and the solvent was removed under reduced pressure, c) The resulting oil was dissolved in THF (25 mL) and cooled to 0°C. Lithium aluminum hydride (5 mL of a 1.0M THF solution) was added. The solution was stirred for 20 minutes. Water (5 mL) was carefully added, followed by 1M HCl (30 mL). The next intermediate, (S)-(E)-4-tert-butoxycarbonylamino-6-phenyl-2-hexenal (Boc-HphVAl) was extracted into ethyl acetate (50 mL), washed with saturated aqueous sodium bicarbonate (30 mL) and brine (30 mL), dried over MgSO4, filtered, and the solvent was removed under reduced pressure. TLC: (30% ethyl acetate/hexane)
Rf = 0.31. The crude material, weighing 1.36 g, was used immediately in the next step, d) To a solution of PSMP (1.38 g, 4.71 mmol) in THF (20 mL) at 0°C was added sodium hydride (0.188 g of a 60% mineral oil dispersion, 4.71 mmol). The mixture was stirred for 15 minutes, whereupon a 5 mL THF solution of Boc-HphVAl from the previous step was added. The. mixture was stirred for
40 minutes. 1M HCl (25 mL) was added. The intermediate, (S)-(E,E)-5-tert-butoxycarbonylamino-7-phenyl- 1 -phenylsulfonyl- 1 ,3-heptadiene (Boc-Hph-DIESPh), was extracted with ethyl acetate (25 mL), washed with saturated aqueous sodium bicarbonate (25 mL), brine (25 mL), dried over MgSO4, filtered, and the solvent was removed under reduced pressure. The residue was crystallized from CH2Cl2/ether/hexane to give 0.80 g (39%) from Boc-homophenylalaninal. TLC: (30% ethyl acetate/hexane) Rf = 0.16. e) To a solution of Boc-HphDIESPh (0.80 g, 1.87 mmol) in ether/CH2Cl2 (3 mL, 2:1) was added a solution of anhydrous p-toluenesulfonic acid (0.80 g, 4.70 mmol) in ether (3 mL). The mixture was stirred at room temperature overnight. An additional 5 mL aliquot of CH2Cl2 was added and stirring permitted to continue for another 24 hours. Ether (80 mL) was then added. The solids were filtered, washed with ether (2×20 mL), and dried in vacuo to give 0.69 g (74%) of the intermediate, (S)-(E,E)-5-amino-7-phenyl-1-phenylsulfonyl-1,3-heptadiene 4-toluenesulfonate (TsOH.HphDIESPh). f) To a solution of Mu-PheOH (0.334 g, 1.20 mmol) in THF (7 mL) at -10°C were added 4-methylmorpholine (0.132 mL, 1.20 mmol) and isobutyl chloroformate (0.156 mL, 1.20 mmol). The mixed anhydride was stirred for 5 minutes, whereupon TsOH.HphDIESPh (0.60 g, 1.20 mmol) was added, followed by 4-methylmorpholine (0.132 mL, 1.20 mmol). The reaction mixture was stirred for 45 minutes. Ethyl acetate (40 mL) was added. The solution was washed with 1M HCl, saturated aqueous sodium bicarbonate, and brine (5 mL each), dried over MgSO4, filtered, and the solvent was removed under reduced pressure. The product, Mu-Phe-HphDIESPh, formed an oil on attempts to crystallize it. The supernantant was discarded and the residue was dried in vacuo, resulting in a foam (0.43 g, 61%).
TLC (50% ethyl acetate/CH2Cl2) Rf = 0.29. 1H NMR (CDCl3): 1.6-1.95 (2H, m, CH2CH2C6H5); 2.57 (2H, m, CH2CH2C6H5); 3.03 (2H, 2xdd, PhCH2CH); 3.25 (4H, NCH2CH2O); 3.59 (4H, m, NCH2CH2O); 4.43 (1H, m*, CHNH (Hph)); 4.48 (1H, q*, J=6 Hz, CHNH (Phe)); 5.05 (1H, d, J=6 Hz, NHCH (Mu)); 5.86 (2H, m*, CH=CH); 6.09 (1H, d, J=6 Hz, NHCH); 6.26 (1H, d, J=12 Hz,
SO2CH=CH); 7.04-7.92 (16H, m, 15 × aromatic and one CH=CH). The presence of a smaller doublet at 4.96 ppm, assigned as an NHCH peak corresponding to the morpholine urea, suggests that the all-trans configuration anticipated by performance of successive Wadsworth-Emmons reactions may in this sequence result in at least one of the double bonds in a minor component of the product being of cis configuration.
Example 31
Synthesis of a cysteine protease inhibitor with a vinyl sulfone as the EWG with a fluoro moiety as an additional EWG attached to the same carbon of the alkene bond
Synthesis of (S)-(E,Z)-1-fluoro-3-(4-morpholinecarbonyl-phenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene (Mu-Phe-Hph-VSPh-VF). a) To a solution of diethyl phenylsulfonylmethylenephosphonate (5.06 g, 17.31 mmol) in THF (100 mL) at 0°C was added sodium hydride (0.83 g of a 60% mineral oil dispersion, 20.77 mmol). The mixture was stirred for 20 minutes.
N-fluorodiphenylsulfonimide (8.73 g, 27.69 mmol) was added as a solid. The mixture was stirred at room temperature overnight. The fluorinated Wadsworth-Emmons reagent, diethylphosphonylphenylsulfonylfluoromethane (PSMP-F) was isolated by partitioning between ethyl acetate (100 mL) and 1M HCl (100 mL). The organic phase was washed with saturated aqueous sodium bicarbonate (100 mL), brine (50 mL), dried over MgSO4, filtered, and the solvent was removed under reduced pressure. The residue was purified by column chromatography (60-200 mesh silica gel, 0-20% ethyl acetate/CH2Cl2, gradient elution) to give 2.03 g (38%) of PSMP-F. TLC: (20% ethyl acetate/CH2Cl2) Rf = 0.5. 1H NMR (CDCl3): 1.37 (6H, 2×t, 2×CH3); 4.26 (4H, m, 2×CH2OP); 5.39 (1H, dd, CHFP); 7.57-8.03 (5H, m*, aromatic), b) To a solution of PSMP-F (1.00 g, 3.22 mmol) in THF (15 mL) at 0°C was added sodium hydride
(0.129 g of a 60% mineral oil dispersion). The mixture was stirred for 10 minutes, whereupon a solution of Boc-homophenylalaninal (0.42 g, 1.59 mmol) in THF (5 mL) was added. The mixture was stirred for 30 minutes. 1M HCl (10 mL) was added. The products, (S)-(E)-1-fluoro-3-tert-butoxycarbonylamino-5-phenyl-1-phenylsulfonyl-1-pentene and (S)-(Z)-1-fluoro-3-tert-butoxycarbonylamino-5-phenyl-1-phenylsulfonyl-1-pentene(Boc-Hph-VSPh-VF)were extracted into ethyl acetate (30 mL), washed with saturated aqueous sodium bicarbonate (10 mL), brine (10 mL), dried over MgSO4, filtered, and the solvent was removed under reduced pressure. TLC: (30% ethyl acetate/hexane) Rf = 0.29 and 0.39. c) The material from the Wadsworth-Emmons coupling was dissolved in ether
(2 mL). A solution of anhydrous 4-toluenesulfonic acid (0.67 g, 3.98 mmol) in ether (2 mL). The mixture was stirred at room temperature overnight. Ether (30 mL) was added. The solids were filtered, washed with ether (2x20 mL), and dried in vacuo to give 0.42 g (54%) (S)-(E)-1-fluoro-3-amino-5-phenyl-1-phenylsulfonyl-1-pentene 4-toluenesulfonate and (S)-(Z)-1-fluoro-3-amino- 5-phenyl-1-phenylsulfonyl-1-pentene 4-toluenesulfonate(TsOH.Hph-VSPh-VF) in an approximately 5:3 ratio as evidenced by NMR. 1H NMR (DMSO-d6): 1.82-2.07 (2H, m, CH2CH2C6H5); 2.28 (3H, s, CH3C6H4SO3 - -); 2.37-2.73 (2H, m*, CH2CH2C6H5); 4.02 (0.63H, m*, CHNH (E isomer)); 4.83 (0.37H, m*, CHNH (Z isomer)); 6.22-6.34 (0.37H, dd, J=6,6 Hz, CH=CF (Z isomer)); 6.43 (0.63H, dd, J=6,18 Hz, CH=CF (trans isomer)); 7.04-8.04 (14 H, m, aromatic) 8.22 (3H, br s, NH3 +). d) To a solution of Mu-PheOH (0.238 g, 0.854 mmol) in THF (5 mL) at -10°C were added 4-methylmorpholine (94 (L, 0.854 mmol) and isobutyl chloroformate (0.111 mL, 0.854 mmol). The mixture was stirred for 5 minutes, whereupon TsOH.HphVSPh-VF (0.42 g, 0.854 mmol) was added, followed by 4-methylmorpholine (94 (L, 0.854 mmol). The mixture was stirred for 45 minutes. Ethyl acetate (20 mL) was added. The mixture was washed with 1M HCl (10 mL), saturated aqueous sodium bicarbonate (5 mL), brine (5 mL), dried over MgSO4, filtered, and the solvent was removed under reduced pressure. Yield = 0.32 g (64%).
Example 32
In vitro activity of selected Michael acceptors as cysteine protease inhibitors against the protozoans of Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei In this table, the in vitro antiprotozoal activities of the indicated compounds were measured as percentage inhibition of Leishmania donovani amastigote infecteda mouse peritoneal macrophages, Trypanosoma cruzi amastigote infected macrophages, and Trypanosoma brucei extracellular bloodstream forms. Where indicated, the term "T" indicates the molecule to have displayed cytotoxicity.
Compound (uM) 90 30 10 3 1 ED50
Mu-Leu-Hph-VSPh
L.donovani T 15.3 0 4.6
T.cruzi T 11.4 0 0
T. brucei 100 84.7 82.2 11.2
Mu-Phe-HphVSPh
L.donovani T 9.4 0 0
T. cruzi T 50.1 10 10
T. brucei 100 100 82.7 90.5 10.2 2.19
Mu-Phe-ArgVSPh.HBr
L.donovani 1.3 0 0 0
T.cruzi 5.8 0 0 0
T. brucei 0 0 0 0
Mu-Phe-Hph-VAMBzl
L.donovani 23.3 14.2 0 0
T.cruzi 5.83 0 0 0
T. brucei 0 0 0 0
Mu-Phe-AlaVSMe
L.donovani 6.7 0 0 0
T.cruzi 12.2 11.2 0 0
T. brucei 0 0 0 0
HCl.Gly-Phe-VSPh
L.donovani 4.02 0 0 0
T.cruzi 0 0.1 0 0
T. brucei 0 0 0 0
Boc-Asp(O-t-Bu)VSMe
L.donovani 12.9 13.4 0 0
T.cruzi 9.9 0 0 0
T. brucei 0 0 0 0
HCl.PheVSMe
L.donovani 100 100 100 100
T.cruzi 17.3 0 0 0
T. brucei 0 0 0 0
Mu-Phe-ValVSPh
L.donovani T 100 100 100
T.cruzi 74.2 18.9 6.2 5.5 61.88
T. brucei 100 72.7 35.4 13.5 11.9 13.85
HCl.(e-Z)LysVSPh
L.donovani T T 100 100
T.cruzi 97.8 82.8 10.6 2.7 18.34
T. brucei 100 100 39.3 13 7.6 8
Mu-Phe-Ser(OBzl)VSPh
L.donovani T 100 100 100
T.cruzi 50.7 15.1 15.7 5.2
T brucei 100 100 93.3 11.5 5.2
Mu-Phe-(e-Z)LysVSPh
L.donovani 0 0 0 0
T.cruzi 0 0 0 0
T. brucei 100 100 81.3 29.9 19.8 3.64
Mu-Phe-HphStyrNO2
L.donovani 20.5 10.8 4 5.3 T.cruzi 12.2 0 0 0
T. brucei 100 100 0 0
Example 33
In vitro activity of selected Michael acceptors as cysteine protease inhibitors against the malarial parasites P. falciparum
(human) and P. vinckei (mouse).
The following table summarizes the comparative IC50 values for selected cysteine protease inhibitors against the human malarial parasite Plasmodium falciparum and the mouse malarial parasite Plasmodium vinckei. The substrate used to measure in vitro protease activity was Z-Phe-Arg-AMC.
Compound P.falciparum IC50 (human) P.vinckeiIC50 (murine)
Mu-Phe-AlaVSMe 20 μM
Mu-Phe-HphVSMe 1 μM 1 μM
Mu-Phe-PheVSMe 2 μM
HCl.Ala-PheVSMe >100 μM
Mu-Phe-ArgVSPh.HBr 50 nM 50 nM
Mu-Phe-HphVSPh 80 nM 50 nM
Mu-Phe-(e-Z)LysVSPh 100 nM 80 nM
Mu-Phe-LysVSPh.HBr 100 nM 60 nM
Mu-Phe-ValVSPh 1 μM 1 μM
Mu-Phe-Ser(OBzl)VSPh 1 μM 500 nM
Mu-Leu-HphVSPh 3 nM 200 nM
Mu-Phe-HphVEOEt 300 nM 300 nM
Mu-Phe-ArgVEOEt.HBr 300 nM 200 nM
Mu-Phe-HphVA 1 μM 2 μM
Mu-Phe-HphVAMLeu-ProOMe 80 nM 600 nM
Mu-Phe-HphVAMBzl 200 nM 2 μM
Mu-Phe-HphVPEt 3 μM
Mu-Phe-HphStyrNO2 2 μM 8 μM
Example 34
Treatment of rheumatoid arthritis with peptidyl vinylsulfones.
At day zero, Female Lewis rats (5/group), 5 weeks old, were given intradermal injection into the base of the tail of Mycobacterium butyricum in 0.1 ml of light mineral oil. The animals were provided Teklad (4%) rat chow mixed with (treated groups) or without compound (control group) and water ad libilum. The compounds used were Mu-Phe-HphVSPh, Mu-Leu-HphVSPh, Mu-Tyr-HphVSPh, Mu-Phe-Lys(ε-Z)VSPh,Mu-Phe-LysVSPh•HBr.The compounds were given to three groups at 3, 10, and 30 mg/kg/day, respectively. The following parameters were noted: biweekly weights and biweekly joint evaluations by the following scoring system: paw swelling 0 = no edema, 1 = slight edema of small digital joints, 2 = edema of the digital joints and foot pad, 3 = gross edema of the entire foot pad below that ankle or elbow, 4 = gross edema of the entire foot pad including the ankle and elbow joint. Erythema was scored as: 0 = normal, 1 = pink, 2 = red, 3 = deep violaceous. The evaluators were blinded as to treatment groups.
After 28 days the animals were killed and the hind paws and knees were removed and fixed in 4% paraformaldehyde. The bones were decalcified in Fisher Decalcifying Solution (chelating agent, 3 mM HCl 1.35 N) and then embedded in paraffin (58°, 3 × 45 min). Joint histopathology scores were calculated by the following method: two sections of each joint were read for synovial cell proliferation, cartilage erosion, bone erosion, fibroproliferative pannus, diffuse inflammatory synovitis, and synovial vasculitis: 0 = normal, 1 = mild, 2 = moderate, 3 = and severe. The sections were examined by two independent investigators blinded as to treatment groups, and the mean score then used as the score for that section.
Mu-Phe-HphVSPh showed a dose dependent beneficial effect on all scores. The high dose of Mu-Leu-HphVSPh also showed a reduction in bone and cartilage destruction. Example 35
Activity of peptidyl vinylsulfones against P. carinii.
Mu-Leu-HphVSPh and Mu-Phe-LysVSPh•HBr were evaluated for their effects on the growth of P. carinii in vitro, according to the procedure of M. S. Bartlett et al. [ Antimicrotubule Benzimidazoles Inhibit In Vitro Growth of P. carinii,
M. S. Bartlett, T. D. Edlind, M. M. Durkin, M. M. Shaw, S. F. Queener, and J. W. Smith, (1992) Antimicrobial Agents and Chemotherapy, 36, 779-782; Antimicrobial susceptibility of P. carinii in culture, M. S. Bartlett, R. Eichholtz, and J. W. Smith (1985) Diagn. Microbiol. Infect. Dis., 3, 381-387.
Mu-Leu-HphVSPh and Mu-Phe-LysVSPh•HBr (10 mM each) inhibited the growth of P. carinii 64% and 50% respectively.
Example 36
Activity of peptidyl vinylsulfones and one vinyl amide against T. cruzi
Irradiated J774 cells were infected with T. cruzi and simultaneously treated with 20 mM of peptidyl vinyl derivatives for 5 days; thereafter without inhibitor.
The following compounds were effective in decreasing order: Mu-Phe-Arg VSPh, Boc-Tyr(I2)-HphVSPh, Mu-Phe-ValVSPh, Boc-Tic-HphVSPh, Mu-Phe-Ser(OBzl)VSPh, Mu-Leu-HphVSPh, Mu-Tyr(I2)-HphVSPh, Mu-Phe-LysVSPh, Mu-Tic-HphVSPh. Example 37
Effect of peptidyl vinylsulfones on glioma cell migration
Two permanent human glioma cell lines (U87MG and U251MGn) and a well characterized low passage primary culture derived from a CB-positive glioblastoma (HF66) were used to assess the migratory behavior in the Matrigel barrier migration assay in the presence of graded concentrations of four compounds.
Using the Matrigel assay, Mu-Leu-HphVSPh, Mu-Tyr-HphVSPh, Mu-Phe-HphVSPh, and Mu-Tyr(I2)-HρhVSPh (all at 10 mM) inhibited U251MGn by 67, 56, 29, & 20% respectively, while the U87MG cells were inhibited 53,
75, 63, & 56% respectively. The primary culture HF66 cells were inhibited only 10% by these compounds at the same concentration.
Example 38
Inhibition of Calpain The inhibitors were tested against calpain at 1 or 2% as for the other enzymes.
The reaction conditions were 50 mM Tris, pH 7.5, 5 mM CaCl2, 2.5 mM DTT, assayed at 25°C. The substrate was 100 μM Suc-Leu-Tyr-AMC. The results are shown in Table 6.
Figure imgf000128_0001
Figure imgf000129_0001

Claims

CLAIMS We claim:
1. A cysteine protease inhibitor comprising a targeting group linked by an alkene bond to an electron withdrawing group (EWG), wherein the second order rate constant for inhibition of a cysteine protease with said inhibitor (kirr/KI) is at least about 1000 M-1sec-1.
2. A chiral cysteine protease inhibitor comprising a targeting group linked by an alkene bond to an electron withdrawing group (EWG).
3. An inhibitor according to claim 2 wherein the second order rate constant for inhibition of a cysteine protease with said inhibitor (kirr/KI) is at least about 1000 M-1sec-1.
4. A cysteine protease inhibitor comprising a compound with a formula
Figure imgf000130_0001
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains;
A-B is a peptide linkage; and
EWG is an electron withdrawing group; wherein the second order rate constant for inhibition of a cysteine protease with said inhibitor (kirr/KI) is at least about 1000 M-1sec-1.
5. A labelled cysteine protease inhibitor according to claim 1, 2 or 4.
6. A cysteine protease inhibitor according to claim 1, 2 or 4, further comprising additional targeting residues linked to the EWG.
7. A cysteine protease inhibitor according to claim 1, 2 or 4 wherein the EWG is a compound that will work in the Wadsworth-Emmons reaction for olefin synthesis.
8. A cysteine protease inhibitor according to claim 1, 2 or 4, wherein the EWG is selected from the group consisting of vinylogous esters, vinylogous sulfones, vinylogous carboxylates, vinylogous amides, vinylogous phosphonates, vinylogous ketones, vinylogous nitriles, vinylogous sulfoxides, vinylogous sulfonamides, vinylogous sulfinamides, vinylogous sulfonates and vinylogous sulfoximines.
9. A cysteine protease inhibitor according to claim 8 wherein the EWG is selected from the group consisting of a vinylogous ester, vinylogous sulfone, vinylogous carboxylate, vinylogous amide or vinylogous phosphonate.
10. A cysteine protease inhibitor according to claim 8 wherein the EWG is a vinylogous ester.
11. A cysteine protease inhibitor according to claim 8 wherein the EWG is a vinylogous sulfone.
12. A cysteine protease inhibitor according to claim 8 wherein the EWG is a vinylogous carboxylate.
13. A cysteine protease inhibitor according to claim 8 wherein the EWG is a vinylogous amide.
14. A cysteine protease inhibitor according to claim 8 wherein the EWG is a vinylogous phosphonate.
15. A composition comprising a chiral vinylogous phosphonate derived from an α-amino acid.
16. A composition comprising a chiral vinylogous sulfone derived from an α-amino acid.
17. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is ethyl (S)-(E)-4-(4-morpholinecarbonyl-phenylalanyl)-amino-6-phenyl-2-hexenoate.
18. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is ethyl (S)-(E)- 7-guanidino-4-(4-morpholine-carbonylphenylalanyl)amino-2-heptenoate hydrobromide.
19. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-5-(4-morpholine-carbonylphenylalanyl)-amino-7-phenyl-2-thia-3-heptene 2,2-dioxide.
20. A cysteine protease inhibitor according to claim 2 wherein said cysteine protease inhibitor is (S)-(E)-3-tert-butoxy-carbonylamino-4-methyl-1-phenylsulfonyl-1-pentene.
21. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3- (4-morpholine-carbonylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
22. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-4- (4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenoic acid.
23. A cysteine protease inhibitor according to claim 4 wherein said cysteine p r o t e a s e i n h i b i t o r i s d i e t h y l ( S ) -(E)-4-(4-morpholinecarbonylphenylalanyl)amino-6-phenyl- 2-hexenephosphonate.
24. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-(N-leucylproline methyl ester)-4-(4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenamide.
25. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-(N-phenylalanine)-4-(4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenamide.
26. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholine-carbonylleucyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
27. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is boc-phenylalanyl-homophenylalanyl-p-nitrostyryl.
28. A cysteine protease inhibitor according to claim 2 wherein said targeting group comprises a aspartic acid side chain at the S, position of the inhibitor.
29. A cysteine protease inhibitor according to claim 4 wherein said "Y" group is an aspartic acid side chain.
30. A method of making a cysteine protease inhibitor comprising a compound with the formula:
Figure imgf000134_0001
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains;
A-B is a peptide linkage; and
EWG is an electron withdrawing group;
wherein said method comprises:
a) coupling a protected α-amino " Y" aldehyde with a Wadsworth-Emmons reagent containing an EWG to form a cysteine protease inhibitor intermediate; b) deprotecting the cysteine protease inhibitor intermediate; and c) coupling the cysteine protease inhibitor intermediate with an N-protected "X" amino acid.
31. A method of inhibiting a cysteine protease comprising irreversibly binding a cysteine protease inhibitor according to claim 1 to said cysteine protease.
32. A method of inhibiting a cysteine protease comprising irreversibly binding a cysteine protease inhibitor according to claim 2 to said cysteine protease.
33. A method of inhibiting a cysteine protease comprising irreversibly binding a cysteine protease inhibitor according to claim 4 to said cysteine protease.
34. A cysteine protease inhibited by a cysteine protease inhibitor according to claim 1.
35. A cysteine protease inhibited by a cysteine protease inhibitor according to claim 2.
36. A cysteine protease inhibited by a cysteine protease inhibitor according to claim 4.
37. A inhibited cysteine protease according to claims 33-37 wherein said inhibited cysteine protease is interleukin 1β converting enzyme.
38. A method of treating cysteine protease associated-disorders comprising administering to a patient a therapeutically effective dose of a cysteine protease inhibitor according to claim 1.
39. A method of treating cysteine protease associated-disorders comprising administering to a patient a therapeutically effective dose of a cysteine protease inhibitor according to claim 2.
40. A method of treating cysteine protease associated-disorders comprising administering to a patient a therapeutically effective dose of a cysteine protease inhibitor comprising a compound with a formula
Figure imgf000136_0001
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X is an amino acid side chain, with either (R) or (S) stereochemical configuration; Y is an amino acid side chain, with either (R) or (S) stereochemical configuration; A-B is a peptide linkage; and
EWG is an electron withdrawing group.
41. A method of treatment according to claims 38, 39, or 40 wherein said disorder is associated with interleukin 1β converting enzyme.
42. A pharmaceutical composition comprising a cysteine protease inhibitor according to claims 1, 2, 4, 45 or 48.
43. A method of detecting a cysteine protease in a sample comprising:
a) assaying said sample for protease activity using a protease substrate; b) assaying for protease activity in the presence of a cysteine protease inhibitor according to claims 1, 2, 4, 45, or 48; and c) calculating the difference between the a) and b) to determine the protease activity due to cysteine protease.
44. A cysteine protease inhibitor comprising a targeting group linked by a diene bond to an electron withdrawing group (EWG).
45. A cysteine protease inhibitor comprising a compound with the formula:
Figure imgf000137_0001
wherein
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains;
A-B is a peptide linkage; and
EWG is an electron withdrawing group.
46. A cysteine protease inhibitor according to claim 45 wherein the second order rate constant for inhibition of a cysteine protease with said inhibitor (kirr/KI) is at least about 1000 M-1sec-1.
47. A cysteine protease inhibitor comprising a targeting group linked by an alkene bond to two electron withdrawing groups (EWG).
48. A cysteine protease inhibitor comprising a compound with the formula
wherein
Figure imgf000138_0001
P is hydrogen, a peptide amino end blocking group, a peptide residue with or without an amino end blocking group, a single amino acid with or without an amino end blocking group, or a label;
X and Y are amino acid side chains;
A-B is a peptide linkage; and
EWG is an electron withdrawing group.
49. A cysteine protease inhibitor according to claim 48 wherein the second order rate constant for inhibition of a cysteine protease with said inhibitor (kirr/KI) is at least about 1000 M-1-sec-1.
50. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-6-guanidino-1-phenylsulfonyl-1-hexene hydrobromide.
51. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
52. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-glycylamino-4-phenyl-1-phenylsulfonyl-1-butene hydrochloride.
53. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-7-(benzyloxycarbonyl)amino-3-(4-morpholinecarbonylphenylalanyl)-amino-1-phenylsulfonyl-1-heptene.
54. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-7-amino-3-(4-morpholinecarbonylphenylalanyl)amino- 1-phenylsulfonyl-1-heptene hydrobromide.
55. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-4-methyl-1-phenylsulfonyl-1-pentene.
56. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-amino-4-phenyl-1-phenylsulfonyl-1-butene hydrochloride.
57. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylvalyl)amino-4-phenyl-1-phenylsulfonyl-1-butene.
58. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonyl-arginyl)amino-6-guanidino-1-phenylsulfonyl-1-hexene dihydrobromide.
59. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-4-benzyloxy-1-phenylsulfonyl-1-butene.
60. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-7-benzoylamino -1-phenylsulfonyl-1-heptene.
61. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (R)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl- 1-phenylsulfonyl-1-pentene.
62. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-[4-morpholinecarbonyl-(3,5-diiodotyrosyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene.
63. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-[4-tert-butoxycarbonyl-(3,5-diiodotyrosyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene.
64. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S,S)-(E)-3-[4-morpholinecarbonyl-(1,2,3,4-tetrahydro-3-isoquinoline-carbonyl)]amino-5-phenyl-1-phenylsulfonyl-1-pentene.
65. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S,S)-(E)-3-[tert-butoxycarbonyl-(1,2,3,4-tetrahydro-3-isoquinolinecarbonyl)]-amino-5-phenyl-1-phenylsulfonyl-1-pentene.
66. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene.
67. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-amino-5-phenyl-1-phenylsulfonyl-1-pentene hydrochloride.
68. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-[(4-morpholinecarbonyl-(R,S)-α-methylphenylalanyl]amino-5-phenyl-1-phenylsulfonyl-1-pentene.
69. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(benzyloxycarbonylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene.
70. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonyltyrosyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
71. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(tert-butoxycarbonyl-2-naphthylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
72. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonyl-2-naphthylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
73. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonyl-4-biphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
74. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-phenylsulfonyl-1-heptene.
75. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-phenylsulfonyl-6-thia-1-heptene.
76. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-methylsulfonyl-1-phenylsulfonyl-1-pentene.
77. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(acetylleucylleucyl)amino-1-phenylsulfonyl-1-heptene.
78. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(acetylleucylleucyl)amino-1-phenylsulfonyl-6-thia-1-heptene.
79. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(acetylleucylleucyl)amino-5-methylsulfonyl-1-phenylsulfonyl-1-pentene.
80. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(carbomethoxypropionylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
81. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-7-(benzyloxycarbonyl)amino-3-(4-morpholinecarbonylphenylalanyl)-amino-1-fluoro-1-phenylsulfonyl-1-heptene.
82. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(acetylleucylleucyl)amino-4-(4-hydroxyphenyl)-1-phenylsulfonyl-1-butene.
83. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(dimethylsulfamoylphenylalanyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
84. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-(4-bromophenylsulfonyl)-5-phenyl-1-pentene.
85. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-(2-napthylsulfonyl)-5-phenyl-1-pentene.
86. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonyl-2-naphthylalanyl)amino-1-(2-napthylsulfonyl)-5-phenyl-1-pentene.
87. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonyl)amino-5-phenyl-1-phenylsulfonyl-1-pentene.
88. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-1-butene.
89. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene.
90. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(tert-2butoxycarbonylalanyl)amino-1-methylsulfonyl-4-phenyl-1-butene.
91. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-Ethyl 8-(benzyloxycarbonyl)amino-4-(4-morpholinecarbonylphenyl-alanyl)amino-2-octenoate.
92. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-Ethyl 8-amino-4-(4-morpholinecarbonylphenylalanyl)amino-2-octenoate hydrobromide.
93. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-Benzyl4-(4-morpholinecarbonylphenylalanyl)amino-6-phenyl-2-hexenamide.
94. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl-1- (4-nitrophenyl)-1-pentene.
95. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-2-chloro-5-[3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl-1-pentenyl]thiophene.
96. A cysteine protease inhibitor according to claim 4 wherein said cysteine protease inhibitor is (S)-(E)-3-(4-morpholinecarbonylphenylalanyl)amino-5-phenyl-1-(4-nitrophenyl)-1-pentene.
PCT/US1995/002252 1994-02-25 1995-02-24 Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups WO1995023222A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US08/700,518 US5976858A (en) 1994-02-25 1995-02-24 Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups
AU20910/95A AU708414B2 (en) 1994-02-25 1995-02-24 Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups
NZ282946A NZ282946A (en) 1994-02-25 1995-02-24 Specific inhibitors of cysteine proteases, amino acid derivatives and medicaments thereof
EP95913490A EP0756625A4 (en) 1994-02-25 1995-02-24 Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20205194A 1994-02-25 1994-02-25
US08/202,051 1994-02-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US20205194A Continuation 1994-02-25 1994-02-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/376,267 Continuation US6287840B1 (en) 1994-02-25 1999-08-18 Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups

Publications (1)

Publication Number Publication Date
WO1995023222A1 true WO1995023222A1 (en) 1995-08-31

Family

ID=22748336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/002252 WO1995023222A1 (en) 1994-02-25 1995-02-24 Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups

Country Status (8)

Country Link
US (2) US5976858A (en)
EP (1) EP0756625A4 (en)
AU (1) AU708414B2 (en)
CA (1) CA2184098A1 (en)
IL (1) IL112759A0 (en)
NZ (1) NZ282946A (en)
WO (1) WO1995023222A1 (en)
ZA (1) ZA951573B (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040066A1 (en) * 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
US5830850A (en) * 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
US5856530A (en) * 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
EP0943624A1 (en) * 1998-03-12 1999-09-22 Universiteit Utrecht Peptidic inhibitors of down-regulation of growth hormone receptor
US5962487A (en) * 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US6020371A (en) * 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US6162828A (en) * 1995-03-31 2000-12-19 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
WO2001083433A1 (en) * 2000-04-21 2001-11-08 Enanta Pharmaceuticals, Inc. Bifunctional inhibitors of malarial proteases and uses thereof
US6331554B1 (en) 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
WO2002048097A1 (en) * 2000-12-12 2002-06-20 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
US6514997B2 (en) 1999-12-03 2003-02-04 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
WO2003016335A2 (en) * 2001-08-13 2003-02-27 Probiodrug Ag Irreversible cysteine protease inhibitors of legumain
US6531452B1 (en) 1998-04-30 2003-03-11 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6579896B2 (en) 2000-09-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies using substituted pyrazoles
US6610730B2 (en) 2000-04-14 2003-08-26 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6632825B2 (en) 2000-06-14 2003-10-14 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6635633B2 (en) 2000-08-14 2003-10-21 Ortho-Pharmaceutical, Inc. Substituted pyrazoles
EP1400530A1 (en) * 1996-04-22 2004-03-24 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin S
JP2004509120A (en) * 2000-09-13 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド Caspase inhibitors and their uses
US6756372B2 (en) 1999-09-13 2004-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US6855843B2 (en) 1998-01-20 2005-02-15 Tanabe Seiyaku Co., Ltd. Inhibitors of α4 mediated cell adhesion
US6953793B2 (en) 2000-08-14 2005-10-11 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7276364B1 (en) 1999-11-18 2007-10-02 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7309703B2 (en) 2000-08-14 2007-12-18 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
WO2010133000A1 (en) * 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
WO2013163567A2 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Novel alpha-helical peptidomimetic inhibitors and methods using same
US8791235B2 (en) 2008-05-21 2014-07-29 Novagenesis Foundation Selective caspase inhibitors and uses thereof
US9944674B2 (en) 2011-04-15 2018-04-17 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
CN112585142A (en) * 2018-04-16 2021-03-30 科学与工业研究会 Novel antimalarial compounds, preparation method and use thereof for drug-resistant malaria
WO2021195183A1 (en) * 2020-03-24 2021-09-30 Exo Therapeutics, Inc. Compositions and methods for inhibiting protein embryonic ectoderm development activity and treating disease

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1067680A (en) * 1996-08-27 1998-03-10 Kaki Kenkyusho Preventive for bacterial infection for larva of fish and shellfish and raising of larva of fish and shellfish
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US20070117785A1 (en) * 2000-08-14 2007-05-24 Butler Christopher R Substituted pyrazoles and methods of treatment with substituted pyrazoles
US20050101587A9 (en) * 2000-08-14 2005-05-12 Butler Christopher R. Method for treating allergies using substituted pyrazoles
EP1315966B1 (en) * 2000-09-06 2007-10-03 Ortho-McNeil Pharmaceutical, Inc. Method of monitoring the effect of cathepsin s inhibitors
DE60120104T2 (en) * 2001-03-20 2006-09-21 Schwarz Pharma Ag New use of peptide compounds in the treatment of non-neuropathic inflammatory pain
US6784288B2 (en) 2001-11-08 2004-08-31 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of monkey cathepsin S
US6780985B2 (en) 2001-11-08 2004-08-24 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of Canine Cathepsin S
MY140707A (en) * 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
US20030125548A1 (en) * 2002-09-13 2003-07-03 Dorit Arad Molecules derived from mechanism based drug design
US20100113328A1 (en) * 2003-05-29 2010-05-06 The Scripps Research Institute Targeted delivery to legumain-expressing cells
DE602006020577D1 (en) * 2005-07-01 2011-04-21 Dako Denmark As MONOMERS AND POLYMERS LEFT FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES
US20090264479A1 (en) * 2005-07-26 2009-10-22 Cameron Black Papain Family Cysteine Protease Inhibitors for the Treatment of Parasitic Diseases
CN101374856A (en) * 2005-11-29 2009-02-25 斯克里普斯研究学院 Inhibiting tumor cell invasion, metastasis and angiogenesis
WO2010065825A2 (en) 2008-12-05 2010-06-10 Abbott Laboratories Kinase inhibitors with improved cyp safety profile
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
US11905249B2 (en) 2021-01-25 2024-02-20 Jackson State University Covalent inhibitors of equine encephalitis virus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04202170A (en) * 1990-11-29 1992-07-22 Taisho Pharmaceut Co Ltd Tripeptide derivative

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
SE8702550D0 (en) * 1987-06-18 1987-06-18 Anders Grubb CYSTEINPROTEASHEMMARE
US5101068A (en) * 1990-02-16 1992-03-31 Prototek Inc. Magnesium fluoromalonates
US5274623A (en) * 1990-07-19 1993-12-28 Fuji Photo Film Co., Ltd. Information recording medium having high modulation degree
JPH04273897A (en) * 1991-02-27 1992-09-30 Taisho Pharmaceut Co Ltd Tripeptide derivative
JPH04273896A (en) * 1991-02-27 1992-09-30 Taisho Pharmaceut Co Ltd Tripeptide derivative
JPH05213990A (en) * 1991-02-27 1993-08-24 Taisho Pharmaceut Co Ltd Tripeptide derivative
AU3479593A (en) * 1992-01-31 1993-09-01 Merck & Co., Inc. Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
ES2118940T3 (en) * 1992-02-21 1998-10-01 Merck & Co Inc PEPTIDIL-DERIVATIVES USEFUL AS INHIBITORS OF THE CONVERTING ENZYME OF INTERLEUKIN-1 BETA.
DE4220757A1 (en) * 1992-06-24 1994-01-05 Schering Ag Derivatives in the vitamin D series with modifications in the 20-position, process for their preparation, intermediates for this process, pharmaceutical preparations containing these derivatives and their use in the manufacture of medicaments
US5374623A (en) * 1992-08-20 1994-12-20 Prototek, Inc. Cysteine protease inhibitors effective for in vivo use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04202170A (en) * 1990-11-29 1992-07-22 Taisho Pharmaceut Co Ltd Tripeptide derivative

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
ANGEW. CHEM. INT. ED. ENGL., Vol. 31, No. 10, issued 1992, T. KOLTER et al., "Configuratively Stable Dipeptide Aldehydes from D-Glucosamine Hydrochloride", pages 1391-1392. *
ANGEW. CHEM. INT. ED. ENGL., Vol. 31, No. 12, issued 1992, M.T. REETZ et al., "Stereoselective Nucleophilic Addition Reactions of Reactive Pseudopeptides", pages 1626-1629. *
COLD SPRING HARBOR CONF. CELL PROLIFERATION, Vol. 2 (PROTEASES BIOL. CONTROL), issued 1975, T. AOYAGI et al., "Structure and Activities of Protease Inhibitors of Microbial Origin", pages 429-454. *
J. AM. CHEM. SOC., Vol. 114, issued 1992, M. HAGIHARA et al., "Reassignment of Stereochemistry and Total Synthesis of the Thrombin Inhibitor Cyclotheonamide B", pages 6570-6571. *
J. MED. CHEM., Vol. 23, No. 1, issued 1980, D.H. RICH et al., "Synthesis of Analogues of the Carboxyl Protease Inhibitor Pepstatin. Effect of Structure on Inhibition of Pepsin and Renin", pages 27-33. *
J. MED. CHEM., Vol. 27, No. 6, issued June 1984, R.P. HANZLIK et al., "Vinylogous Amino Acid Esters: A New Class of Inactivators for Thiol Proteases", pages 711-712. *
J. MED. CHEM., Vol. 29, No. 1, issued 1986, S.A. THOMPSON, "Carboxyl-Modified Amino Acids and Peptides as Protease Inhibitors", pages 104-111. *
J. MED. CHEM., Vol. 31, No. 7, issued 1988, C.W. SMITH et al., "Synthesis and Renin Inhibitory Activity of Angiotensinogen Analogues Having Dehydrotstatine, Leu-Phi(CH2S)Val, or Leu-Phi(CH2SO)Val at the P1-P1' Cleavage Site", pages 1377-1382. *
J. MED. CHEM., Vol. 35, No. 6, issued 1992, S. LIU et al., "Structure-Activity Relationships for Inhibition of Papain by Peptide Michael Acceptors", pages 1067-1075. *
PROC. NATL. ACAD. SCI. U.S.A., Vol. 90, issued September 1993, B.E. MARYANOFF et al., "Molecular Basis for the Inhibition of Human alpha-Thrombin by the Macrocyclic Peptide Cyclotheonamide A", pages 8048-8052. *
See also references of EP0756625A4 *
TETRAHEDRON, Vol. 43, No. 19, issued 1987, D.H.R. BARTON et al., "Synthesis of Novel alpha-Amino Acids and Derivatives Using Radical Chemistry Synthesis of L- and D-alpha-Amino Adipic Acids, L-alpha-Aminopimelic Acid and Appropriate Unsaturated Derivatives", pages 4297-4308. *
TETRAHEDRON, Vol. 47, No. 32, issued 1991, Q. MENG et al., "Synthetic Approaches Toward Glidobamine, the Core Structure of the Glidobactin Antibiotics", pages 6251-6264. *

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162828A (en) * 1995-03-31 2000-12-19 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
EP1400530A1 (en) * 1996-04-22 2004-03-24 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin S
US6608030B1 (en) 1996-04-22 2003-08-19 Brigham & Women's Hospital, Inc. Suppression of immune response via inhibition of cathepsin S
US7427591B2 (en) 1996-04-22 2008-09-23 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin S
US7285525B2 (en) 1996-04-22 2007-10-23 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin S
AU723447B2 (en) * 1996-04-22 2000-08-24 Brigham And Women's Hospital Suppression of immune response via inhibition of cathepsin S
WO1997040066A1 (en) * 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
US6362166B1 (en) 1996-05-14 2002-03-26 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US5856530A (en) * 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US5830850A (en) * 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
US6331554B1 (en) 1997-03-28 2001-12-18 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds, compositions containing them, and methods for their use
US6649639B2 (en) 1997-03-28 2003-11-18 Peter S. Dragovich Antipicornaviral compounds, compositions containing them, and methods for their use
US6020371A (en) * 1997-03-28 2000-02-01 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds compositions containing them and methods for their use
US5962487A (en) * 1997-12-16 1999-10-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US6855843B2 (en) 1998-01-20 2005-02-15 Tanabe Seiyaku Co., Ltd. Inhibitors of α4 mediated cell adhesion
AU768248B2 (en) * 1998-03-12 2003-12-04 Recharge B.V. Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments
EP0943624A1 (en) * 1998-03-12 1999-09-22 Universiteit Utrecht Peptidic inhibitors of down-regulation of growth hormone receptor
US6855546B1 (en) 1998-03-12 2005-02-15 Universiteit Utrecht Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments
WO1999046298A3 (en) * 1998-03-12 1999-10-21 Univ Utrecht Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments
US6531452B1 (en) 1998-04-30 2003-03-11 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6995142B2 (en) 1998-04-30 2006-02-07 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
US6730671B2 (en) 1999-03-02 2004-05-04 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathespin S
US7279472B2 (en) 1999-09-13 2007-10-09 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7056915B2 (en) 1999-09-13 2006-06-06 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US6982272B2 (en) 1999-09-13 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7265132B2 (en) 1999-09-13 2007-09-04 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cysteine proteases
US6756372B2 (en) 1999-09-13 2004-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7276364B1 (en) 1999-11-18 2007-10-02 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
US6514997B2 (en) 1999-12-03 2003-02-04 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6610730B2 (en) 2000-04-14 2003-08-26 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US6872745B2 (en) 2000-04-14 2005-03-29 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
WO2001083433A1 (en) * 2000-04-21 2001-11-08 Enanta Pharmaceuticals, Inc. Bifunctional inhibitors of malarial proteases and uses thereof
US6632825B2 (en) 2000-06-14 2003-10-14 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
US7429591B2 (en) 2000-08-14 2008-09-30 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7265102B2 (en) 2000-08-14 2007-09-04 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6953793B2 (en) 2000-08-14 2005-10-11 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6949540B2 (en) 2000-08-14 2005-09-27 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6936603B2 (en) 2000-08-14 2005-08-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7452890B2 (en) 2000-08-14 2008-11-18 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7417046B2 (en) 2000-08-14 2008-08-26 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7393850B2 (en) 2000-08-14 2008-07-01 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6635633B2 (en) 2000-08-14 2003-10-21 Ortho-Pharmaceutical, Inc. Substituted pyrazoles
US7772236B2 (en) 2000-08-14 2010-08-10 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6951851B2 (en) 2000-08-14 2005-10-04 Hui Cai Substituted pyrazoles
US7589202B2 (en) 2000-08-14 2009-09-15 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7309703B2 (en) 2000-08-14 2007-12-18 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US7388011B2 (en) 2000-08-14 2008-06-17 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
US6583155B2 (en) 2000-09-06 2003-06-24 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies using substituted pyrazoles
US6579896B2 (en) 2000-09-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies using substituted pyrazoles
US6858623B2 (en) 2000-09-08 2005-02-22 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
JP2004509120A (en) * 2000-09-13 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド Caspase inhibitors and their uses
JP2008297321A (en) * 2000-09-13 2008-12-11 Vertex Pharmaceut Inc Caspase inhibitor and use thereof
WO2002048097A1 (en) * 2000-12-12 2002-06-20 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
US7279550B2 (en) 2001-08-13 2007-10-09 Probiodrug Ag Irreversible cysteine protease inhibitors of legumain
WO2003016335A3 (en) * 2001-08-13 2003-08-28 Probiodrug Ag Irreversible cysteine protease inhibitors of legumain
WO2003016335A2 (en) * 2001-08-13 2003-02-27 Probiodrug Ag Irreversible cysteine protease inhibitors of legumain
US9562069B2 (en) 2008-05-21 2017-02-07 Genesis Technologies Limited Selective caspase inhibitors and uses thereof
US10167313B2 (en) 2008-05-21 2019-01-01 Genesis Technologies Limited Selective caspase inhibitors and uses thereof
US8791235B2 (en) 2008-05-21 2014-07-29 Novagenesis Foundation Selective caspase inhibitors and uses thereof
WO2010133000A1 (en) * 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
US9045524B2 (en) 2009-05-21 2015-06-02 Novagenesis Foundation Selective caspase inhibitors and uses thereof
US9944674B2 (en) 2011-04-15 2018-04-17 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
US10975119B2 (en) 2011-04-15 2021-04-13 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
US9670250B2 (en) 2012-04-27 2017-06-06 The Trustees Of The University Of Pennsylvania Alpha-helical peptidomimetic inhibitors and methods using same
WO2013163567A3 (en) * 2012-04-27 2014-03-20 The Trustees Of The University Of Pennsylvania Novel alpha-helical peptidomimetic inhibitors and methods using same
WO2013163567A2 (en) * 2012-04-27 2013-10-31 The Trustees Of The University Of Pennsylvania Novel alpha-helical peptidomimetic inhibitors and methods using same
CN112585142A (en) * 2018-04-16 2021-03-30 科学与工业研究会 Novel antimalarial compounds, preparation method and use thereof for drug-resistant malaria
CN112585142B (en) * 2018-04-16 2024-01-19 科学与工业研究会 Novel antimalarial compounds, method for the production thereof and use thereof for the resistance of malaria
WO2021195183A1 (en) * 2020-03-24 2021-09-30 Exo Therapeutics, Inc. Compositions and methods for inhibiting protein embryonic ectoderm development activity and treating disease

Also Published As

Publication number Publication date
EP0756625A4 (en) 1999-07-28
CA2184098A1 (en) 1995-08-31
IL112759A0 (en) 1995-05-26
AU708414B2 (en) 1999-08-05
NZ282946A (en) 1998-05-27
US5976858A (en) 1999-11-02
EP0756625A1 (en) 1997-02-05
US6287840B1 (en) 2001-09-11
ZA951573B (en) 1995-12-12
AU2091095A (en) 1995-09-11

Similar Documents

Publication Publication Date Title
US5976858A (en) Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups
US5776718A (en) Reversible protease inhibitors
AU713492B2 (en) Reversible protease inhibitors
ES2200010T3 (en) INHIBITORS OF MULTI-CATALYTIC PROTEASE.
KR890004784B1 (en) Process for the preparation of homologues of aprotinin
CA2056911C (en) Hiv protease inhibitors
AU609900B2 (en) Amino acid derivatives of phosphorus acids
CA1329862C (en) Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
Yuan et al. Development of selective tight-binding inhibitors of leukotriene A4 hydrolase
US7521427B2 (en) Peptidyl allyl sulfones
JP4903716B2 (en) Tripeptide and tetrapeptide thioethers
EP0048159A2 (en) Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents
HUT64084A (en) Process for producing pharmaceutical compositions comprising quininogenase inhibitors
CZ38094A3 (en) Novel isosteric peptides
KR19990022395A (en) Reversible cysteine protease inhibitor
US5508266A (en) Gem-disubstituted amino acid derivatives
EP2288615A1 (en) Selective caspase inhibitors and uses thereof
AU599177B2 (en) 2,3-disubstituted isoxazolidines, a process for their preparation, agents containing them, and their use
CA2227198A1 (en) Cysteine protease inhibitors for use in treatment of ige mediated allergic diseases
IE873505L (en) Aminoacid derivatives
JPH02256657A (en) N-substituted amide
US5462964A (en) Dipeptide boronic acid inhibitors of trypsin-like enzymes
JPH11500433A (en) Serine protease inhibitor
JPH07316191A (en) Acyloxyhexanoic acid derivative
CA2354476A1 (en) Methods for the synthesis of alpha-hydroxy-beta-amino acid and amide derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2184098

Country of ref document: CA

Ref document number: 08700518

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 282946

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995913490

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995913490

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995913490

Country of ref document: EP